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Abstract 
 
 
CA4P leads to rapid vascular shutdown of tumour core, with minimal effects at the 
well perfused periphery. CA4P showed minimal anti-tumour activity in single agent 
phase I studies. This thesis examined the feasibility of CA4P combination therapy, 
examining the hypothesis that two agents may be additive or synergistic, eliminating 
separate tumour cell subpopulations and thus increasing the effectiveness of both 
drugs. Chemotherapy using paclitaxel & carboplatin (UKCTC-207) or 
131Iodine anti-
CEA radioimmunotherapy (A5B7) was studied. CA4P toxicity was mild and similar 
to single agent studies - fatigue, tumour pain, flushing, pruritis, headache and 
hypertension. The DLT was ataxia. A5B7 combination therapy led to dose limiting 
myelosuppression with minimal efficacy at a 
131I-A5B7 dose 66% of single agent 
antibody MTD. In UKCTC-207, 70% of patients either responded or had disease 
stability with symptomatic improvement. 
 
We also investigated whether CA4P effect is mediated via decreases in cardiac output 
(CO) and also evaluated heterogeneity of blood flow related dynamic contrast 
enhanced MRI (DCE-MRI) parameters between different patients and in lesions 
within patients on the A5B7 study. Increases in CO (mean +14%, p=0.026) occurred 
after CA4P whilst falls in tumour K
trans values were seen (mean -25.1%; p=0.011). 
There was no evidence for CO fall as a cause for reduced K
trans. Metastatic lesions 
within-patients were more similar compared to between-patients in DCE-MRI 
kinetic parameters, both at baseline and in their response to CA4P. A separate 
perfusion CT analysis revealed no late alterations (over weeks) in tumour blood flow 
parameters.   
 
Correlating DCE-MRI kinetic variable changes following CA4P with tumour 
immunohistochemical angiogenic markers using standard immunohistochemical 
techniques, we studied whether the angiogenic profile can explain differential 
sensitivity of human tumours to CA4P. We found no strong relationships between 
DCE-MRI variable change following CA4P and the angiogenic markers. Contents 
  4
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Chapter 1 - Background Information 
 
 
Introduction 
Targeted drug therapies fall into two categories; agents which act against cell surface 
receptors and second messenger signalling systems, or against tumour vasculature - 
Vascular Disrupting Agents (VDAs) or antiangiogenic agents (Chaplin et al., 2006; Cooney 
et al., 2006; Gaya & Rustin, 2005; Lippert, 2007) (Rhee & Hoff, 2005). VDAs act against 
pre-existing vasculature, whilst antiangiogenic agents prevent new vessel formation. These 
agents compliment conventional cytotoxic agents and radiation, and are currently being 
integrated into clinical practice. 
 
Angiogenesis & VDAs 
In 1971 Judah Folkman first proposed that tumour growth required the formation of new 
vasculature, and that blockage of this process could provide novel anti-cancer therapies 
(Folkman, 1971).  
 
Tumour angiogenesis is under dynamic regulation by stimulatory and inhibitory factors 
released by tumour and host cells. Tumours can grow to about 1mm without 
neoangiogenesis by obtaining oxygen and nutrients through diffusion from surrounding 
tissues (Hanahan & Folkman, 1996). For further growth they must acquire an angiogenic 
phenotype. Angiogenesis involves several processes including proliferation of endothelial 
cells, proteolytic degradation of the extracellular matrix and migration of endothelial cells, 
leading to the formation of a functioning vessel with a lumen (Risau, 1997). VDAs 
selectively block or destroy the pre-existing blood vessels of tumours, leading to rapid 
vascular shutdown, and thereby killing tumour cells by depriving them of oxygen and 
nutrients. VDAs exploit the known differences between the vascular endothelium and 
basement membranes of tumours and normal tissues (Morikawa et al., 2002) (Table 1.1). Chapter 1 – Background Information 
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Table 1.1 - Differences Between Tumour And Normal Vasculature (Kakolyris et al., 2000) 
 
 
 
 
 
 
 
 
 
 
Two classes of VDA are being developed: Biological or ligand-directed VDAs, which use 
antibodies or peptides to target toxins or pro-coagulants to the tumour endothelium; and 
the small molecule VDAs (Figure 1.1 & Table 1.2). Both types produce a characteristic 
pattern of central necrosis, leaving a peripheral rim of viable tumour cells (Blakey et al., 
2002; Ching et al., 1999; Huang et al., 1997; Thorpe et al., 2003; Tozer et al., 2002) (Figure 
1.2) . 
Table 1.2 - Current Vascular Disrupting Agents in Development (Thorpe et al., 2003) 
 
 
 
Vessel tortuosity 
Thin walled and fragile 
Increased Interstitial Pressure within tumour 
Immunohistochemical immaturity 
Increased permeability 
Variable flow rates & vascular density 
Poor vascular smooth muscle & pericyte coverage 
Poor lymphatic drainage 
Constant vascular remodelling 
Abnormalities of endothelial cell and pericyte structure and function 
Biological VDAs 
Antibody – TF  Induces coagulation 
Anti – VCAM1 – TF  Induces coagulation 
L19 scFv – TF  Targets fibronectin 
VEGF – Gelonin  Plant toxin 
Anti – Endoglin – Ricin A  Antibody – Toxin 
Anti – TES-23 – Neocarzinostatin  Antibody – Cytotoxic 
L19 scFv – IL12  Antibody – Cytokine 
L19 scFv – TNFα  Antibody – Cytokine 
Anti – PS  Antibody 
Targeted ATPµ - Raf gene  Blocks signalling 
Flk – 1 fused to Fas  Induces apoptosis 
 
Small Molecule VDAs 
 
CA4P (Combretastatin A4 Phosphate)  Prodrug of CA4 
ZD6126  Prodrug of N-acetylcolchinol 
AC7700 (AVE8062A)  Combretastatin analogue 
Oxi4503 (Combretastatin A1 Phosphate)  Prodrug of CA1 
TZT-1027  Synthetic derivative of dolastatin 10 
DMXAA  Flavonoid Chapter 1 – Background Information 
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Figure 1.1 - Chemical Structure of Selected Small Molecule VDAs 
CA4P 
 
 
Figure 1.2  -  VDA Tumour Effect (N=central necrosis, V=viable tumour cells at periphery) Courtesy of Dr Gill Tozer 
 
 
Advantages of VDAs 
There are a number of potential advantages of VDAs over other classes of anticancer drug. 
There can be a significant bystander effect to vascular shutdown as one single vessel may 
provide oxygen and nutrients for thousands of downstream tumour cells. The endothelial 
cell itself does not need to be killed by the VDA – a change of structure or local initiation 
of the coagulation cascade may be all that is needed. As the endothelium comprises normal 
untransformed cells, it is unlikely to become drug resistant by genetic alteration (Boehm et 
al., 1997). The endothelium has a very slow turnover, with 99.9% of endothelial cells being 
quiescent at any one time. However, it has already been shown that some tumours can 
form luminal blood vessels lined with tumour cells and devoid of endothelium entirely Chapter 1 – Background Information 
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(Folberg et al., 2000; Griggs et al., 2001a; Maniotis et al., 1999; McDonald et al., 2000). 
VDAs do not need to exert their effects for long. One study suggested that greater than 
99% of tumour cells in vivo can be eradicated within a 2 hour period of ischaemia (Chaplin 
& Horsman, 1994), although other studies suggest longer periods of ischaemia are required.  
 
Ligand-Directed VDAs 
Vascular endothelial cells in different tissues express unique surface markers, and so the 
development of drugs to selectively target tumour endothelium is gathering pace (Thorpe, 
2004). The result may be thrombosis within tumour vasculature caused by direct injury or 
apoptosis, initiation of an immune attack on the tumour vasculature, or a change of 
conformation of the tumour endothelium, which leads to occlusion of tumour vessels. 
 
Small Molecule VDAs 
Flavonoids 
Flavone acetic acid (FAA) was originally synthesised as a non-steroidal anti-inflammatory 
agent, but was found to have widespread anti-cancer effects in pre-clinical studies (Smith et 
al., 1987), inducing haemorrhagic necrosis within animal tumours (Corbett et al., 1986). 
Unfortunately, it was inactive in human clinical trials (Kerr & Kaye, 1989). DMXAA(5,6 – 
dimethylxanthenone-4-acetic acid) was developed as a more active analogue(figure 1.1), 
and is twelve times more potent (Rewcastle et al., 1991). 
DMXAA 
DMXAA induces vascular shutdown in murine tumours within 30 minutes of 
administration (Lash et al., 1998) and apoptosis in tumour endothelial cells (Ching et al., 
2002). There is a dose dependent increase in plasma 5HT, released by platelets in response 
to the vascular damage (Baguley et al., 1997). DMXAA induces synthesis of TNF and nitric 
oxide(NO) in plasma and tumour tissue (Ching et al., 1999; Thomsen et al., 1991). FAA, 
unlike DMXAA, cannot induce synthesis of TNF in cultured human cells in vitro, and this 
may explain why FAA was inactive in human phase I trials (Philpott et al., 2001). 
 
DMXAA damages tumour vascular endothelium, causing DNA strand breaks and the 
induction of apoptosis (Ching et al., 2002).  The exact molecular target is unknown, but its 
action involves pathways leading to upregulation of the nuclear transcription factor NFκB 
(Ching et al., 2002) which leads to production of TNF and other cytokines. There is a rapid 
reduction in tumour blood flow and an increase in 5HT which is a marker for vascular Chapter 1 – Background Information 
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damage (Lash et al., 1998; Zwi et al., 1994). 5HT is probably released from platelets, and is 
a likely factor required for the vascular effect of DMXAA as the serotonin inhibitor 
cyproheptadine reduces the degree of induced haemorrhagic necrosis. Following this, TNF 
production is induced which mediates the anti tumour effects of DMXAA and probably its 
toxicity. Antibodies to TNF can prevent the reduction in blood flow caused by these agents 
(Mahadevan et al., 1990), and tumour growth delay is shorter in mice with an inactivated 
TNF gene. 
 
NO induces vascular smooth muscle relaxation, which actually improves blood flow to the 
tumour. It also increases vascular permeability, which increases the effect of TNF and 5HT 
(Moilanen et al., 1998). The balance of these two opposing forces depends on where NO is 
released. Local increase within tumour tissue increases the vascular permeability and anti 
vascular effect in contrast to systemic release which leads to vasodilatation. It is still unclear 
whether DMXAA induces nitric oxide production in human tumour tissue. 
Clinical Trials of DMXAA 
Phase I trials in patients with advanced cancer were conducted in parallel by Cancer 
Research UK in New Zealand and the UK (Jameson et al., 2003; McKeage et al., 2006; 
Rustin et al., 2003a). In the UK study 46 patients received 247 twenty-minute weekly 
infusions of DMXAA over 15 dose levels ranging from 6 – 4900mg/m
2. In New Zealand, 
63 patients received DMXAA every 3 weeks also as a twenty-minute infusion. Reversible 
DLT at 4900mg/m
2  was neurological – tremor, anxiety, visual disturbance, urinary 
incontinence and expressive dysphasia. There was also an episode of left ventricular failure 
in one patient. The drug was otherwise well tolerated; the most frequent side effects were 
visual disturbance, tumour pain, nausea, vomiting, headache, hypertension and malaise. 
There was no significant haematological toxicity. MTD was 3700mg/m
2.  
 
Brief partial responses were seen in a patient with metastatic melanoma at 1300mg/m
2 , and 
a patient with metastatic cervical carcinoma at 1100mg/m
2. DMXAA was highly protein-
bound to albumin(>99%) until saturation occurred at higher doses, leading to a rapid 
increase in the free fraction (up to 20%) and greater concentrations of DMXAA bound to 
non-albumin proteins. The main determinant of the non-linearity of the PK appeared to be 
sequential saturation of elimination mechanisms, including hydroxylation and 
glucuronidation (Jameson M 2000; Jameson et al., 2007; McKeage et al., 2006). Terminal 
elimination half-life was 8.1±4.3h. At doses of DMXAA ranging from 500 – 4900mg/m
2, 
evidence of reduction in tumour blood flow was seen with DCE-MRI (Galbraith et al., Chapter 1 – Background Information 
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2002b; Zhao et al., 2005). There was also a dose-dependent increase in the plasma 
concentration of 5-hydoxy indole acetic acid(5-HIAA), which is the measurable metabolite 
of 5HT, at DMXAA dose levels of 650mg/m
2 and above, which correlated with the MRI 
findings. There were no consistent dose-dependent increases in plasma nitrate or TNFα, 
however the finding of elevated TNF in tumour biopsies suggests that DMXAA actions 
are predominantly local (M Jameson,personal communication,2003).  
 
It is too early to know if there is sufficient local TNF induction after tolerable doses of 
DMXAA to induce tumour regression in humans when given alone. The way forward is to 
try combination therapy with DMXAA (Cliffe et al., 1994; Lash et al., 1998; Lippert, 2007; 
Pruijn et al., 1997; Wilson et al., 1998). Pedley et al (Pedley et al., 1996; Pedley et al., 1999) 
have demonstrated cure of human colorectal tumour xenografts in mice treated with a 
combination of DMXAA and radioimmunotherapy at a dose of DMXAA that produced 
no growth delay as a single agent.  
 
The visual toxicities of DMXAA such as blurring, colour disturbance and photophobia are 
thought to be due to inhibition of phosphodiesterase type 6 (PDE6), which exists 
exclusively in the retina. DMXAA has been shown to inhibit this enzyme in vitro at 
therapeutic concentrations (Jameson et al., 2003). In the UK study, all patients receiving 
≥1750mg/m
2 experienced some disturbance of colour vision(usually mild) following 
infusion. 
 
DMXAA is currently in Phase II clinical trials for the treatment of prostate cancer 
(sponsored by Antisoma Research; AS1404). In this trial a DMXAA/docetaxel regimen is 
being compared with docetaxel alone. DMXAA is also undergoing three additional Phase 
II clinical trials in combination with carboplatin and paclitaxel for the treatment of lung, 
ovarian, and prostate cancer. 
 
Tubulin Binding Agents 
Spindle poisons such as colchicine and vinblastine disrupt tumour vasculature only at doses 
close to their MTD, which has prevented their use as VDAs. Newer agents have since been 
developed which have a much wider therapeutic window such as Dolastatins and 
Combretastatins (Chaplin et al., 1996). Vessels with low flow rates may be particularly 
sensitive to VDAs, as they will have longer to act and are more likely to induce thrombosis. Chapter 1 – Background Information 
  21
The increased proliferative activity of tumour endothelium renders it more susceptible to 
the anti vascular effects of these agents (Galbraith et al., 2001; Griggs et al., 2001c).  
 
VDAs act near the colchicine binding site on the β-subunit of endothelial cell tubulin, 
resulting in depolymerisation of microtubules and disorganisation of actin and tubulin. 
Endothelial cells are particularly reliant on the cellular cytoskeleton to maintain their 
elongated shape. A rapid change in endothelial cell shape (Galbraith et al., 2001) causes 
micro vessel blockage and loss of flow; it also disrupts the endothelial cell layer, exposing 
the basement membrane and increasing tumour vascular permeability. This leads to high 
interstitial pressures, vessel congestion and further loss of flow (Figure 1.3). Exposure of 
the basement membrane may also lead to induction of the coagulation cascade and local 
thrombus formation. Newly formed endothelial cells in tumour vessels are more sensitive 
to anti tubulin drugs because mature cells have a highly developed actin cytoskeleton which 
maintains cell shape despite depolymerisation of the tubulin cytoskeleton (Chaplin & 
Dougherty, 1999). 
 
Figure 1.3 -  Mechanism of Vascular Shutdown (Tozer et al., 2005) 
 
Combretastatin A4 Phosphate 
Combretastatin-A4(CA4) [cis-1-(3,4,5,-trimethoxyphenyl)-2-(4
’-methoxyphenyl) ethene-3
’-0-
phosphate, disodium salt] was originally isolated from the bark of the African Bush Willow 
Combretum Caffrum and binds much more avidly than colchicine to tubulin (Lin et al., 1989; Chapter 1 – Background Information 
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Pettit et al., 1989; Pettit et al., 1995). CA4P is the synthetic water-soluble prodrug of CA4. 
Light promotes isomerisation to the less active trans-CA4 form of the drug, so it is stored 
and administered protected from light. The exact mechanism of action of CA4 is unknown, 
but it induces apoptosis rather than necrosis indicating that intracellular signalling pathways 
are involved (Iyer et al., 1998). The morphological changes induced by CA4, including cell 
retraction and membrane blebbing, involve reorganisation of the actin cytoskeleton, leading 
to the formation of actin stress fibres and focal adhesions. Specific cell signalling pathways 
linking the actin and tubulin cytoskeleton entail activation of the GTP binding protein 
RHO (Dachs et al., 2006; Kanthou & Tozer, 2002)(Figure 1.4).  
 
Figure 1.4  -  Proposed Molecular Mechanism of CA4P Action (Tozer et al., 2005) 
 
 
The endothelial cell shape changes induced by CA4 can be reversed on drug removal in 
vitro (Galbraith et al., 2001). The irreversibility of the effects of colchicine and vinblastine 
on tubulin is one explanation of why these drugs primarily have effects on long-term 
processes like cell division, which takes place over many hours. At doses that cause 
vascular effects in the tumour, colchicine and vinblastine induce a profound inhibition of 
rapidly proliferating stem cell populations in critical normal tissues. The reduced toxicity of 
CA4P can be attributed to its reversible effects on tubulin as well as its rapid clearance 
from the plasma and tissues(Hill et al., 2002b). Chapter 1 – Background Information 
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CA4P Preclinical Studies 
Studies in mice have shown that a single administration of CA4P does not significantly 
affect tumour growth (Chaplin et al., 1999; Grosios et al., 1999; Grosios et al., 2000), 
however repeated doses can result in substantial growth delays (Griggs et al., 2001b). In all 
studies the effect of CA4P was seen as haemorrhagic necrosis. Further studies (Dark et al., 
1997; Horsman et al., 1998) support the hypothesis that CA4P causes rapid vascular 
collapse and shutdown leading to haemorrhagic necrosis. Acute anti vascular effects are 
seen at about 10% of the MTD (Dark et al., 1997). Tumour blood flow reduction is rapid 
and can drop to 1% of the starting value as soon as one hour after administration, 
accompanied by increased vascular permeability (Tozer et al., 2001). Animal DLT was 
gastrointestinal haemorrhage or ulceration. In rats, 360 mg/m
2 caused severe toxicity or 
death in 10%  
 
Histological studies as well as DCE-MRI show that the anti vascular effects of CA4P are 
restricted to the core of the tumour, leaving viable tumour cells at the periphery which 
rapidly regrows (Beauregard et al., 1998). The drug caused a 100 fold decrease in blood 
flow to p22 carcinosarcomas, with a much smaller reduction in blood flow to spleen, 
skeletal muscle and brain. No significant reduction was observed in heart, kidney and 
intestine (Tozer et al., 1999).  
 
The change in tumour blood flow after administration of CA4P is much greater than that 
seen with drugs affecting systemic haemodynamics. Limited changes in tumour blood flow 
in rats have been seen with hypertensive agents such as angiotensin II (Tozer & Shaffi, 
1993), but only at doses that caused much larger changes in systemic blood pressure and 
heart rate than CA4P. Also, larger reductions were seen in normal tissue blood flow. 
Reduced tumour blood flow has also been observed after treatment with high doses of the 
vasodilator hydralazine (Horsman et al., 1992), which reduced systemic blood pressure by 
50%. This evidence indicates that changes seen after CA4P are due to a direct effect on 
local tumour vasculature rather than systemic effects such as change in cardiac output(CO). 
There may be tissue specific differences in CA4P vascular response. The haemodynamic 
changes seen after CA4P probably reflect a response to increased peripheral vascular 
resistance in a range of tissues. The lack of effect on stroke volume indicates that CA4P 
has no direct effect on the heart (Anderson et al., 2003). Microtubule depolymerisation is 
known to affect vasomotor tone and peripheral resistance – the changes in heart rate and 
BP possibly reflect this as well. The effect of CA4P on CO is studied in Chapter 5. Chapter 1 – Background Information 
  24
CA4P Phase I Studies 
Three Phase I trials of CA4P in humans investigated three different dose schedules based 
on toxicity data from animals (Dowlati et al., 2002): 1) Case Western Reserve University, 
Cleveland, OH(CWRU), 2) University of Pennsylvania, Philadelphia, PA(UPENN), and 3) 
London, United Kingdom at Mount Vernon and Hammersmith Hospitals . A small 
unpublished study was also performed by Bristol Myers Squibb (Table 1.3).  
 
Table 1.3 - Phase I Trials of CA4P 
 
 
The UK trial (Anderson et al., 2003; Galbraith et al., 2003; Rustin et al., 2003b) used a 10 
minute weekly infusion of CA4P for 3 weeks every 28 days, starting at 5 mg/m
2, with intra 
patient dose escalation and accelerated titration (Simon et al., 1997). Doses were doubled 
until CTC grade 2 toxicity was seen after which subsequent dose escalation was by a factor 
of 1.3. Thirty-four patients with advanced solid tumours received 167 infusions. The MTD 
was 68mg/m
2 and the recommended Phase II dose was 52 - 68mg/m
2.  
 
Significant reductions in tumour blood flow were seen at these doses by PET and DCE-
MRI (Anderson et al., 2003; Galbraith et al., 2003). Increases in neutrophil counts of mean 
80% were seen 4 hours following CA4P at doses ≥55mg/m
2, corresponding with a rise in 
the patients’ core temperature – This would be consistent with an inflammatory/cytokine 
response to endothelial attack by CA4P.  
  UK CRC PH1/066(Rustin 
et al., 2003b) 
UPENN CA4P-
102(Stevenson et 
al., 2003) 
 
CWRU CA4P-
101(Dowlati et al., 
2002) 
BMS CA178 - 002 
Schedule  Weekly x 3 every 28 days  Daily x 5 every 21 
days 
Single dose every 21 
days 
Initially a single dose every 
21 days then changed to 
weekly x 3 every 28 days 
Infusion Time  10 mins  10 mins 
10 mins 
60 mins in 7 pts at 54 
mg/m2 
10 mins 
Number Pts  34  37  25  18 
CA4P Dose Range  5 – 114 mg/m2  6 – 75 mg/m2  18 – 90 mg/m2  30 – 70 mg/m2 
DCE-MRI  Yes  Yes  Yes  No 
PET  Yes  No  No  Yes 
MTD (per dose)  68 mg/m2  75 mg/m2  60 mg/m2  70 mg/m2 
DLT 
Ataxia 
Motor neuropathy 
Syncope 
Diplopia 
Tumour pain 
Dyspnoea 
Tumour pain 
Sensorimotor 
neuropathy 
Syncope 
Dyspnoea 
Cardiac ischaemia 
Dyspnoea 
Tumour pain 
Cardiac ischaemia 
Recommended Ph. 2 Dose  52 – 68 mg/m2  52 mg/m2  ≤60 mg/m2  - 
No. Doses of CA4P given  167  700  104  - 
Terminal half life CA4P (hr)  0.489  0.36  0.47  - 
Terminal half life CA4 (hr)  2.23  3.3  4.26  - Chapter 1 – Background Information 
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The UPENN trial (Stevenson et al., 2003), the most dose intense of the Phase I trials, used 
a 10min infusion daily for 5 days every 3 weeks. Thirty-seven patients with advanced solid 
tumours received 133 cycles at doses ranging from 6 – 75mg/m
2. All patients were 
assessable for toxicity. The MTD was 65mg/m
2 and recommended Phase II dose was 
52mg/m
2.  
 
The CWRU trial (Dowlati et al., 2002) used a single dose schedule of CA4P every 21 days 
using doses up to 90mg/m
2 in advanced solid tumours. Both ten-minute and sixty-minute 
infusion schedules were investigated. Twenty-five patients received 107 cycles of treatment 
(dose ranges 18 – 90mg/m
2). The MTD was 60mg/m
2.  
 
The unpublished BMS study used single doses of CA4P 30 – 70mg/m
2 every 21 days, in 18 
patients. The primary purpose of this study was to evaluate myocardial blood flow and 
tumour blood flow changes with PET, not CA4P pharmacokinetics and safety. Tumour 
blood flow decreased for all five patients by up to 78% 
 
CA4P Pharmacokinetics (PK) 
In humans CA4P is rapidly converted by endogenous phosphatases to CA4, which has a 
half-life of 2-10min, and an elimination half-life of 1-2h. 
 
Pharmacokinetics of CA4P was assessed from plasma and urine for all patients in the three 
Phase I trials. 
 
PK data from all three trials was in agreement that plasma AUC and plasma Cmax of CA4P 
and CA4 have dose proportional linear kinetics. There was rapid dephosphorylation of 
CA4P to CA4 and rapid glucuronidation of CA4. There was no evidence of accumulation 
of CA4P over time with repeated doses. 
 
Linear kinetics was seen in the terminal half-life and systemic clearance of CA4P across all 
dose levels in all studies. 58% - 67% of the dose was excreted as CA4G in the first 24 
hours of urine collection. The mean plasma half-life(t1/2) across the three trials for CA4P, 
CA4 and CA4G were 0.4, 3.8 and 4.5 hours respectively. Volume of distribution ranged 
from 3.8 to 7.5 litres, and clearance ranged from 24.5 to 28.2 l/hr. Cmax(μM) of CA4P 
ranged from 4.9 at 6mg/m
2 to 48.7 at 114mg/m
2. Corresponding AUC (μM/hr) for CA4P Chapter 1 – Background Information 
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were 1.31 and 11.6 respectively. CA4 Cmax ranged from 0.31 at 6mg/m
2 to 4.2 at 114mg/m
2 
with corresponding AUC of 0.24 and 2.49 respectively. 
 
CA4P Toxicity (Non Dose Limiting) 
Across all three studies, adverse events were generally mild and manageable, and very 
different from the usual cytotoxic effects of alopecia, myelosuppression, nausea and 
mucositis. No significant haematological toxicity was seen in any of the studies. 
Cardiotoxicity was reported in one study.  
 
In the UK study the only drug related toxicity seen up to 40mg/m
2 was grade 1 tumour 
pain in 35% of infusions. It is not clear whether this pain relates to tumour ischaemia or to 
acute swelling of the tumour caused by alteration in endothelial cell permeability after 
CA4P. The most common site of pain was in the abdomen, which was the most frequent 
site of tumours. It was not possible to exclude mesenteric angina as a possible cause of pain 
in some patients. Median time to onset of tumour pain was 40min from the start of the 
CA4P infusion (range 2min to 10h, duration 1 – 180min). Other side effects were mainly 
cardiovascular – tachycardia (53%), hypertension (35%), hypotension (30%), bradycardia 
(24%), fatigue (23%), nausea (21%), visual disturbance (9%) and dyspnoea (6%). Mean 
increase in blood pressure at doses ≥52 mg/m
2 was 8–10% over the first hour followed by 
a mean decrease in blood pressure of 6-7%, most obvious at four hours.  
 
Toxicity in the UPENN and CWRU studies was very similar to the UK experience. 
Tumour pain did not appear to correlate with either clinical response or DCE-MRI 
parameters, and appeared more common following the 60-minute infusion schedule.   
Gastrointestinal side effects were considered to be the DLT in animals. Whilst GI side 
effects were common in the human phase I trials, they were usually mild. 
 
A wide range of neurological effects were seen mainly at the higher doses. Effects such as 
perineal and perirectal paraesthesia, peripheral neuropathy, visual blurring, diplopia, ataxia 
and leg weakness were seen; they were transient, mild and self-limiting at lower doses. 
 
CA4P DLT 
In the UK study, four DLTs were reported. The first was a grade 3 vasovagal episode that 
occurred on the patient’s second dose (88mg/m
2). This began 4½ hours following CA4P Chapter 1 – Background Information 
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and lasted three minutes. The patient recovered fully with supportive treatment. It is 
possible that an early swelling of this patient’s neck mass might have contributed to the 
vasovagal episode by compressing the carotid body. There were two cases of transient and 
reversible grade 2 ataxia at 114mg/m
2. Upon reducing the dose back to 88mg/m
2 there was 
an episode of reversible grade 4 ataxia, grade 3 diplopia and grade 3 leg weakness in one of 
the patients who experienced ataxia at the higher dose level.  The final DLT in this study 
was an episode of grade 4 small bowel ischaemia at 52mg/m
2, which led to the patient’s 
death. Autopsy revealed small bowel ischaemia was confined to a previously treated radical 
radiation field, which contained evidence of late radiation fibrosis and small vessel damage. 
The patient’s tumour also involved the mesentery of the affected bowel segment. Concern 
that normal tissue vasculature might be compromised by previous radical radiotherapy has 
led to patients who have received radical radiotherapy being excluded from future CA4P 
trials. 
 
In the CWRU study, four DLTs were also reported: Dyspnoea at 90mg/m
2 in a patient 
with ovarian cancer and pleural involvement, and stridor and apnoea at 60mg/m
2 in a 
patient with advanced thyroid cancer. The third and fourth DLTs were cardiac, and will be 
discussed below. 
 
In the UPENN study, there were also four DLTs. Two episodes of grade 3 tumour pain at 
75 mg/m
2, transient and reversible grade 3 hypoxia, and grade 4 dyspnoea. This patient had 
poor lung function at baseline and had been requiring home oxygen therapy. Lastly, there 
was an episode of syncope, secondary to dehydration-induced grade 2 hypotension and 
grade 3 hypoxia also at 75 mg/m
2. 
 
CA4P Cardiotoxicity 
Significant cardiotoxicity was only reported in the CWRU Phase I trial (the least dose 
intense regimen). This was probably related to chance or patient selection. Cardiovascular 
effects such as transient hypertension, hypotension, tachycardia or bradycardia were seen in 
all three studies. 
 
In the CWRU trial, two cases of cardiotoxicity were reported at 60mg/m
2 and one at 
90mg/m
2. The first patient (60 mg/m
2) was a diabetic with known ischaemic heart disease, 
although this was not initially disclosed. The patient’s screening ECG revealed a QTc 
interval in excess of 450ms. Shortly after CA4P he experienced shoulder and neck pain, Chapter 1 – Background Information 
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followed by bradycardia and hypoxia. He was treated with opiate analgesia and oxygen. 
Approximately 90min later he developed stridor, lethargy, sinus tachycardia, ventricular 
arrhythmia and dizziness, and after 3h, apnoea. Naloxone was given successfully to reverse 
the effects of opiate toxicity. The following day the patient’s QTc interval peaked at 533ms, 
most likely due to hypomagnesaemia, hyperglycaemia and myocardial ischaemia (T-wave 
changes on ECG). Cardiac enzymes remained within normal limits. Post mortem 
examination several weeks later revealed metastatic carcinoma within the heart in addition 
to the known ischaemic disease. 
 
The second cardiac event occurred in a male with a long history of hypertension, on triple 
antihypertensive therapy. The patient was hypomagnesaemic and bradycardic at baseline, so 
their  β-blocker was stopped. The following morning the patient’s BP rose as high as 
210/88, and following CA4P 229/95. Approximately 90min post CA4P, ECG revealed ST 
segment depression, and an hour later there was evidence of myocardial infarction 
associated with raised serum troponin. It was subsequently shown that the patient’s 
ejection fraction had declined prior to the study from 60% (eight months before) to 42% 
(post CA4P) and ischaemic heart disease was also diagnosed. Abrupt cessation of β-
blockers has been previously documented to cause MI (Astra Zeneca Pharmaceuticals 
(Macclesfield ). 
 
The third cardiac event occurred at 90mg/m
2, one hour following the second infusion of 
CA4P. The patient had ischaemic ECG changes and underwent immediate cardiac 
angiography, which revealed minimal occlusion of the distal left anterior descending 
coronary artery. There was no rise in cardiac enzymes, and the ECG normalised within a 
few hours. His only cardiac risk factor was smoking. 
 
CA4P ECG Repolarisation (QTc) Effects 
In vitro ion channel studies have demonstrated that CA4P and CA4 are weak inhibitors of 
the HERG potassium channel, and CA4P is also a weak inhibitor of the L-type calcium 
channel. CA4 decreased the action potential duration (APD) and CA4G increased the APD 
by less than 20% in rabbit Purkinje fibres at a concentration of 30μM. The human PK data 
indicates that plasma concentrations of CA4P, CA4 and CA4G are well below these levels 
and should not have any significant clinical safety effects (Young & Chaplin, 2004). In all 
three Phase I studies, ECGs were performed hourly for 6h and at 24h following CA4P. Chapter 1 – Background Information 
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ECGs were analysed centrally, and both Bazett’s(QTcB) and Fridericia’s(QTcF) formulae 
were used (Bazett, 1920; Fridericia, 1920).  
 
There was inconsistency of QTc results between the three studies. In the CWRU study, 
there were significant increases in QTc interval at the 3h (27.2ms, p<0.0001) and 4h 
(30.8ms, p<0.0001) time points (Cooney et al., 2004). Three of 25 patients had prolonged 
QTc intervals at baseline, whereas 15 (60%) of 25 and 18(75%) of 24 patients had 
prolonged QTc interval at 3 and 4 hours. The slope of HR and QTc increasing as a 
function of time during the first 4 hours was correlated to dose of CA4P (p=0.005, r=0.55 
for QTc) and also to CA4 AUC (p=0.02, r=0.44 for QTc). No patients had a QTc 
>500ms, and no patients’ QTc increased more than 25% over baseline (Cooney et al., 
2004).  
 
In the UK study, two patients had a mean QTc prolongation of ≥30ms, but less than 60ms. 
This study used doses as high as 114mg/m
2 CA4P. The UPENN study, the most dose 
intensive Phase I trial, showed mean increases in QTcB of >20ms at Day 1 hours 3-4 at 
56mg/m
2, and Day 1 hour 4 at 75mg/m
2.  
 
In conclusion, there may be a dose dependent prolongation of QTc interval at doses 
≥56mg/m
2, but the data should be interpreted with caution due to the variable time points 
of the data collection, large standard deviations, small sample sizes and lack of control 
groups. 
 
CA4P Anti-tumour Activity 
Significant clinical benefit from single agent CA4P was not anticipated. In the UK study, 
one patient with metastatic adrenocortical carcinoma had an unmaintained partial response 
of their liver metastases to therapy. The tumour shrank by 51% however this effect was not 
sustained for long enough to be classified a partial response. 
 
In the UPENN study, one patient with lung metastases from a fibrosarcoma had a partial 
response at 56mg/m
2, and 14 patients showed stable disease over 3–29 cycles of CA4P. 
One patient with metastatic medullary thyroid carcinoma received 29 cycles of CA4P with 
stable disease and no cumulative toxicity.  
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In the CWRU study, one pathological and radiological complete response was observed in 
a patient with metastatic anaplastic thyroid cancer (60mg/m
2) who received eight cycles of 
therapy, with the patient disease free 48 months later. Two further patients, one with 
metastatic colorectal cancer (24 cycles over 19 months at 60mg/m
2) and another with 
advanced medullary thyroid cancer (15 cycles over 12 months at 50mg/m
2) both had 
prolonged responses to therapy of >12 months. One patient with metastatic kidney cancer 
had stable disease for 6 months on 18mg/m
2.  
 
CA4P Recommendations 
Since these studies completed, it has been recommended that patients with a history of 
ischaemic heart disease, myocardial infarction, uncontrolled hypertension, arrhythmias, 
clotting disorders, or patients who have previously received radical doses of radiation 
therapy should not receive CA4P.  
 
Rat data shows that CA4P induced hypertension can be effectively controlled with 
prophylactic antihypertensive therapy, and that these agents do not alter the effects of 
CA4P on tumour blood flow (Tozer, 2003). In the combination phase I/II studies, patients 
experiencing a rise in blood pressure above 160/100 following the first dose of CA4P are 
given sublingual GTN, and subsequently treated with prophylactic doses of dexamethasone 
and amlodipine. In addition to controlling blood pressure the steroid also appears to 
reduce the incidence of neurological toxicity (Gordon Rustin, personal communication, 
2007). It is hoped that these measures will improve the safety profile of this otherwise well 
tolerated drug. To date, no further significant cardiotoxicity has been reported. 
 
CA4P DCE-MRI Assessment 
In the UK trial, changes in kinetic DCE-MRI parameters K
trans, ve, kep and IAUGC60 over 
24 hours after treatment with CA4P were measured in 18 patients, and compared with 
those obtained in the rat p22 carcinosarcoma model (Galbraith et al., 2003). A similar 
pattern and time course of change in tumour and normal tissue parameters was seen in rats 
and humans. After treatment there was a marked reduction in K
trans values, particularly in 
the centre of the tumour, with some sparing of the peripheral rim. Significant reductions 
were seen in tumour K
trans in 6 of 16 patients treated at ≥52 mg/m
2 (up to 77%), with a 
significant group mean reduction of 37% and 29% at 4 and 24 hours respectively after 
treatment. The reduction in K
trans showed evidence of a dose effect, with the magnitude of Chapter 1 – Background Information 
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reduction correlating with an increase in CA4 AUC. No change was seen in muscle or 
kidney parameters.  
 
In the CWRU study, seven patients underwent DCE-MRI at 60mg/m
2. A significant 
decrease in the gradient peak signal intensity, consistent with a decrease in tumour blood 
flow, was seen in six out of the seven patients 4 – 6h post CA4P. In the UPENN study, 8 
of 10 evaluable patients had decreases in K
trans values. Three patients demonstrated a 
marked loss of perfusion following CA4P. There was a more consistent pattern of 
alteration in tumour leakage space (ve) after CA4P, with 7 of 10 patients demonstrating a 
decrease in assessable volume fraction of  ≥10%.  
 
The MRI data should be interpreted with caution due to the small numbers of patients, the 
wide variety of tumour types, and the fact that the imaging techniques were being altered 
and fine tuned during the course of the studies. Current ongoing CA4P studies are also 
using these techniques and will increase the volume of data available on the use of DCE-
MRI in assessing tumour perfusion. 
 
ZD6126 
ZD6126 (Astra Zeneca, Macclesfield,UK) is rapidly converted by serum phosphatases to 
N-acetylcolchinol(NAC), a tubulin binding agent that inhibits tubulin polymerisation and 
causes microtubule destabilisation. ZD6126 disrupts endothelial cell morphology in a 
similar manner to CA4P. ZD6126 has significant anti tumour activity against a broad range 
of human xenografts in rodent models (Blakey et al., 2002; Davis et al., 2002). The vascular 
targeting activity of ZD6126 was seen at doses 1/8 to 1/16 of the MTD, and was selective 
for tumour blood vessels (Blakey et al., 2002; Davis et al., 2002). 
 
In Phase I clinical trials (Beerepoot et al., 2006; DelProposto Z 2002; Gadgeel SM 2002; 
LoRusso S, 2001; Radema SA 2002; SC, 2002; Thorpe et al., 2003), illustrated in Table 1.4, 
stable disease lasting 4 or more cycles was seen in three patients, and one patient had a 
minor response lasting 19 cycles. Radema et al reported vascular damage in 4 of 5 patients 
4 – 6h post infusion of ZD6126, indicated by a doubling of circulating endothelial cells, 
which were viewed as a surrogate marker for vascular damage (Radema SA 2002). Adverse 
events seen include hypokalaemia, anorexia, constipation, dyspnoea, fatigue, headache, 
nausea, pain and vomiting. One patient had asymptomatic, reversible, grade 2 ischaemic 
changes on ECG and grade 3 elevation of Troponin I, with subsequent demonstration of Chapter 1 – Background Information 
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coronary artery disease (Gadgeel SM 2002). Two other patients developed transient 
reversible declines in left ventricular ejection fraction(LVEF). Two patients with 
undiagnosed brain metastases developed symptoms of raised intracranial pressure shortly 
after treatment (Radema SA 2002).  
 
In the largest study (Beerepoot et al., 2006), one patient treated at 10mg/m
2 with a history 
of ischaemic heart disease experienced acute myocardial infarction two weeks after drug 
discontinuation. Four others had asymptomatic creatine phosphokinase elevation. DLT’s at 
28mg/m
2 were hypoxia from a pulmonary embolism and an asymptomatic decrease in 
LVEF. No antitumour responses were observed. 
Table 1.4 - Phase I Trials of ZD6126 
 
ZD6126 was in Phase II clinical trials in the United States for the treatment of metastatic 
renal cell carcinoma, and an additional separate trial incorporating combination therapy 
with oxaliplatin, 5-fluorouracil and leucovorin in metastatic colorectal cancer.  Cardiac 
events have halted these studies. 
 
AVE8062A (AC7700) 
AVE8062A (Aventis Pharmaceuticals) is a synthetic water soluble Combretastatin 
analogue, which has more potent effects on tumour blood flow stasis and anti tumour 
effects when compared to CA4P (Hori & Saito, 2003). AVE8062A has undergone single 
agent Phase I trials in humans (Tolcher AW 2003), and synergism has been seen in animal 
models when the drug is given in combination with conventional cytotoxic agents 
(Vrignaud, 2004).  
 
(LoRusso S, 
2001) 
(Gadgeel SM 
2002)  (Radema SA 2002)  (DelProposto Z 
2002) 
(Beerepoot et al., 
2006) 
Schedule  Single dose, 
q21d 
Single dose, 
q21d  Weekly infusion  Single dose, 
q21d  Weekly infusion 
Infusion Time  10min  10min  10min  -  10min 
Number Pts  19  27  12  6  32 
ZD6126 Dose 
Range  5 – 40mg/m2  5 – 112mg/m2  5 – 7mg/m2  56 – 112mg/m2  5 – 28mg/m2 
Elimination 
T1/2  2 – 3h  2 – 3h  2 – 3h  -  1 – 3h 
DLT 
Anaemia 
Cardiac 
Ischaemia 
Anorexia, 
Constipation 
Dyspnoea, 
Fatigue 
Headache, Pain 
Nausea 
Hypokalaemia 
Reduced LVEF 
Increase ICP with 
brain mets 
- 
Myocardial 
Infarction 
Pulm Embolism 
Reduced LVEF 
CPK-MB 
Increase 
Hypokalaemia Chapter 1 – Background Information 
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Nine reported patients with advanced cancer received 48 infusions of AVE8062 (4.5–
30mg/m
2) weekly for 3 weeks every 28 days over 30min (Tolcher AW 2003). 
Asymptomatic hypotension without any other cardiac toxicity was dose limiting at 
30mg/m
2. Preliminary evidence of decreased vascular flow by DCE-MRI was observed at 
15.5mg/m
2. AVE8062A was rapidly eliminated with a t½ of 15min and a clearance of 50 
L/h/m
2, leading to an active metabolite, RPR258063, with a t½ of 7h. 
 
OXi4503 
OXi4503 (Oxigene Inc, Boston,MA) is the diphosphate pro-drug of Combretastatin 
A1(CA1). OXi4503 shows comparable effects to CA4 in vitro, however head to head 
comparisons indicate that OXi4503 is at least 10 times more potent in vivo when tumour 
vascular shutdown is used as the endpoint (Hill et al., 2002a). Over 50% of tumour blood 
vessels are no longer perfused 24 hours after a dose as small as 1mg/kg of OXi4503. Single 
dose studies indicate that the MTD in mice is similar to CA4P therefore OXi4503 has a 
much larger therapeutic window. Pre-clinical studies have demonstrated prolonged tumour 
growth retardation, regressions and even prolonged complete responses in some tumour 
models (Hill et al., 2002a; Malcontenti-Wilson et al., 2007; Salmon et al., 2006; Salmon & 
Siemann, 2006). Additional activity may be due to the rate of dephosphorylation, or the 
production of a quinone metabolite with cytotoxic activity (Hill et al., 2002a).  
 
Oxi4503 commenced human Phase I trial in July 2005 (Patterson & Rustin, 2007). It was 
administered by 3 weekly iv infusions to a maximum of 6 cycles. Starting dose was 
0.06mg/m
2. 100% dose escalation in single patient cohorts proceeded to 3.84mg/m
2, when 
cohorts were expanded to three patients and 30% dose escalation due to emergence of 
grade 2 thrombocytopaenia. Several pharmacodynamic asessments were performed prior to 
and after the first infusion of OXi4503 including functional MRI or PET imaging with 
[
18F]-FDG and 
15O-labelled water. By March 2007, 16 patients had received OXi4503 
(median age 53 years). Common adverse events included pyrexia, lethargy and 
hypertension. Pharmacokinetic profiles show a dose-dependent linear increase in peak 
plasma concentrations and AUC of both OXi4503 and CA1. CA1 concentrations at 
6.5mg/m
2 are close to that seen at the MTD in animals. DCE-MRI showed significant 
reduction in K
trans in one patient. Changes in standard uptake values were observed in all 
four patients studied with FDG-PET. H2O-PET showed that the distribution volume of 
water was reduced in 3 out of the 5 metastases in one of the three patients studied. Of the Chapter 1 – Background Information 
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14 patients fully assessed, 3 have stable disease and 11 disease progression (Daniel 
Patterson, personal communication, 2007). 
 
Combination VDA Therapy 
Combined approaches can be used to target viable tumour cells remaining at the well-
oxygenated peripheral rim after VDA treatment. Cells in this viable rim of tumour tissue 
are likely to be in a state of rapid proliferation and excellent nutrition and more susceptible 
to killing by conventional therapies. Additional response and delays in tumour regrowth 
have been seen in animal studies when CA4P is combined with 5-Fluorouracil (Grosios et 
al., 2000) , cisplatin, Irinotecan (Wildiers et al., 2004), Paclitaxel (Chaplin & Dougherty, 
1999; Rustin GJ 2005), doxorubicin (Nelkin & Ball, 2001), radiation (Chaplin et al., 1999; Li 
et al., 1998; Ng et al., 2007), or radioimmunotherapy (Pedley et al., 2002; Pedley et al., 
2001). Tumour cell kill by cisplatin or cyclophosphamide was enhanced 10 – 500 times by 
post treatment administration of CA4P and with no additional bone marrow toxicity 
(Siemann et al., 2002). Other groups have also reported enhancement of response or cures 
by combining various anticancer therapies with antiangiogenic agents or VDAs (Burrows & 
Thorpe, 1993; Lode et al., 1999; Mauceri et al., 1998).  
 
Combining a VDA with radiation would allow the two treatments to act in a 
complementary and synergistic manner in tumours. Sequencing is vital as giving the VDA 
before radiotherapy could increase the hypoxic radio-resistant cell population. Giving 
VDAs after radiotherapy is the obvious approach at a time when vessels may be more 
permeable, and when prevention of radiation damage repair is most important. This 
approach has proven effective when combining DMXAA, CA4P and ZD6126 with 
radiation (Horsman & Murata, 2002; Landuyt et al., 2001; Li et al., 1998; Murata et al., 
2001; Ng et al., 2007; Siemann & Rojiani, 2002; Siemann & Rojiani, 2005; Siemann & Shi, 
2003; Wilson et al., 1998). The radiosensitising effects of CA4P do not appear to enhance 
either acute or late toxicity of radiotherapy (Murata et al., 2001). 
 
Cures were obtained when CA4P was combined with radioimmunotherapy (Pedley et al., 
2001). Single agent CA4P was initially given to nude mice implanted with SW1222 
colorectal xenografts. CA4P rapidly reduced tumour blood flow by 62% at 1h and 32 – 
36% from 6 – 24h after administration. This induced central haemorrhagic necrosis, 
however the peripheral rim continued to grow and survival was unaffected. In further 
studies, 7.4MBq 
131I-labelled anti-CEA antibody plus a single 200mg/kg dose of Chapter 1 – Background Information 
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intraperitoneal CA4P given 48 hours later produced cures in 5 out of 6 mice. The success 
of this novel approach is probably synergism between the two agents. 
 
A phase I trial of CA4P in combination with radiotherapy in patients with advanced lung & 
prostate cancer is also currently recruiting patients in the UK. To date, 12 patients with 
NSCLC and 10 patients with prostate cancer have received 50mg/m
2 CA4P either as a 
single dose, or as a weekly infusion, in combination with their radiotherapy treatment, with 
no grade 3 or 4 drug related toxicity. The CA4P dose is due to be escalated to 63mg/m
2 
(Quan Ng, personal communication, 2006 (Ng QS, 2005; Ng et al., 2007)). 
 
Other active studies include a phase II trial of single agent CA4P in advanced anaplastic 
thyroid carcinoma, a phase I/II trial of CA4P in combination with doxorubicin and 
cisplatin in newly diagnosed anaplastic thyroid carcinoma, a phase I trial of CA4P + 
cisplatin in advanced or recurrent cervical cancer, a phase I/II study of CA4P in patients 
with age related macular degeneration, and a phase I study of CA4P with the VEGF 
inhibitor Bevacizumab in advanced cancer. 
 
DMXAA when combined with Antibody Dependent Enzyme Pro-drug Therapy (ADEPT) 
or radioimmunotherapy in colorectal xenografts also gave significantly enhanced therapy, 
with no increase in systemic toxicity (Pedley et al., 1996; Pedley et al., 1999).The 
combination of DMXAA with Paclitaxel has been very successful, with some cures seen in 
animal models (Siim, 2004).. 
 
Combining VDAs with antiangiogenic approaches is also likely to achieve a complementary 
tumour effect. Encouraging pre-clinical data has been seen with the combination of 
ZD6126 and ZD6474(antiangiogenic) (Siemann, 2004; Varghese HJ, 2004), and ZD6126 
with ZD1839(Iressa) (Raben et al., 2004). 
 
Tumour Vascular Maturity 
Tumours contain a high proportion of immature blood vessels due to continuous 
angiogenesis and the production of high levels of pro-angiogenic growth factors by the 
tumour, and the surrounding stromal tissues. Neoangiogenesis is essentially a change in the 
balance of proangiogenic to antiangiogenic factors. 
 
Neovascularization is tightly regulated during embryogenesis and during a variety of 
biological processes in adults. In response to angiogenic factors, pre-existing vessels Chapter 1 – Background Information 
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become dilated and supporting cells such as smooth muscle cells and pericytes detach from 
the vessel wall. Endothelial cells then migrate into the perivascular space by degrading 
basement membrane and extracellular matrix, multiply and form new vascular sprouts. 
Under normal circumstances, this transient proliferation phase is followed by the 
establishment of a stable, hierarchical vascular network. Pericytes are again recruited to the 
vasculature in response to growth factors such as platelet derived growth factor B (PDGF-
B); these pericytes reduce endothelial cell proliferation and stabilize the newly formed 
vasculature (Ganss, 2006; Jain, 2003). 
 
There is increasing evidence that pericytes, characterized as αSMA , desmin, NG2 
proteoglycan or PDGFRβ positive cells, play an important role during tumour growth 
(Abramsson et al., 2003). Tumour pericytes are loosely associated with the endothelium, 
having cell processes that extend away from the vessel wall, and in contrast to their normal 
tissue counterparts, are sensitive to PDGF signalling (Benjamin et al., 1998; Morikawa et 
al., 2002). Pan-endothelial cell markers (e.g. CD31, CD34) are used to identify all vessels 
present in a histological section. A pericyte coverage index (PCI), can be defined as the 
percentage of blood vessels staining positive for αSMA or desmin. 
 
100
Vessels   Of Number    Total
Vessels   Positive   desmin) (or  SMA 
(%) × ⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
=
α
PCI  
 
PCI for most normal tissues is usually in the range 85 – 95%, however there are exceptions 
in angiogenic tissues such as the corpus rubrum of the ovary, where the PCI is ≈ 60% (Goede 
et al., 1998). Human tumours have an enormous range of PCI, as illustrated in figure 1.5 
(Eberhard et al., 2000). The PCI would be inaccurate if a proportion failed to stain 
positively for αSMA or desmin, or if partial coverage was missed in very thin, non co-
planar histological sections (Morikawa et al., 2002). 
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Figure 1.5 - PCI For Various Human Tumour Types (Eberhard et al., 2000) 
 
Among the pathways involved in pericyte recruitment during embryonic development, the 
contribution of PDGF-B and sphingosine 1-phosphate is confirmed in tumour 
angiogenesis. The effect of angiopoietin 1 depends on the tumour model. Transforming 
growth factor-β1 enhances tumour vascularization and microvessel maturation. The 
number of proliferating endothelial cells is reduced by half when tumour vessels are 
covered by pericytes (Gee et al., 2003). 
 
Pericyte plasticity is demonstrated by their capacity to transdifferentiate into other 
mesenchymal cell types such as smooth muscle cells, fibroblasts, osteoblasts and adipocytes 
(Farrington-Rock et al., 2004). The most reliable criterion for the identification of pericytes 
is that they are surrounded by a basement membrane shared with EC, as demonstrated by 
electron microscopy (Gerhardt & Betsholtz, 2003). Pericytes are in contact with EC 
through discontinuities in the shared basement membrane.  
 
In physiological angiogenesis, pericytes have multiple functions that seem to be relevant in 
the development and the maintenance of tumour microvasculature (Fig. 1.6).  
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Fig. 1.6 - Regulation of pericyte recruitment by four major pathways: (1) PDGF-B released by endothelial cells 
binds to PDGFRβ on pericytes and stimulates their migration and proliferation; (2) sphingosine 1-phosphate (S1P) 
binding to endothelial differentiation gene-1 (EDG-1) promotes cell migration; (3) angiopoietin 1 (Ang1)/receptor 
tyrosine kinase with immunoglobulin and epidermal growth factor homology domains-2 (Tie2) enhances cell–cell 
and cell–extracellular matrix (ECM) interactions and activates the expression and release of heparin-binding 
epidermal growth factor like growth factor (HB-EGF), that also promotes cell migration and proliferation; and (4) 
transforming growth factor-β1 (TGF-β1) binding to receptor II (TGFβR-II) leading to activin-like kinase-5 (ALK5), 
stimulates pericyte differentiation and ECM deposition. Figure taken from Chantrain (Chantrain et al., 2006). 
 
In Chapter 7, I describe a study to assess the vascular maturity of a broad range of human 
tumours immunohistochemically, using a panel of vascular markers. It is thought that 
CA4P has a preferential effect on tumour vessels because they are relatively immature, 
lacking the smooth muscle coat and pericytes of mature vessels. Vessels lacking a smooth 
muscle coat would be more prone to a catastrophic effect once the endothelium has been 
damaged by CA4P.  The current ‘gold standard’ surrogate marker of CA4P effect is DCE-
MRI. What is not currently known is whether CA4P effect measured by DCE-MRI 
correlates with a more immature vasculature in human tumours. 
 
VEGF 
VEGF was initially identified in 1983 as a tumour-produced factor capable of increasing 
vascular permeability (Senger et al., 1983). VEGF is essential for normal development in 
the embryo, where it promotes the differentiation, proliferation and survival of endothelial 
cells, and growth of the vascular tree (Glade Bender et al., 2004).  Chapter 1 – Background Information 
  39
VEGF signaling (Fig.1.7) elicits a rapid angiogenic response from endothelial cells in 
arteries, veins and lymphatics. Activation of the VEGF receptor VEGFR2(flk-1) appears to 
be the principle pathway supporting its proliferative functions (Ferrara, 2004).  
 
VEGF is ubiquitously expressed in nearly all human tumours. Higher levels of expression 
have been associated with increased tumour vascularity, rapid growth, invasion, metastasis, 
and poor clinical prognosis in various tumours including breast (Linderholm et al., 2000), 
colon (Tokunaga et al., 1998), lung (Fontanini et al., 2002; O'Byrne et al., 2000), kidney 
cancer (Jacobsen et al., 2000), and head and neck cancer (Sauter et al., 1999).  
 
CD105 (Endoglin) 
CD105 is a proliferation-associated marker on endothelial cells that binds with high affinity 
to TGFβ1 and TGFβ3. The TGFβ family of cytokines regulates a wide range of cellular 
processes, including proliferation, differentiation, apoptosis and migration CD105 is 
strongly expressed in the vascular endothelium of tumour tissues, with weaker expression 
in normal vascular tissue (Burrows et al., 1995). CD105 MVD can vary widely (Fig. 
1.8)(Akagi et al., 2002). Higher levels of CD105 have been associated with a worse 
prognosis in patients with prostate cancer (Joseffson et al., 2005). 
 
Fig. 1.7 The VEGF Family & Receptors. The family consists of seven ligands (VEGF A,B,C,D,E, placenta growth 
factor (PIGF1, PIGF2). mRNA splicing leads to several isoforms of some ligands e.g. VEGF-A. VEGF family members 
have specific binding affinities to the various tyrosine kinase receptors. Neuropilin (NRP-1, NRP-2) are also co-receptors 
for certain VEGF isoforms. From(Hicklin & Ellis, 2005)  
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Glut-1 
Tumour cells have an increased rate of glucose uptake and glycolysis. This up regulation 
helps maintain the increased energy requirements of rapidly proliferating cells. In tumours, 
increased glucose uptake is largely achieved through the up regulation of a family of 
proteins, known as “facilitative glucose transporters”. 
 
Glut-1 is a target gene of the HIF-1α transcription factor, and has been considered a 
candidate endogenous marker of tumour hypoxia (Mayer et al., 2005). Expression of Glut-
1 may also serve as an indicator for the induction of the transcriptional response to 
hypoxia, which has been linked to enhanced proliferation, resistance to therapy, and 
metastatic potential of tumours (Sullivan & Graham, 2007). Over expression of Glut-1 has 
been shown to correlate with poor prognosis and clinical outcome in several human 
tumour types, including cervical cancer (Airley et al., 2001), lung cancer (Younes et al., 
1997), bladder cancer (Younes et al., 2001), colorectal cancer (Cooper et al., 2003), and 
head and neck cancer (Oliver et al., 2004). 
 
Ki-67 
Ki-67 has an essential role in cell proliferation (Scholzen & Gerdes, 2000), although its 
exact biological function has not been fully determined. During cell cycle interphase, the 
antigen can be exclusively detected within the nucleus, whereas in mitosis the protein 
relocates to the chromosomes. The fact that the Ki-67 protein is present during all active 
phases of the cell cycle but is absent from resting cells (G0), makes it an excellent marker 
for determining the growth fraction of a cell population (Scholzen & Gerdes, 2000). 
 
Fig. 1.8 – CD105 in 
Carcinoma Development 
Alteration of CD105 MVD in the 
development of colorectal 
carcinoma. From Akagi (Akagi et 
al., 2002) Chapter 1 – Background Information 
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The fraction of Ki-67 positive tumour cells (Ki-67 labelling index) is often correlated with 
clinical outcome, for example in soft tissue sarcoma (Heslin et al., 1998), astrocytomas 
(Kirla et al., 2000), prostate cancer (Borre et al., 1998; Pollack et al., 2004), and breast 
cancer (Haerslev et al., 1996). 
 
Angiopoietins 
The angiopoietins(ang-1,2,3,4) are critically involved in angiogenesis, and belong to a family 
of proteins that bind to the Tie-2 receptor (Tait & Jones, 2004). Ang-3 represents the 
murine orthologue of human ang-4. 
 
The involvement of angiopoietins in the angiogenic switch has been suggested by Tanaka 
(Ahmad et al., 2001a; Tanaka et al., 2003). The angiogenic switch is a change in balance, in 
which a higher relative level of angiogenic inducers leads to angiogenesis and a higher 
relative level of inhibitors leads to inhibition of angiogenesis (Fig. 1.9). The angiopoietins 
are known for their antagonistic roles on Tie-2 receptors where ang-1 stabilises the vessels 
by maintaining pericyte endothelial cell coverage, and ang-2 permits the removal of these 
cells from the vessel, which in the presence of VEGF facilitates the angiogenic response 
and in the absence of VEGF induces vessel regression (Bach et al., 2007; Moon et al., 2006; 
Shim et al., 2007; Winter et al., 2007). VEGF expression is not modulated by 
overexpression of ang-1 or ang-2 (Hawighorst et al., 2002). However, depending on the 
tumour model, stabilization of blood vessels by ang-1 may either promote tumour 
angiogenesis or reduce tumour growth, possibly by rendering endothelium unresponsive to 
further angiogenic stimulation (Metheny-Barlow & Li, 2003). Ang-1 and ang-2 are 
expressed in the cytoplasm and sometimes membrane of tumours.  Chapter 1 – Background Information 
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Fig. 1.9 – The Angiogenic Signaling Network - from Abdollahi (Abdollahi et al., 2007) 
 
Overexpression of ang-1 has been documented in various types of human tumours 
including glioblastoma, neuroblastoma and lung cancer but others studies have suggested a 
selective loss of ang-1 expression during tumour progression (Metheny-Barlow & Li, 2003). 
Depending on the tumour model, stabilization of blood vessels by ang-1 may either 
promote tumour angiogenesis or reduce tumour growth, possibly by making EC 
unresponsive to further angiogenic factors (Metheny-Barlow & Li, 2003). 
 
Hypoxia results in increased levels of ang-1 and ang-2 in tumours, although ang-2 is 
elevated to a far greater extent. Tait (Tait & Jones, 2004) collected angiopoietin expression 
data from 56 publications in order to determine a consensus expression profile. They 
found that although ang-1 and ang-2 are both upregulated in tumours, ang-2 is more 
frequently upregulated than ang-1 or Tie-2. Ang-2 seems to be particularly increased in 
highly vascular tumours. Ang-1 expression is generally restricted to tumour cells, whereas 
ang-2 is also found in EC.  
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Overexpression of ang-2 leads to a more invasive tumour. Colorectal tumours transfected 
with ang-2 grew significantly larger and heavier in nude mice compared to those 
transfected with the ang-1 construct or the vector alone (Ahmad et al., 2001b).  
 
PDGF 
PDGF was first identified in a search for serum factors that stimulate the proliferation of 
arterial smooth muscle cells (Ross et al., 1974). The PDGF family has been shown to drive 
cellular responses including proliferation, survival, migration, and the deposition of 
extracellular matrix and tissue remodelling factors.  
 
The PDGF signalling network consists of four ligands, PDGF-A, B, C, and D, and two 
receptors, PDGFRα and PDGFRβ ( Fig.1.10)(Hoch & Soriano, 2003). PDGFs are 
receptor tyrosine kinases, and the PDGF family is closely related to the VEGF family. 
 
Fig. 1.10 – PDGF / PDGFR Binding Interactions (Hoch & Soriano, 2003) 
 
PDGFB and PDGFRβ have essential roles in the recruitment of VSMC and pericytes to 
newly formed blood vessels, whereas PDGFA and PDGFRα have essential roles in 
numerous processes, including CNS, neural crest and organ development (Betsholtz, 2000; 
Karlsson et al., 2000; Leveen et al., 1994). PDGF-B can also induce intratumoural 
lymphangiogenesis and lymphatic metastasis by a VEGFR-3 independent mechanism Chapter 1 – Background Information 
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(Vincent & Rafii, 2004). PDGFB has an essential role in recruitment of pericytes to newly 
formed vessels. PDGFB and PDGFR-β deficient mice have a lack of pericytes that leads to 
microvascular aneurysms and lethal microhaemorrhages (Lindahl et al., 1997). 
 
CD61 (β3-Integrin) 
Integrins are cell-surface adhesion receptors that play an important role in mediating 
numerous physiological processes, including inflammation, migration, adhesion and 
proliferation. Integrins are composed of α and β subunits, which form heterodimers. Eight 
β and 18 α subunits have been described to date, and form 24 distinct integrins (Zhao et 
al., 2004). Each integrin performs specific functions depending upon the ligand-binding 
specificity (Table 1.5). Angiogenesis depends on specific molecular interactions between 
vascular cells and components of the extracellular matrix. 
 
 
Table 1.5  Integrin Diversity & Binding Specificity (Stouffer & Smyth, 2003) 
 
The β3-integrin family consists of αIIbβ3 (glycoprotein IIb/IIIa), found on platelets and 
megakaryocytes, which has an essential role in haemostasis, and the more widely distributed 
αvβ3, found on endothelial cells, smooth muscle cells, platelets, lymphocytes, neutrophils, 
macrophages and osteoclasts (Eliceiri & Cheresh, 1999).  Chapter 1 – Background Information 
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Endothelial cells exposed to growth factors, or those undergoing angiogenesis in tumours, 
express high levels of αvβ3 (Eliceiri & Cheresh, 1999). The expression of αvβ3 on activated 
endothelial cells suggests that this integrin may have an important function during 
angiogenesis (Cai & Chen, 2006; Cowden Dahl et al., 2005; Lamar et al., 2007; Nam et al., 
2005; Wang et al., 2006). Disruption of αvβ3 with antibody (LM609) disrupts blood vessel 
formation in mouse retina (Drake et al., 1995). These antagonists disturb the growth and 
maturation of new blood vessels without detectably influencing the preexisting blood 
vessels. Systemic administration of αvβ3 antagonists to animals with ongoing angiogenesis 
shows blood vessels containing high levels of apoptotic endothelial cells (Eliceiri & 
Cheresh, 1999). The humanised form of the anti-αvβ3 monoclonal antibody LM609 
(Vitaxin) has shown promise in early clinical trials. 
 
Magnetic Resonance Imaging (MRI) 
A brief overview of MRI is presented in Appendix 1 
 
Dynamic Contrast Enhanced MRI 
Introduction 
DCE-MRI, using low-molecular-weight (<1 kDa) gadolinium-based paramagnetic contrast 
media, is an attractive technique for assessing the vascular physiology of tumours, by 
combining good anatomical detail with the ability to quantify vascular parameters. The rate 
at which contrast medium passes from the intravascular space to the extravascular 
extracellular space and then back to the intravascular space over time after bolus injection 
differs between normal tissue and tumour tissue and can be assessed qualitatively and 
quantitatively. MRI has the advantage of a good intrinsic signal-to-noise ratio, but 
quantification of tissue contrast agent concentrations is challenging, because there is no 
simple relation between signal-intensity change and contrast-medium concentration, 
especially for large vessels. Changes in signal intensity are dependent on many factors, 
including native tissue relaxation rates, contrast-agent dose, rate of injection, chosen 
imaging sequence and parameters, and machine gain and scaling factors (Goh et al., 2007). 
For kinetic parameter quantification to be feasible, careful calibration of contrast 
concentration with signal intensity has to be done to establish the exact relation between 
these two entities over the measured range of values. 
 Chapter 1 – Background Information 
  46
Theory 
DCE-MRI involves the rapid acquisition of a set of T1-weighted images through the 
tumour as an intravenous bolus of contrast agent is injected. The change in signal intensity 
over time following contrast injection can be analysed with mathematical models (Tofts, 
1997). Quantitative kinetic parameters are derived which provide information about 
tumour microcirculation as they are indirectly related to perfusion, vascular permeability 
and vessel surface area (d'Arcy, 2006). 
 
The theory underlying the use of DCE-MRI to measure physiological parameters such as 
tissue blood flow and permeability is based on the Kety equation for a freely diffusible 
tracer.   
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where E is the extraction fraction, F is blood flow rate (ml whole blood per g of tissue per 
minute), λ is the tissue-blood partition coefficient of the substance, Ca is the arterial blood 
concentration and Ct is the tissue concentration. This can be adapted for intravenous bolus 
injection of an extracellular tracer such as Gd-DTPA (Tofts et al., 1999): 
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where Cp is arterial plasma concentration of Gd-DTPA, K
trans is the volume transfer 
constant for Gd-DTPA from the vessel into the extracellular extravascular space (EES), 
and kep is the rate constant for the transfer of Gd-DTPA from the EES back into the 
plasma. From the above two equations, 
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where ρ is tissue density (g/ml) and Hct is haematocrit. K
trans has several physiological 
interpretations depending on the balance between capillary permeability to Gd-DTPA and 
blood flow rate in the tissue of interest. In tissues with highly permeable vessels, where flux 
across the endothelium is flow limited, E is close to 1 so K
trans is equal to the blood plasma 
flow rate per unit volume of tissue (ml plasma per ml tissue per minute): Chapter 1 – Background Information 
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Adapting Renkin’s equation (Renkin, 1959) for extraction fraction for a freely diffusible 
tracer to an extracellular tracer, 
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where PS is the permeability (P) vessel surface area (S) product. Therefore, when PS<<F, 
as in tissues such as brain with low vessel permeability, flux across the endothelium is 
permeability limited,  
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and K
trans is equal to the permeability surface area product per unit volume of tissue: 
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In tumours there will be heterogeneity of vessel permeability, and K
trans will be determined 
by a combination of flow, permeability and vessel surface area. The ratio of K
trans to kep 
gives the volume of EES per unit volume of tissue, ve, otherwise known as the Gd-DTPA 
leakage space: 
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This model assumes an instantaneous bolus, instant mixing of Gd-DTPA within the blood 
and within the leakage space after transfer from the vessel, and ignores the contribution of 
intravascular tracer to the tissue concentration. 
 
Unlike CT imaging, the change in signal intensity on the MR image does not reflect 
contrast agent concentration directly but rather is a map of the effect of Gd-DTPA on the 
relaxation times of hydrogen nuclei present in the tissue.  Therefore it is difficult to 
compare non-quantitative results from different institutions as different sequences, Chapter 1 – Background Information 
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machines and injection procedures will produce different changes in signal intensity for the 
same change in contrast agent concentration (Parker et al., 1997).  For quantitative analysis 
(to obtain comparable results between institutions) and tracer kinetic model application, 
measurement of tissue contrast agent concentration is required (appendix 1).  
 
T1-weighted DCE-MRI kinetic parameters 
The T1-weighted quantitative parameters derived for the work presented in this thesis are 
IAUGC60 (the initial 60s area under the Gd-DTPA concentration vs time curve) and the 
kinetic parameters obtained from the Tofts model (Tofts & Kermode, 1991): the transfer 
constant for Gd-DTPA from plasma to tumour extracellular space, K
trans (and back again 
kep) and the volume of the EES or leakage space, ve. 
 
IAUGC 
The IAUGC (units: mM.min or mM.s) is usually calculated for the first 60 or 90 seconds 
following Gd-DTPA injection (Evelhoch, 1999; Evelhoch et al., 2004).  It cannot be 
related simply to tumour physiology, but has the advantage of being a quantitative 
parameter that is obtained without mathematical modelling or knowledge of the arterial 
input function (AIF).  As such, changes in pixels that are excluded from the mathematical 
modelling analysis are evaluated by the IAUGC parameter.  It is a measure of how much 
contrast agent is taken up by the tumour in the first 60 or 90s post-Gd-DTPA injection 
and is influenced by tumour blood flow rate and tumour vessel permeability.  IAUGC 
values can be easily and robustly calculated for individual pixels within a tumour region of 
interest.  An average IAUGC value for the whole tumour can then be determined.  Figure 
1.11 below shows the derivation of IAUGC. By using AUC from the Gd-DTPA 
concentration time curve rather than from the signal intensity time curve, the problem of 
dependence of signal enhancement on tissue T1 levels is avoided. The larger vascular 
contribution to the tissue Gd-DTPA concentration time curve in liver spleen and kidney 
means that the initial AUC parameter in these tissues has a greater contribution from blood 
volume than in muscle or tumour. Thus the same DCE-MRI parameter in these different 
tissues reflects a different combination of blood flow, vessel permeability to Gd-DTPA 
and blood volume. 
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Fig. 1.11 - Diagram to show derivation of IAUGC90 
 
K
trans and ve 
The transfer constants for Gd-DTPA diffusion into the tumour EES from blood plasma 
(K
trans) and back again (kep) can be calculated using Tofts’ mathematical model (Figure 1.12) 
(Tofts et al., 1999; Tofts & Kermode, 1991).  This is an adaptation of the Kety model, 
which was developed to describe the uptake of a freely diffusible inert tracer from the 
plasma to tissue EES (Kety, 1960a; Kety, 1960b).  The main differences between the Tofts 
and Kety models are that Gd-DTPA is not a freely diffusible tracer (which is a requirement 
of the Kety model) and that the transfer constants elicited are expressed per unit volume 
rather than per unit gram of tissue.  
 
Fig. 1.12 - Diagram to show Toft’s model for Gd-DTPA uptake kinetics. 
 
K
trans (and kep) have both blood flow rate and permeability components as Gd-DTPA is not 
freely diffusible and their biological meaning is dependent on the balance between capillary 
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permeability and blood flow in the tissue of interest (Tofts, 1997; Tofts et al., 1999).  In 
high permeability tissues, K
trans is equal to the blood plasma flow per unit volume of tissue.  
In low permeability tissues, such as in the brain, it is equal to the permeability surface area 
product between the blood plasma and the EES per unit volume of tissue (Tofts, 1997). In 
liver metastases the situation is likely to be somewhere between these two extremes. 
 
There are many assumptions in the Tofts model so these parameters should be regarded as 
the ‘apparent’ blood flow rate/permeability and leakage space (Parker et al., 1997).  As the 
values of K
trans and ve that are derived are based on Gd-DTPA concentration, comparisons 
between different studies and different MRI centres can be made.   
 
Techniques for assessing the effects of VDAs 
The effects of VDAs can be assessed using DCE-MRI, perfusion CT, contrast enhanced 
microbubble ultrasound, and with PET. DCE-MRI is the most established technique, with 
the greatest volume of data available. Mount Vernon Hospital have pioneered 
developments in the use of MRI to assess the VDAs, and the team there have great 
experience in the technique, hence it was the modality of choice for us. The Phase I CA4P 
UK study also used PET (at Hammersmith Hospital) to assess CA4P effects (see previous 
section). There is increasing data with perfusion CT, and we use this technique in Chapter 
4 to look for late effects of CA4P. CT obviously involves a radiation dose to the patient, in 
contrast to MRI, but it is readily available and gives a direct measure of arterial input. MRI 
involves no radiation, but the dynamic parameters are calculated using models based on an 
arterial input estimate. Newer MRI scanners however are much faster and so this issue is 
gradually being resolved. 
 
MRI in the assessment of VDAs 
T1-weighted DCE-MRI has been used to investigate the acute effects of the VDAs CA4P 
(Beauregard et al., 2001; Beauregard et al., 2002; Beauregard et al., 1998; Galbraith et al., 
2003; Maxwell et al., 2002), DMXAA (Beauregard et al., 2002) & ZD6126 (Evelhoch et al., 
2004; Robinson et al., 2003a) in animal models.  Acute reductions in semi-quantitative 
and/or quantitative parameters are seen within 24 hours of treatment in a range of tumour 
types.  Similar results were seen in phase I clinical trials of VDAs which used change in 
DCE-MRI parameters as biomarkers for the anti-vascular effects of CA4P (Dowlati et al., Chapter 1 – Background Information 
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2002; Galbraith et al., 2003; Stevenson et al., 2003), DMXAA (Galbraith et al., 2002b), & 
ZD6126 (Evelhoch et al., 2004).   
 
As K
trans has both blood flow and permeability components, reduction in K
trans cannot be 
directly equated to the acute blood flow shutdown seen with CA4P.  However, the use of 
DCE-MRI to assess response to VDAs has been validated by Maxwell (Maxwell et al., 
2002) and Padhani (Padhani, 2005; Padhani et al., 2007; Padhani & Leach, 2005).  Changes 
in K
trans in response to CA4P in a rat carcinosarcoma model matched changes in blood flow 
rate measured using uptake of radiolabelled 
125iodoantipyrine (IAP).  Reductions in absolute 
tumour blood flow rate at 4 and 24 hours as measured by IAP correlated with reductions in 
K
trans(and IAUGC) as measured by DCE-MRI.  Although the size of the decrease seen in 
K
trans was smaller than that seen in tumour blood flow rate, the time course and dose-
dependency patterns were very similar.  Reductions in ve were also seen, with no significant 
change in kep.  Treatment with CA4P may alter Gd-DTPA kinetics such that, in this 
situation, blood flow rate is the dominant influence on K
trans.   
 
The pattern and time course of changes in K
trans seen in a Phase I trial of CA4P was similar 
to that seen in animal models (Galbraith et al., 2003) indicating the appropriateness of 
using K
trans as a surrogate marker of vascular response to treatment.  This view has been 
endorsed by a specialist panel meeting under the auspices of Cancer Research UK - who 
considered the measurement and analysis methodology requirements for robust application 
of DCE-MRI to anti-vascular clinical trials (Leach et al., 2003). BOLD-MRI has also been 
used to monitor the acute effects of anti-vascular agents (Robinson et al., 2003b). 
 
DCE-MRI analysis was undertaken in six patients following a single dose of ZD6126 every 
three weeks (three patients at 56mg/m
2, two patients at 80mg/m
2 and one patient at 
112mg/m
2) (DelProposto Z 2002). The overall tumour IAUGC60 decreased to 13 – 84% of 
the baseline value 6 hours after ZD6126 administration in all but one subject (56mg/m
2). 
As expected, the effects were most noticeable in the tumour core. The IAUGC increased 
to baseline within 24h in three of the five patients with an initial decrease, but remained 
below baseline for two patients even after 18 – 21 days (DelProposto Z 2002).  Robinson 
(Robinson et al., 2007) has demonstrated the potential of susceptibility contrast MRI with 
ultrasmall superparamagnetic iron oxide contrast agents to provide a quantitative imaging 
biomarker of fractional tumour blood volume to assess response to ZD6126. 
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A significant amount of experience has now been gained with DCE-MRI, and 
reproducibility between serial dynamic scans obtained daily in patients has been excellent 
(Evelhoch et al., 2001; Galbraith et al., 2002a; Taylor et al., 2004a; Taylor et al., 2004b; 
Taylor et al., 2006). CO and LVEF can now be measured during MRI scans, leading to 
better understanding of changes in kinetic parameters. 
 
Dynamic Perfusion CT 
Introduction 
Dynamic contrast enhanced CT, also known as perfusion CT, describes the use of CT to 
capture physiological parameters that reflect the vasculature within tumours and other 
tissues following conventional iodinated contrast agent administration (Miles, 2002). 
Following intravenous injection contrast agent passes from the intravascular to EES, at a 
rate determined by the rate of tissue delivery, vessel surface area, and the leakiness of these 
vessels. There is subsequent return of contrast from the EES to vessels over time, and 
contrast is eventually excreted by the kidneys. Differences in contrast agent kinetics 
between normal tissue and tumour can be exploited to provide tissue-specific information. 
 
By performing perfusion CT in the early phase (first pass and delayed phase) following a 
bolus injection of intravenous contrast agent and measuring the change in vascular and 
tissue contrast enhancement from the series of CT images obtained over time, it is possible 
to estimate both semi-quantitative (e.g. peak enhancement, maximum slope of 
enhancement and time to peak enhancement) and quantitative vascular parameters (e.g. 
perfusion, blood volume, and vascular leakage as expressed by extraction fraction or 
permeability surface area product).  
 
The technique was first described in 1979 only 8 years after the introduction of CT into 
clinical practice; Leon Axel proposed a method for determining tissue perfusion from 
dynamic contrast enhanced CT data (Axel, 1980). Due to the computer processing 
requirements it took until the 1990s before perfusion CT could be performed with 
conventional CT rather than electron beam systems, thereby broadening the technique’s 
availability (Miles et al., 1991; Miles et al., 1993).  
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Mathematical Modeling 
Mathematical modeling techniques employed during Perfusion CT are summarized in 
Appendix 4. 
 
Acquisition Techniques 
A typical perfusion CT acquisition includes a series of sequential images obtained during 
the first pass of the bolus of contrast agent through the vascular system At this time the 
contrast material is predominantly intravascular which allows assessment of perfusion, 
blood volume and transit time. The delayed extravascular phase (>60sec) allows assessment 
of vascular leakage. In order to assess the contrast enhancement change over time at least 
one non contrast-enhanced baseline image is needed. By subtracting the baseline dataset 
from the remaining contrast enhanced datasets on a pixel by pixel or regional basis, the 
resulting temporal changes in contrast enhancement within the input vessel and for the 
tissue of interest may be displayed as attenuation-time curves. Direct application of 
mathematical modeling techniques to the enhancement data is possible as there is a direct 
linear relationship between enhancement change and iodine concentration. Absolute 
quantification of perfusion is possible and has been hailed as an advantage of CT. 
 
The manner in which contrast is administered is also an important consideration. When 
using compartmental analysis to obtain perfusion values, a short sharp bolus is necessary 
because the validity of the method requires that peak arterial concentration occurs prior to 
the time of maximal increase in tissue enhancement. Thus, compartmental analysis 
methods need a relatively small bolus (40–50 ml) administered with higher injection rates 
of 5-10ml/s. Rates higher than 10 ml/s do not appear to produce further benefit due to 
buffering in the venous system. Typical acquisition parameters are shown in Table 1.6. 
 
Comparison With MRI 
In comparison with DCE-MRI, Perfusion CT is more straightforward to implement, 
provides direct quantification of vascular parameters, and demonstrates good spatial 
resolution. The ionizing radiation burden associated with a perfusion CT acquisition 
protocol is determined by the number of images in the sequence and the tube current 
(mAs) used for each image. A greater number of images results in more data points on the 
time–attenuation curve, and therefore higher quality perfusion measurements but a larger Chapter 1 – Background Information 
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patient dose. A larger tube current results in less photon noise within each image and 
greater certainty in the attenuation measurement at each time point but again imposes a 
greater patient dose.  
 
Table 1.6 - Typical perfusion CT and DCE-MRI Acquisition Parameters (Goh & Padhani, 2006) 
  MDCT Single 
Level (2D) 
MDCT Volume 
(3D) 
T1 DCE-MRI 
(2D/3D) 
T2* DCE-MRI 
(2D) 
Contrast Agent  >300mg/ml iodine  >300mg/ml iodine  0.5mmol/ml 
gadolinium 
0.5mmol.ml 
gadolinium 
Dose  0.5ml/kg  1.0ml/kg  0.1mmol/kg  ≥0.2mmol/kg 
Typical Volume  40mls  100mls  10 – 15mls  25 – 35mls 
Injection Rate  3 – 5mls/sec bolus  2mls/sec infusion  3mls/sec bolus  4 – 6mls/sec bolus 
Acquisition Type  Single Level  Multiple Helical  Single Level  Single Level 
Slice Thickness  4 – 5mm  Whole Tumour  2 – 8mm  2 – 8mm 
Data Sampling  1s for 1 – 2min  5s for 1 – 2min  5 – 12s for 5 – 
12min  1 – 2s for 1 – 2min
Signal to Noise 
Ratio  Low  Low  Very High  Low 
Signal Change 
Observed / 
Magnitude of 
Effect 
Increase/Small  Increase/Small  Increase/Large  Decrease/Small 
Analysis 
Technique 
Deconvolution, 
Distributed 
Parameter Model 
Patlak Analysis 
General 
Multicompartment 
Pharmacokinetic 
Model(e.g.Tofts) 
Central Volume 
Theorem 
Parameter 
Typically 
Measured 
Blood Flow 
Blood Volume 
Mean Transit 
Time 
Permeability 
Permeability 
Relative Blood 
Volume 
Transfer Constants 
Leakage Space 
Blood Volume 
Blood Flow 
Relative Blood 
Flow 
Relative Blood 
Volume 
Mean Transit 
Time 
 
To date, no studies have compared the performance of perfusion CT and DCE-MRI in 
tumour assessment, although a recent study compared them in the evaluation of solitary 
pulmonary nodules and concluded that there were no significant differences (Kim et al., 
2004). There are anatomic regions where perfusion CT is preferable, mainly due to the 
presence of artefacts that would interfere with MRI evaluations. These include the upper 
abdomen, the mediastinum and at the pulmonary hila. Phase-encoded artefacts arising 
from vascular pulsatility, exaggerated by concentrated contrast medium, would render 
DCE-MRI potentially uninterpretable.  
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Perfusion CT for tumour assessment 
CT is widely used in oncologic imaging, and perfusion studies can be incorporated 
relatively easily into routine examinations. The rationale for using CT for assessing tumour 
perfusion and blood volume is that these parameters are generally increased in malignant 
tissue reflecting the greater MVD found in tumours. Similarly vascular permeability, as 
tumour blood vessels are abnormally permeable to circulating molecules, including contrast 
media. To date perfusion CT has been validated against a variety of other techniques, and 
has been correlated against histologic markers of angiogenesis in lung, renal and colorectal 
cancer (Cenic et al., 1999; Gillard et al., 2000; Jinzaki et al., 2000; Tateishi et al., 2002; Yi et 
al., 2004). 
 
Perfusion CT has been used for therapeutic assessment in a variety of cancers including 
rectal, lung and oropharyngeal cancer (Gandhi et al., 2006; Meijerink et al., 2007; Ng et al., 
2007; Willett et al., 2004) and to monitor radiotherapy effects in rectal cancer (Bellomi et 
al., 2007; Rudisch et al., 2002; Sahani et al., 2005), prostate cancer (Harvey et al., 2001), and 
as a predictor of response in head and neck cancer (Hermans et al., 1997; Hermans et al., 
2003). MDCT has also been used in lymphoma (Dugdale et al., 1999), and hepatic 
metastatic disease (Leggett et al., 1997; Sheafor et al., 2000a). In a series of 107 patients 
with indeterminate pulmonary nodules(IPN), Swensen (Swenson et al., 1996)  was able to 
distinguish benign from malignant nodules using simple measurements of peak 
enhancement on CT. Peak enhancement (Miles, 1999) was also shown to correlate with 
histological assessments of MVD. A subsequent multicentre trial of 356 patients 
demonstrated a sensitivity of 98% and specificity 58% for IPN enhancement values in the 
diagnosis of malignancy (Swenson et al., 2000). Similarly Perfusion CT has been shown to 
be better than standard morphological criteria for differentiating colorectal cancer and 
diverticular disease (Goh et al., 2006). 
 
Perfusion CT for hepatic assessment: a special case 
As approximately three-quarters of the blood supply is derived from the portal vein in the 
normal liver rather than from the hepatic artery, modelling to derive quantitative vascular 
parameters ideally has to take this into account. In the 1990s Miles described a technique to 
assess hepatic perfusion. Using a dynamic single-section technique with temporal 
resolution imaging of 3–7sec, enhancement-time curves were generated for a ROI placed 
over the liver, aorta, and spleen (Miles et al., 1993). By assuming that peak splenic Chapter 1 – Background Information 
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enhancement marked the beginning of dominant PVP, hepatic parenchymal enhancement 
was resolved into arterial and portal venous components. Hepatic arterial and PVP values 
were calculated by dividing the slopes of the rise in attenuation during the arterial and 
portal venous phases of liver enhancement, respectively, by peak aortic enhancement. A 
hepatic perfusion index (HPI) was derived by dividing the calculated arterial perfusion by 
the sum of arterial and portal perfusion values (Miles et al., 1993). In 1995, Blomley 
(Blomley et al., 1995) revised this approach by subtracting the arterial phase hepatic 
enhancement (modeled after splenic enhancement) from the original hepatic enhancement 
curve to derive a “corrected” hepatic enhancement curve. PVP was calculated by dividing 
the slope of the rise in attenuation during the portal phase of liver enhancement by peak 
portal venous or splenic venous enhancement (Blomley et al., 1995). These slope-ratio 
methods of deriving perfusion indices have dominated the field of hepatic imaging 
(Blomley et al., 1995; Leggett et al., 1997; Miles et al., 1993), but tracer kinetic (Van Beers et 
al., 2001) and linear system approaches have also been applied to perfusion CT imaging of 
the liver (Cuenod et al., 2001). The slope method has been validated for the measurement 
of hepatic perfusion, including separate estimation of arterial and portal components 
(Bader et al., 1998; Blomley et al., 1995; Miles et al., 1993; Tsushima et al., 1999). However, 
simple use of the maximal rate of portal phase enhancement and an arterial rather than 
portal venous input function has been shown to result in underestimation of portal 
perfusion. 
 
In the presence of metastatic disease, relative increases in hepatic arterial perfusion have 
been found on a global basis. Perfusion CT can also reveal occult hepatic metastases 
undetected by conventional CT (Cuenod et al., 2001; Platt et al., 1997; Sheafor et al., 
2000b). CT measurements of hepatic perfusion amongst patients with colon cancer have 
been shown to provide risk stratification that is superior to the Dukes’ classification (Miles 
et al., 2004). 
 
Radioimmunotherapy (RIT) 
Introduction 
RIT is a form of cancer therapy that entails the use of molecular vectors to deliver 
radionuclides to tumours. The molecular vectors must have biological specificity for the 
target and are antibody-based whether intact, fragments or engineered constructs. Beta-
emitting radionuclides are by far the most commonly used clinically. In principle it is the Chapter 1 – Background Information 
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ability to deliver enhanced radiation dose to systemic, and especially occult, disease that is 
their main theoretical advantage. 
 
With targeted RIT, doses depend on such factors as the level of expression of cell surface 
or membrane transport proteins, metabolic pathways, vascular supply, capillary 
permeability and cellular conformation. The interaction between targeting agents and their 
biological targets can be divided into four factors:  
 
1) Specificity: The main theoretical advantage - Enhanced levels of therapy can be 
delivered to tumours even if they are too small to be detected by imaging. This ability is 
compromised by cross-reactivity with other cell types, non-specific accumulation of 
radiolabeled molecules or metabolites in excretory pathways, and irradiation of normal 
tissues by activity in the systemic circulation.  
 
2) Non-uniformity: The uptake of targeting agents in tumours is characteristically 
heterogeneous. This may be due to mechanisms such as elevated interstitial fluid pressure 
within tumours or to binding site barriers. A heterogeneous radionuclide distribution gives 
rise to a non-uniform dose distribution with the degree of correspondence determined by 
the range of emissions from the radionuclide (Humm JL, 1995; Yorke ED, 1993). 
 
3) Potency: This is influenced by the nature of particulate emissions (alpha, beta or Auger 
electrons), the cellular conformation and radiobiological characteristics of the tumour and 
the uniformity of the dose distribution. 
 
4) Range: Ionizing particles emitted as a consequence of nuclear decay have a finite range. 
This has the potential advantage that radionuclides do not have to be internalized or in 
contact with every tumour cell in order to deliver effective treatment. Tumour cells in 
regions with restricted radionuclide uptake may be sterilized by “bystander effect” radiation 
from activity in other parts of the tumour. The amount of bystander effect depends on the 
spatial configuration of tumour cells and the emission range of the radionuclide. The finite 
emission range also means that radionuclides present in the blood pool can produce 
incidental irradiation of the entire body and particularly the bone marrow.  
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Basic dosimetric and radiobiological factors 
A large number of beta-emitting radionuclides have potential clinical application. From the 
point of view of radiation dosimetry the most important parameters of a radionuclide are 
its energy emission spectrum and half-life, T1/2. If the number of radionuclide atoms per 
unit mass is N and the energy emitted per disintegration is E, then the absorbed dose-rate 
is proportional to  NE T 12 / for conditions of electronic equilibrium. The ratio E/T1/2 is 
thus a useful indicator of the intrinsic radiotherapeutic potency of the radionuclide. Table 
1.7 shows E/T1/2 for a number of β-emitting radionuclides. 
Table 1.7 -  Physical Properties of Medical Radionuclides  
 
In targeted therapy, the absorbed dose-rates experienced by both tumours and normal 
organs vary with time and are generally more complex than in other forms of radiation 
Radionuclide  T1/2(day)  E/T1/2(keV/day)  Optimal size(mm) 
32P  14.3  49  18 – 30 
33P  25.4  3  <0.2 - 1.0 
47Sc  3.35  49  2.0 - 3.8 
67Cu  2.58  60  1.6 - 2.8 
77As  1.62  140  3.6 - 6.0 
90Y  2.67  352  28 – 42 
105Rh  1.47  104  2.0 - 3.6 
109Pd  0.56  780   6 – 9 
111Ag  7.45  47  7 – 13 
121Sn  1.13  101  1.0 - 2.0 
131I  8.02  24  2.6 - 5.0 
142Pr  0.80  1012  24 – 34 
143Pr  13.6  23  6 – 11 
149Pm  2.21  162  8 – 12 
153Sm  1.95  138  2.8 - 5.0 
159Gd  0.77  403  6 – 9 
166Ho  1.12  620  18 – 25 
177Lu  6.71  22  1.2 - 3.0 
186Re  3.78  90  7 – 12 
188Re  0.71  1096  23 – 32 
194Ir  0.80  1003  24 – 34 
199Au  3.14  45  0.4 - 1.2 Chapter 1 – Background Information 
  59
therapy. This is caused by biological processes of accumulation and clearance 
superimposed on a background of physical decay. 
 
The size dependency of tumour response 
If the tumour sphere is large in comparison to the emission range, most of the emitted 
energy is absorbed and the absorbed fraction will be close to one. If the tumour sphere is 
small in comparison to the range, a proportion of the emitted energy will escape and the 
absorbed fraction may be significantly less than one (Figure 1.13). 
Fig. 1.13  -  Calculated values of the absorbed fraction (φ) as a function of sphere diameter for a selection of 
radionuclides with different emission spectra (Bardiès M, 1994)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data such as these enable the probability of tumour cure to be modelled as a function of 
tumour size for targeted therapies (O'Donoghue JA, 1995). In this simple model of tumour 
response it is assumed that tumours are spherical and are composed of a mixture of 
spherical tumour cells and an unspecified intercellular matrix of unit density material. 
 
The relationship between tumour size and cure probability derived from this model is 
shown in Figure 1.14 for 
131I. This is based on the assumption that clonogenic cell density 
and activity per unit mass are size-independent. Each curve corresponds to a different 
value of initial activity per gram of tumour. The model suggests that there will be a certain 
tumour size where the probability of cure is maximized. In the case of 
131I this occurs at a 
tumour diameter of around 3.5mm. The difference is caused by the reduction in energy 
absorption, and consequently absorbed dose, as tumours get smaller. Corresponding 
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relationships for other radionuclides have the same general shape, but the position of the 
maximum value depends on the details of the emission spectrum. Optimal tumour sizes for 
higher energy emitters are larger than for lower energy emitters. This is summarized in 
Table 1.7 for a selection of radionuclides. 
 
Fig. 1.14  -  Relationship between tumour size and cure probability for 131I. From O’Donoghue & Hopkins – 
Biologically Targeted Radionuclide Therapy – Biomodelling In Clinical Radiation Oncology 
 
 
 
 
 
 
 
 
 
 
 
 
 
A5B7 
RIT is effective in patients, particularly in the treatment of lymphoma, and encouraging 
responses have also been seen in the treatment of solid tumours (Boerman et al., 2007; 
Boswell & Brechbiel, 2007; Dearling & Pedley, 2007; Karagiannis, 2007; Napier MP, 1998; 
Park & Press, 2007).  
 
A5B7 is a murine IgG anti-CEA monoclonal antibody that can be shown to localise in 
human colon carcinoma xenografts (Pedley, 1987). A5B7 is most effective at the tumour 
rim but has poor penetration of the tumour centre (Flynn AA, 1999) whereas CA4P is 
most effective in the tumour centre with sparing of the tumour rim (Dark et al., 1997). 
Also, trapping of radiolabelled antibody in the tumour by CA4P enhances the effect of RIT 
(Pedley B, personal communication, 2005). Therefore, the combination of RIT and CA4P 
is a promising therapeutic strategy for patients with advanced gastrointestinal carcinoma. 
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A5B7 is utilised to specifically target CEA positive cells. 
131I is a radioisotope with a beta 
emission capable of killing tumour cells over a range of up to 40 cell diameters and a 
gamma emission of 364keV, which is suitable for imaging with a gamma camera for 
quantitative analysis of normal tissue and tumour biodistribution. Radioimmunotherapy 
with 
131I-A5B7 has been shown to result in significant tumour growth delays in animal 
tumour models (Pedley et al., 1996) 
 
A phase I/II study of RIT with 
131I-A5B7 was performed in patients with CEA expressing 
metastatic colorectal carcinoma (Lane D, 1994). 10 patients received RIT with 
131I-A5B7. 
Cyclosporin was administered to prevent the formation of Human Anti-mouse Antibodies 
(HAMA) and to allow repeated therapy. The MTD was established at 2400MBq/m
2 with 
DLT of thrombocytopenia and neutropenia. Cyclosporin was thought to be responsible for 
the other toxicities experienced, including nausea, vomiting and mild abnormalities in liver 
and renal function tests (Ledermann JA, 1991). Localisation of the radiolabelled antibody 
to tumour was demonstrated by quantitative gamma camera imaging. The mean half-life of 
131I-A5B7 in blood was 28.6h and in tumour was 59.5h. One PR was seen in a patient with 
a lung metastasis. 
 
If small volume solid tumours are treated with RIT then higher response rates than those 
reported by Lane et al are seen. A phase I/II study of patients with colorectal cancer with 
total tumour bulk ≤2.5cm produced a complete or partial response rate of 26% with an 
additional 39% patients having stabilisation of previously rapidly progressing disease for up 
to 18 months (Behr T, 1999). These data suggest that, particularly in small volume disease, 
which has relatively little hypovascular component, RIT alone may be as effective as 
current conventional chemotherapy, with the advantage of having more tolerable side 
effects such as reduced gastrointestinal mucosal toxicity. 
 
Pre-clinical efficacy studies of the combination of 
131I-A5B7 and CA4P were performed in 
a xenograft model, using the SW1222 human colon adenocarcinoma implanted in the 
f l a n k s  o f  n u d e  m i c e .  
131I-A5B7 was administered intravenously at a dose of 7.4MBq. 
200mg/kg of CA4P was given intraperitoneally 48h after the RIT. 5 out of 6 mice (85%) 
that received the combination showed complete tumour eradication that continued to be 
sustained until the experiment was terminated after 9 months (Pedley et al., 2001). No 
viable tumour cells were subsequently found at the implantation site of the cured mice. The 
only tumour to regrow did so after 97 days. CA4P alone had no effect on tumour growth 
compared to the controls, and 
131I-A5B7 alone produced tumour growth inhibition of Chapter 1 – Background Information 
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approximately 35 days, but all tumours subsequently regrew – Fig. 1.15 (Pedley et al., 
2001).  
 
 
 
 
 
Biodistribution studies show that administering CA4P 48 hours after 
131I-A5B7 results in 
trapping of the radioantibody within the tumour. Tumours retain an average of 90% 
greater radioantibody after CA4P administration compared with controls receiving 
radioantibody alone (Pedley et al., 2001). This retention appears most marked around the 
periphery of the tumour. The biodistribution of radioantibody in normal tissues remains 
unaffected by the addition of CA4P. Similar results were obtained when 
131I-A5B7 was 
combined with DMXAA (Pedley et al., 1996). It is therefore likely that 
131I-A5B7 and 
CA4P are working in a complementary and synergistic manner on different areas of the 
tumour.  
 
There are three possible mechanisms:  
 
1) Additive killing of the tumour centre by CA4P and the rim by 
131I-A5B7  
2) Enhancement of the effect of 
131I-A5B7 by increased retention of radioantibody 
following CA4P-induced vessel collapse  
3) A combination of 1 and 2, with option 3 being the most probable.  
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The basis for this hypothesis is that CA4P induced vascular collapse will trap radioantibody 
in the tumour, providing the CA4P is administered long enough after radioantibody to 
allow for biodistribution into the tumour. As CA4P has a much smaller effect on normal 
vasculature, the trapping phenomenon appears specific to tumours. Whether this 
phenomenon actually leads to any significant clinical benefit is debateable.  
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Chapter 2 
A Phase Ib Trial of Radioimmunotherapy with 
131Iodine-Labelled A5B7 
Anti-CEA Antibody in Combination with Combretastatin-A4-
Phosphate In Advanced Gastrointestinal Carcinomas. 
 
Abstract 
 
In pre-clinical models the combination of RIT with 131I-A5B7 and the VDA CA4P was synergistic, 
curing 5/6 mice with CEA-positive colon carcinoma xenografts. The antibody attaches to the 
tumour periphery with poor penetration of the core because of relative hypoxia and its high 
molecular weight. CA4P, a tubulin-binding small molecule vascular disruptive agent, leads to central 
tumour vascular shutdown with relative sparing of the periphery. Previous single agent phase I trials 
have defined the MTD for 131I-A5B7 at 2400MBq/m2 and CA4P between 60-68mg/m2. We 
performed a trial to determine DLT, MTD and efficacy of this combination in patients with 
advanced gastrointestinal cancer. The initial drug doses were set 25% below MTD of single agent 
studies. Patients had advanced gastrointestinal adenocarcinoma, CEA 10-1000μg/L, disease 
measurable by RECIST, QTc ≤450ms, no cardiac arrhythmia/ischaemia and adequate 
haematology/biochemistry. Disease had to be suitable for evaluation by DCE-MRI. All patients 
received a test dose of CA4P up to 2 weeks prior to day 1, to document blood flow response. The 
starting dose was 1800MBq/m2 of 131I-A5B7 given on day 1 and 45mg/m2 CA4P given 48 and 72 
hours post A5B7, and then weekly for up to seven weeks. Between October 2003 and April 2007 
88 patients were screened, and twelve patients treated; eleven colorectal and one pancreatic 
adenocarcinoma, mean age 63(32-77), WHO PS 0(6) and 1(6). 2/6 patients at the first dose level 
had DLTs (grade 4 neutropenia) attributed to 131I-A5B7. The dose was reduced to 1600MBq/m2 
and CA4P escalated to 54mg/m2. Again, 2/6 patients had DLTs attributable to 131I-A5B7 (grade 4 
neutropaenia), and one patient had grade 3 ataxia attributable to CA4P. Other toxicities were 
manageable and included infusion reactions, pyrexia, thrombocytopenia (up to grade 3), QTc 
prolongation within the normal range - mean 10ms at 4h(2p=0.0016), hypertension - mean increase 
in systolic BP 12mmHg at 1h(2p<0.0001), tachycardia - mean increase in HR 10bpm at 
3h(2p<0.0001), nausea, fatigue, tumour pain and pruritis. Of ten evaluable patients 1 had SD and 9 
had PD, confirmed by FDG-PET in four. CA4P and A5B7 pharmacokinetics were similar to 
previous studies. SPECT confirmed tumour antibody uptake in all 5 patients studied. This is the 
first clinical trial reporting on the combination of RIT and a VDA; each therapy component was 
shown to function but with dose-limiting myelosuppression from the combination at 66% of the 
single agent antibody MTD (Gaya et al., 2008). Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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Introduction 
 
Colorectal cancer is the second leading cause of cancer death in the UK, with 
approximately 35000 new cases per year (CR-UK figures). Conventional systemic treatment 
modalities remain ineffective at curing patients with metastatic disease, although significant 
advances have been made using combination chemotherapy, pre-operative 
chemoradiotherapy, biological therapies, and hepatic surgery. Five year overall survival is 
now approaching 50%, however there remains a need for novel therapies. 
 
Carcinoembryonic antigen (CEA) is a membrane bound glycoprotein that is expressed by 
most gastrointestinal tumours; normal expression is usually limited to the luminal surface 
of the gastrointestinal tract. CEA represents a good target for RIT. The mouse monoclonal 
antibody A5B7 was raised against CEA (Harwood et al., 1986) and localises to human 
colon carcinoma xenografts (Pedley, 1987). A5B7 was purified from supernatant culture by 
protein A chromatography and ion-exchange chromatography (Ledermann et al., 1988), 
and radiolabelled with 
131I using the N-bromosuccinamide method (Adam, 1989). This 
method has a labelling efficiency of 88-94% without loss of immunoreactivity (Lane et al., 
1994). 
131I is a beta emitter capable of destroying tumour cells over a range of 40 cell 
diameters. The isotope also releases gamma radiation of 364keV, which is suitable for 
imaging with a gamma camera for quantitative analysis of normal tissue and tumour 
biodistribution. There was a 10% response rate in advanced colorectal cancer patients with 
single agent 
131I-A5B7 (Lane et al., 1994). MTD was 2400MBq/m
2 and DLT were 
neutropenia and thrombocytopenia. 
 
Pre-clinical studies have confirmed the antivascular activity of the tubulin binding VDA 
CA4P (Chaplin et al., 1996) and it has completed single agent Phase I trials in the UK and 
USA (Dowlati et al., 2002; Rustin et al., 2003; Stevenson et al., 2003) and Chapter 1. MTD 
was 60 – 68mg/m
2 and DLT was ataxia. Cardiovascular toxicity was seen in patients with 
active ischaemic heart disease or uncontrolled hypertension. Although central vascular 
shutdown was detected by DCE-MRI, minimal antitumour activity was seen due to 
regrowth from the tumour periphery.  
 
A5B7 is most effective at the tumour rim but is a large molecule and has poor penetration 
of the hypoxic tumour centre (Flynn AA, 1999). CA4P is most effective at destroying the 
tumour core with sparing of the peripheral rim (Dark et al., 1997). In addition, trapping of Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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radiolabelled antibody in the tumour by CA4P enhances the effect of RIT (Pedley B, 
personal communication,2005). When this combination was administered to mice, cure was 
achieved in 5/6 animals whereas CA4P alone was ineffective and RIT merely delayed 
tumour growth (Pedley et al., 2001).  
 
There were also limitations to the design of the study. Yttrium has a better affinity for 
carrier molecules than iodine, with higher specific activity, less dissociation and better 
stability. Patients could also be subjected to biopsies to determine histologically vascular 
damage and tumour necrosis following CA4P, and allow for direct immunohistochemical 
studies. The starting dose of CA4P was also below the activity level of 50 mg/m
2. A5B7 
was non humanised meaning it could only realistically be given as a single dose due to the 
development of HAMA. Clinically, for example in the treatment of lymphoma, 
radioantibodies are given in multiple doses.  
 
Combining A5B7 RIT with CA4P may therefore be a promising therapeutic strategy in 
which the action of the two agents is complimentary.  We undertook a phase 1b dose 
escalation trial to define the MTD & DLT of the combination with toxicity as the primary 
endpoint. This study (PH1-092) was sponsored by CR-UK, CTA Number 
21106/0002/001, EudraCT Number 2004-004788-31 
 
Methods 
 
Study Objectives 
1) Define DLTs and MTD 
2) Gain preliminary evidence of efficacy of the combination. 
3) Pharmacokinetic and pharmacodynamic assessments. 
 
Study Design 
This was a phase I dose-escalation trial sponsored by CR-UK. The study was conducted at 
Mount Vernon Hospital, Northwood and the Royal Free Hospital, London. The study was 
approved by participating hospitals’ ethical review boards, and all patients provided written 
informed consent. 
 
It was proposed that the combination of 
131I-A5B7 and CA4P should not result in major 
additional toxicity over that experienced by each agent individually. This was based on the Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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different toxicity profiles and mechanism of action of each agent, and pre-clinical studies 
confirming no additional toxicity. The starting dose of each drug (1800MBq/m
2 A5B7 and 
45mg/m
2 CA4P) was 25% below MTD in the Phase I single agent studies (Lane et al., 
1994; Rustin et al., 2003). CA4P was to be escalated by 20% to 54mg/m
2 (above the 
activity threshold of 50 mg/m
2). A5B7 was to be dose escalated initially in 2 steps up to the 
single agent MTD of 2400 mg/m
2.  
 
Up to two weeks before A5B7 treatment two DCE-MRI scans were performed at Mount 
Vernon Hospital for repeatability analysis prior to a single intravenous CA4P infusion, and 
a further scan 4h post-CA4P to assess changes in vascular kinetic parameters (Chapter 3). 
A5B7 treatment was administered as an inpatient on day 1, and CA4P on days 3 and 4 
before hospital discharge, then as an outpatient weekly from d11 until disease progression 
was documented or other withdrawal criteria were met. A5B7 treatment could be repeated 
after d57 if no HAMA developed. In the absence of DLT, three patients were to be treated 
at each dose level. Adverse events were the primary endpoint.   
 
All patients were evaluable for safety.  Patients who received one cycle of combination 
treatment were evaluable for response. One cycle of combination treatment was defined as 
a single dose 
131I-A5B7 plus 3 doses of CA4P (first dose up to two weeks before 
131I-A5B7, 
second and third doses on d3 and 4 after 
131I-A5B7). Any patient not receiving this 
minimum number of infusions was replaced. Adverse events and other symptoms were 
graded according to the NCI Common Toxicity Criteria v2.0. A minimum time interval of 
four weeks had to elapse between the first patient being treated on a previous dose level 
and entry of a new patient at the next dose level, to take into consideration experience 
gained at the lower dose level. 
 
The study commenced recruitment in October 2003 and was set to continue for 24 
months. It was initially expected that the accrual rate would be 1-2 patients per month for a 
total of 30-40 patients to be recruited. 
 
Patient Selection 
Patients with histologically confirmed gastrointestinal adenocarcinoma not amenable to 
standard therapy or refractory to conventional therapy were eligible for this study.  Other 
eligibility criteria included a plasma CEA 10-1000 μg/L; disease measurable by RECIST 
criteria (Therasse et al., 2000); QTc interval ≤450ms and no evidence of cardiac arrhythmia Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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or ischaemia; disease assessable by DCE-MRI and no contraindication to MRI scanning; 
age ≥18 years; life expectancy ≥3 months; WHO performance status 0/1; adequate bone 
marrow function with neutrophils ≥1.5 x 10
9/L, haemoglobin ≥9g/dl, platelets ≥100 x 
10
9/L; adequate clotting with INR ≤1.3, normal plasma potassium and magnesium levels 
and EDTA creatinine clearance ≥50mls/min; adequate hepatic function with plasma 
bilirubin ≤ twice upper limit of normal (ULN), ALT or AST ≤ twice ULN (or 5x ULN in 
the presence of liver metastases). To be suitable for DCE-MRI the tumour had to be ≥2cm 
diameter and away from areas of major vascular pulsation such as the heart, mediastinum 
or aorta. 
 
Patients were excluded if they had a history of ischaemic heart disease, congestive heart 
failure or significant cardiac arrhythmia; uncontrolled hypertension (defined as BP 
consistently greater than 150/100 despite medication); ECG evidence of clinically 
significant pathology or QTc >450ms; taking any drug known to prolong the QTc interval;  
conditions associated with QTc prolongation; major thoracic or abdominal surgery in the 
preceding four weeks; symptomatic brain metastasis; autoimmune disorders, inflammatory 
bowel disease or ≥ grade 2 peripheral neuropathy; previous radical radiotherapy;  hepatitis 
B,C or HIV; positive HAMA; previous anti-cancer therapy within four weeks. 
 
Treatment Administration 
Unlabelled CA4P was supplied by OXiGene Inc to the CR-UK formulations unit where it 
was labelled and released. CA4P was supplied as a sterile lyophilized cake in amber glass 
vials containing 90mg of CA4P as free acid with 10% additional overfill. CA4P was stored 
in the dark to prevent conversion to the less active trans isomer. The drug was reconstituted 
with 10-11 ml sterile water (depending on the batch) for injection and further diluted with 
100-150 ml of normal saline, and was administered IV over 10 minutes protected from 
light. Particulate matter was removed by administration through a 5 micron line filter. 
 
 A5B7 was produced by the Biotherapeutics Development Unit of CR-UK, formulated in 
isotonic phosphate buffered saline and stored at 4°C. A fixed dose of 10mg A5B7 was 
radiolabelled with 
131I in the department of medical physics at the Royal Free Hospital 
using the N-bromosuccinamide method. The % iodine incorporation of the labelled 
product was measured by thin layer chromatography and the CEA binding by a CEA Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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column. A5B7 was administered within 4hrs via an indwelling central venous catheter in 
50ml 0.9% saline over 30-40 minutes using a syringe driver. 
 
Routine pre-medication was not mandatory prior to CA4P but if significant toxicity 
occurred with the first dose pre-medication with dexamethasone 8mg IV and 
metaclopramide 10mg IV was recommended prior to subsequent cycles. If systolic BP was 
>180 mmHg on two readings following CA4P glyceryl trinitrate  0.3mg  was given 
sublingually or amlodipine 10mg orally. No routine allergic prophylaxis was offered prior to 
A5B7; however hydrocortisone 100mg and chlorpheniramine 10mg IV were administered 
if clinically necessary. 
 
Potassium iodide 60mg three times daily for 8 days was commenced 48h before A5B7 to 
block thyroid 
131I uptake.  
 
The first CA4P dose was administered within 14 days of 
131I-A5B7 to assess DCE-MRI 
response. On Day 1, patients received 
131I-A5B7 infusion at the Royal Free Hospital. The 
patients were kept in protective isolation and appropriate radioprotection procedures were 
followed. CA4P was given on d3 and 4 as this timing has been shown to increase trapping 
of 
131I-A5B7 within tumours (B Pedley, Personal Communication 2005). The patient was 
sent home when radiation levels had fallen within acceptable limits. Weekly CA4P was then 
administered until disease progression or other withdrawal criteria were met. Treatment 
limits were for platelets to be above 50x10
9/L, and neutrophils above 0.5x10
9/L. If below 
these parameters, CA4P treatment was delayed until recovery.  
 
Patients were assessed by RECIST criteria for response on d29 and 57 (Therasse et al., 
2000). If the patient developed HAMA, repeat treatment would be with CA4P alone at 
weekly intervals. If the patient remained negative for HAMA, the combination treatment 
could be repeated.  Providing no DLT occurred in any of the three patients per cohort, 
doses were increased as shown in Table 2.1. If one DLT was seen three additional patients 
could be recruited to that dose level. If two out of three to six patients experienced DLT, 
three more patients would be treated at a lower dose level to define MTD. Patients were 
followed up for eight weeks after the last administration of study drug, or until all drug-
related toxicity had returned to baseline. 
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Table 2.1 – Dose Escalation Strategy 
Dose Cohort  CA4P Dose mg/m
2 * 
131I-A5B7 RIT Dose 
(MBq/m
2) 
1  45 (50) 
2 
1800 
3  2100 
4 
55 (60.5) 
2400 
A
1  54 (60) 
B
1  63 (70) 
1600 
*Figure in brackets is the salt dose (higher) with the actual free acid dose approximately 10% lower. 
1 – Dose cohorts A and B were subsequently introduced to replace cohorts 2 – 4 due to DLT (Grade 4 neutropenia) seen 
in two patients in dose cohort 1. Dose cohorts 2 – 4 were abandoned (see discussion). 
 
At the MTD, the trial was to consist of two stages: First, 14 evaluable patients would be 
entered. If there were no responses the trial would be terminated. If there were one or 
more responses in the first 14 patients, 11 additional patients would be added in the second 
stage. This scheme ensured that if the drug was active in 20% or more patients, the chance 
of erroneously rejecting the drug after the first 14 patients was 0.044 (80% power, α=0.05).  
 
Study Procedures and Observations 
Medical history, physical exam, performance status, ECG, chest X-ray, urinalysis, calculated 
creatinine clearance, pregnancy test (if appropriate), HAMA, haematology, biochemistry 
(renal,liver,glucose,clotting,thyroid,CEA,Ca19.9), baseline RECIST CT/MRI assessment 
(within 4 weeks of study), and PET scan (optional) were performed prior to study entry.  
 
Vital signs (heart rate, blood pressure, temperature) were obtained prior to administration 
of CA4P and at ½,1,2,3,4,5 and 6h. Vital signs monitoring was continued hourly if clinically 
indicated. Vital signs were also recorded prior to administration of 
131I-A5B7, at the end of 
the infusion, & at 1,2,3 and 4h after the infusion. Three pre-treatment ECGs were obtained 
at least 5 minutes apart before each infusion of CA4P, and post-CA4P at 1,2, and 4h. 
Following the 1
st four doses of CA4P an optional full blood count was also taken 4h post 
infusion. SPECT scans were performed 4h post 
131I-A5B7 and at 24,48,72 & 96 hours post 
infusion. Further assessments were as set out in Tables 2.2 and 2.3 
 
Pharmacokinetic Sampling 
CA4P pharmacokinetics was performed up to 14 days prior to A5B7 infusion prior to 
DCE-MRI scanning. Samples were taken immediately before completion of CA4P Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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infusion, and at 5, 30, 45, 60, 120 & 240 minutes after the end of infusion. Blood samples 
were kept on ice. Blood was centrifuged at 3000 rpm as soon as possible after collection at 
4
0C for 10-15 min, and not stored longer than 30 minutes at 4
0C. Following separation, 2 x 
500μl plasma aliquots were removed and stored at -70
0C.  
 
The fluorescence method of Stratford (Stratford & Dennis, 1999) was used. CA4P and 
CA4 levels were quantified by HPLC on a system from Waters comprising a 2695 
Separations module, 2996 photodiode array detector and W474 fluorescence detector. The 
resulting concentration/time data was analysed using a non-compartmental method, 
plotted by Stratford et al using Microcal ‘Origin’ software, and fitted using non-linear least 
squares regression analysis to determine the half-life.  
 
1ml 
131I-A5B7 blood PK samples were taken into an EDTA tube pre-administration, 5min 
after completion of the infusion, and at 4, 24, 48, 72 & 96h post infusion. Samples were 
kept in an approved radioactive storage area until they had decayed to appropriate levels 
for 
131I activity analysis. Radioactivity was measured using a Packard Cobra 11
th Series Auto 
gamma counter. The time of measurement was recorded and a decay correction applied as 
appropriate to calculate the percentage injected dose/kg blood at each time point. 
Antibody distribution and dosimetry was determined using SPECT analysis. Planar imaging 
was performed on an ADAC Vertex Plus Dual Headed gamma camera. Reconstruction of 
SPECT images was iterative with scatter and attenuation correction applied. ROI analysis 
was performed on tumour, liver, lung, spleen, blood/heart and kidney. This resulted in a 
calculation of decay corrected % injected dose of radioactivity/kg in each of these organs. 
 
Dose Limiting Toxicity 
DLT was defined as any of the following, considered probably or definitely related to 
therapy: QTc prolongation ≥500ms, >Grade 2 ventricular/supraventricular arrhythmia, 
grade 3/4 non-haematologic toxicity (except: alopecia grade 3, nausea grade 3/4, diarrhoea 
or vomiting (in patients who hadn’t received optimal anti-emetics or anti-diarrhoeals), 
grade 3 tumour pain, grade 3 hypertension (controlled by antihypertensives), neutrophils 
<500 cells/mm
3 for ≥5 consecutive days or febrile neutropenia with neutrophils <1000 
cells/mm
3, platelets <10,000 cells/mm
3 for >5 consecutive days or a bleeding episode 
requiring platelet transfusion, haemoglobin <8.0g/dl, grade ≥2 neurotoxicity. Non 
tolerated dose was defined as the dose when any of the above drug-related toxicities Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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occurred in 2 of up to 6 patients. MTD was defined as the highest dose level of CA4P 
administered with A5B7, at which one or fewer patients experienced DLT.  
 
End-of-Study Assessments 
To ensure that adverse events had resolved, the following were performed at least 30 days 
after the final dose of study drug: Performance status; physical examination; weight; vital 
signs; full blood count; biochemical profile; urinalysis; ECG; adverse event analysis. C
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Results 
 
Between January 2004 and April 2007, 88 patients were screened and twelve enrolled. 
Reasons for screening failure included patient unsuitable for DCE-MRI (19), patient refusal 
(11), CEA negative or >1000 (9), WHO PS>1 (9), no RECIST assessable disease (5), 
cardiac ischaemia or arrhythmia (5), previous radical radiotherapy (4), abnormal 
biochemistry (4), and other reasons (10). 
 
Mean age was 63 (range 32–77). There were 7 males and 5 females. Eleven patients had 
metastatic colorectal adenocarcinoma, and one metastatic pancreatic adenocarcinoma. 
Performance status was WHO 0 (6) and 1 (6). Results are presented primarily for patients 
1–7, recruited during my time as clinical research fellow, although I have included data for 
subsequent patients where available. Tables 2.4, 2.5 and 2.6 illustrate the demographics, 
underlying diagnosis and previous treatment of the patients. 
 
Recruitment 
Recruitment initially proceeded as anticipated. However, following two cases of grade 4 
neutropenia in the first six-patient cohort (1800MBq/m
2 A5B7, 45mg/m
2 CA4P), the study 
was suspended as a major protocol amendment was required to reduce the A5B7 dose to 
1600MBq/m
2. The CA4P dose was escalated to 54mg/m
2 as it was felt the 
myelosuppression seen was due to 
131I-A5B7 in a group of heavily pre-treated patients. In 
addition CA4P at 45mg/m
2 was felt to be below the threshold to see any significant 
vascular effect (Galbraith et al., 2003). The amendments were approved by CR-UK, main 
Research ethics Committee and the MHRA, but resulted in significant delays to patient 
accrual. Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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Table 2.4 – Patient Diagnosis & Recruitment 
Patient 
ID 
Age / 
Sex 
Histology at Diagnosis & 
Sites of Metastases at 
Study Entry 
Previous Cancer Treatment 
01  59F 
Adenocarcinoma 
rectum,local recurrence,liver 
mets,ascites 
Pelvic chemoradiation to 36 Gy for local recurrence (stopped due to 
toxicity) with concomitant 5FU/Mitomycin C .Liver mets 06/03 6 
cycles FOLFOX(PD) 
02  72F 
Adenocarcinoma of 
caecum,liver, 
lung,bone,(brain) mets 
FOLFOX x 6 12/01, FOLFIRI  12 cycles 4/02,RFA Liver 
10/02,ADEPT 4/03,RFA Liver 7/03,RFA Lung & Liver 10/03,RT Rt 
hip & T/Spine 12/03 
03  57F  Adenocarcinoma sigmoid 
colon,liver mets  Irinotecan/5FU 5 cycles 6/03 , Oxaliplatin/5FU 4 cycles 9/03 
04  65M  Adenocarcinoma sigmoid 
colon,liver,lung mets  Weekly 5FU/FA x 30 (11/01)  Irinotecan x 5 (10/02) ,ADEPT (6/03) 
05  70M  Adenocarcinoma ascending 
colon,liver mets  FOLFOX x 5 PD 
06  32F 
Adenocarcinoma of caecum, 
peritoneal,para-aortic,Iliac 
nodes 
De Gramont x 12 (1/03), Completion panproctocolectomy -  
Laparotomy (open & shut - carcinomatosis) 9/2003, Oxaliplatin + de 
Gramont x 9 (10/03) 
07  72M  Adenocarcinoma of 
rectum,liver,lung mets 
Weekly 5FU/FA x 24 (11/03) Liver resection 7/04 ,Oxaliplatin + 5FU 
4 cycles 12/04 
08  77M  Rectal adenocarcinoma with 
liver & lung metastases 
Pelvic chemoradiation 45Gy +Capecitabine (01/05), weekly 5FU x 
26 (06/05) 
09  66F 
Adenocarcinoma of 
pancreas with liver 
metastases 
Gemcitabine x 6 (08/05) 
10  61M  Rectal adenocarcinoma with 
liver metastases 
Rectal RT (05/97), 5FU/FA x 6 (NK/97), Oxaliplatin/5FU x 8 (03/00), 
Liver resection (11/01), Rectal RT (05/04), Irinotecan/5FU x 6 
(07/04), Irinotecan x 8 (06/05)& x 4 (03/06), Cetuximab x 8 (06/05) & 
x 4 (03/06) 
11  58M  Colorectal adenocarcinoma 
with liver & lung metastases 
Sigmoid colectomy (07/05), FOLFOX x 8 (11/05), FOLFIRI x 4 
(08/06) 
12  63M 
Rectal  adenocarcinoma with 
adrenal and bone 
metastases 
Liver resection + 5FU/FA pre & post resection (NK/00), 
Irinotecan/Capecitabine (NK/02), Oxaliplatin/Capecitabine (07/05), 
IMRT to para-aortics (NK/05) 
RFA = Radiofrequency ablation, FOLFOX = Oxaliplatin with the de Gramont infusional & bolus 5FU/Folinic Acid 
regimen, FOLFIRI = Irinotecan with the de Gramont infusional & bolus 5FU/Folinic Acid regimen, ADEPT = 
Antibody Dependent Enzyme Prodrug Therapy Phase I Study. N/A – Data for patients 08 – 12 not available from 
central database at time of writing 
 
Further significant delays to accrual occurred with the introduction of the European Union 
Clinical Trials Directive (2004). As the A5B7 radiolabelling was considered an on-site 
manufacturing process, an application for an Investigational Medicinal Product (IMP) 
license from the MHRA had to be processed. During this time a new radiopharmacist was 
recruited and trained at the Royal Free Hospital. Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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Table 2.5 – Amount Of Trial Drug Received & Reason Patients Removed From Study 
Patient 
ID 
Dose 
Cohort 
Number  
of A5B7 
Infusions 
Received 
Number of 
CA4P 
Infusions 
Received 
A5B7 
Activity 
(MBq/m2) 
Dose of 
CA4P 
(mg/m2) 
Day 
Withdrawn 
From Study 
Reason Patient 
Withdrawn From 
Study 
01  1  4  18 
PD Liver & ascites. 
Haematuria. DLT 
Grade 4 Neutropenia 
02  1  5  25  New brain/lung mets. 
SD liver 
03  1  4  18  PD Liver.concern over 
ECG ischaemia 
04  2**  16  95  PD Liver 
05  1  6  29  PD Liver 
06 
1* 
1  10 
1800  45 
57  PD Peritoneal mass. 
DLT G4 neutropenia 
07  1  3  11 
SAE ataxia & 
hypotension. Hickman 
line sepsis 
08  1  8  46  Progressive disease. 
DLT G4 neutropenia 
09  1  3 
1600 
4  Cardiac Ischaemia & 
hypertension. PD. 
10  0  1  -  1  Not evaluable. 
Consent withdrawn 
11  1  5  29  PD liver 
12 
A* 
1  7 
1600 
54 
32  PD – New brain mets 
DLT – G4 neutropenia 
*Dose cohorts explained in Table 2.1  
**2nd A5B7 Infusion only received if HAMA negative by ELISA at Day 53 assessment.   
PD = Progressive disease by RECIST criteria, SD = Stable disease, SAE = Serious Adverse Event, DLT = Dose Limiting 
Toxicity 
 
Toxicity 
The following Table 2.6 illustrates the drug related toxicity seen. Other than 
myelosuppression, toxicity was manageable. The majority of SAE’s were not drug related. 
Myelosuppression did not result in excess morbidity because the gastrointestinal mucosa 
was intact. This is a feature of the haematological toxicity associated with RIT. 
Conventional systemic therapy can lead to septicaemia when myelosuppressed if there is 
gastrointestinal mucositis. The grade 4 neutropenia seen in patient 01 meant cohort 1 was 
expanded to six patients. However the occurrence of a second case necessitated the revised 
dose levels A&B (Table 2.1). Two further cases of grade 4 neutropenia occurred in cohort 
A. It was felt that reducing the dose of A5B7 and/or CA4P further would be unlikely to 
result in an active combination, and the trial was terminated early. Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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Table 2.6 – Drug Related Toxicity patients 1 - 6 
A5B7/CA4P Related (No. Episodes) 
System  CTC Toxicity Criteria 
Grade 1  Grade 2  Grade 3  Grade 4 
Anaemia  3  5  0  0 
Leucopenia  2  0  2  2 
Lymphopenia  1  5       3  0 
Neutropenia  0  3  0  2 
Blood / Bone Marrow 
Thrombocytopenia  4  0  3  0 
Hypermagnesaemia  0  0      0  0 
Hypomagnesaemia  1  0  0  0 
Hypoalbuminaemia  3  0  0  0 
Metabolic 
Hyperkalaemia  1  0  0  0 
High APTT  1  0  0  0  Coagulation 
High Prothrombin time  1  0  0  0 
ECG Changes  1  0  0       0 
QTc Prolongation (normal 
Range)  1  0       0  0 
Sinus Tachycardia  10  0  0  0 
Sinus Bradycardia  4  0  0  0 
Hypertension  14  1  0  0 
Cardiovascular 
Hypotension  4  0  0  0 
Fever  11  0  0  0 
Rigors  4  0  0  0 
Sweating  5  0  0  0 
Constitutional Symptoms 
Fatigue  1  2  0  0 
Dermatology  Pruritis  6  0  0  0 
Low TSH  1  0  0  0  Endocrine 
Hypothyroidism  1  0  0  0 
Nausea  3  0  0  0 
Vomiting  1  0  0  0 
Diarrhoea  3  0  0  0 
Stomatitis  1  0  0  0 
Constipation  1  0  0  0 
Anorexia  0  1  0  0 
Gastrointestinal 
Taste Disturbance  1  0  0  0 
Hepatic  Hepatomegaly  1  0  0  0 
Neurology  Sensory Peripheral Neuropathy  1  0  0  0 
Tumour Pain  4  2  0  0 
Liver Pain (Tumour)  4  1  0  0 
Hip Pain  0  1  0  0 
Abdo Pain  0  1  0  0 
Pelvic Pain  1  0  0  0 
Chest Pain (muscular)  1  0  0  0 
Pain 
Headache  1  0  0  0 
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Vital Signs 
Temperature 
The following Figures 2.1–2.4, illustrate changes in vital signs following A5B7 or CA4P. 
Pyrexia following infusion was common, in 4/7 patients, as high as 39°C. Two patients felt 
unwell with rigors. This phenomenon was felt to be a hypersensitivity immune reaction to 
the foreign antibody, and has been seen with other non-humanised & partially humanised 
monoclonal antibody biological therapies e.g. Rituximab, Trastuzumab, Cetuximab (Lenz, 
2007). Very modest rises in core temperature were also seen following CA4P. 
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Figures 2.1 (above) & 2.2 (below) 
Core Temperature Following A5B7 and CA4P Infusion (n=7 patients, 1800MBq/m2 A5B7 and 45 
mg/m2 CA4P in the first 6).  Mean ± Standard Error
Temperature at 
2hrs significantly 
higher than 
baseline 2p=0.011 
Paired T-Test 
48 Infusions in 7 
Patients. Significant rise 
at 4 hours from baseline 
2p=0.0093 Paired T-test Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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Blood Pressure 
Changes seen in HR/BP following A5B7 probably relate to the infusion reaction. BP 
change at 3h from baseline is significant 2p=0.011. The changes following CA4P are as 
previously described by Rustin (Rustin et al., 2003). A BP rise is seen because of 
alterations in peripheral resistance with a compensatory increase in HR at 4 hours. For 
CA4P HR at 3h against baseline, and BP at 1h against baseline, highly significant rises 
seen 2p<0.0001 
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Figures 2.3 & 2.4 
Heart Rate & BP  Following A5B7 or CA4P Infusion (n=7 patients) Mean ± Standard Error Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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ECG Changes 
QTc prolongation within the normal range has previously been described following CA4P 
infusion and is presented below for this study in Figure 2.5. There is significant QTc 
prolongation at 4h by 11ms (2p=0.0016). The aetiology is reviewed in Chapter 1 and also 
see UKCTC-207 Study (Chapter 6).  
 
Figure 2.5 - QTc Interval Following CA4P Infusion (n=7 patients) Mean ± Standard Error 
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Haematological Toxicity 
This is illustrated in Figures 2.6–2.7. Significant falls in neutrophil counts were seen 32 
days following A5B7 (2p=0.036). The significant rise in neutrophil count 4h following 
CA4P (2p=0.016) (Figure 2.8) is likely to be an inflammatory response to the vascular 
endothelial assault. This rise was also documented in the UK Phase I study of CA4P and is 
resolved by 24h (Rustin et al., 2003). In the Rustin study, significant falls in lymphocytes 
were also seen 4h after CA4P administration. Our result (Figure 2.9), which included only 
the first seven patients, did not achieve statistical significance (2p=0.18). Figures 2.10–2.11 
illustrate the thrombocytopenia and neutropenia seen in patient 06. 
At 4 hours, significant 
change in QTc from 
baseline 2p=0.0016 Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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Figures  2.6 & 2.7 – Thrombocytopenia & Myelosuppression following A5B7 Infusion (n=7). 1800MBq/m2 
A5B7 administered on day 1 in first 6 patients, 1600MBq/m2 patient 7. Mean ± Standard Error 
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Figure 2.8 - Neutrophil Count  4 hours Following CA4P Infusion (n=7) 
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Figure 2.9 - Lymphocyte Count  4 hours Following CA4P Infusion (n=7). Mean ± SE 
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2p=0.18
2p=0.016 Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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Figures 2.10 – 2.11 – Patient 6, WBC and platelets Following A5B7. Data chosen to illustrate delayed and dose-
limiting grade 4 neutropenia and grade 3 thrombocytopenia lasting for a week following 1800MBq/m2 A5B7. Growth 
factors were not administered. Recovery was uncomplicated without pyrexia. CA4P was witheld until recovery. Arrow 
indicates drug infusion. 
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Tumour Markers 
Figures 2.12 & 2.13 – Serum CEA & Ca19.9 Following Combination Treatment - Tracking of patient tumour 
markers throughout study. A minor response was seen in patient 06 
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ECG Changes 
 
Patient 03 was removed from the study on safety grounds on March 19
th 2004 following 
ECG changes, which were deemed ‘possibly related’ to CA4P. The history of events is 
illustrated in figures 2.14 a-g. The pre-study screening ECG A showed no evidence of T-
wave inversion. There was left ventricular hypertrophy by voltage criteria present in leads 
v4 to v6 (red arrow); however this was entirely consistent with known longstanding 
hypertension, which was well controlled. There was no evidence of significant ischaemic 
heart disease, which would exclude her from the study. ECG B, d3 Pre-CA4P illustrates 
anterior T-wave inversion in leads v2 and v3. The patient was completely asymptomatic. 
This ECG was reviewed by a cardiologist prior to CA4P, who confirmed a degree of 
undiagnosed coronary artery disease; this was not felt significant enough to warrant further 
immediate investigation. The infusion proceeded without incident although the patient was 
hypertensive. Two hours post CA4P (ECG C), the ischaemic ECG changes had resolved. 
Four hours post CA4P (ECG D) T wave inversion had reappeared in v2 (arrow), but not 
V3, without patient symptoms.  
 
On day 11, baseline ECG E shows T wave inversion present in the anterior leads. A repeat 
ECG (not shown) had normal T-waves, so CA4P was administered. One hour after CA4P 
(ECG F)  T wave inversion was again present in anterior leads. The patient was 
asymptomatic, and cardiac enzymes (CPK and Troponin C) were negative for an acute 
cardiac event. Because of the poor prognosis from her underlying metastatic cancer, it was 
felt inappropriate to proceed with further investigation. The patient was withdrawn from 
the study for her own safety. Six hours post CA4P (ECG G) T-wave inversion was still 
present. Although the T-wave inversion appeared intermittent and random, it could not be 
excluded that CA4P exacerbated the changes. Following these episodes, a protocol 
amendment was passed to allow prophylactic antihypertensive treatment for patients 
experiencing grade 2 rises in BP following CA4P 
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Figure 2.14 A – G 
– ECG Changes 
In Patient 03 
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Response Assessment 
 
In the eleven patients who received A5B7 and CA4P there was one case of stable disease 
(patient 04) and one minor response seen in patient 06 at d29, best overall RECIST SD. A 
pelvic node reduced in size by >50% however other marker lesions were of similar size 
(figure 2.15). These responses were short lived and a total of ten patients were withdrawn 
from the study due to progressive disease. 
 
 
Figure 2.15a,b- Patient 06 
Pre-Study & Day 29 CT 
Scan 
 
Following A5B7 and six CA4P 
infusions a response was seen 
in this target lesion (an 
enlarged pelvic lymph node), 
however the overall RECIST 
response was stable disease. Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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Pharmacokinetics 
 
The pharmacokinetic data was analysed by Dr Mike Stratford at the Gray Cancer Institute 
and is summarised in Table 2.7.  
Table 2.7 – Summary Pharmacokinetic Data (Courtesy of Dr M Stratford) The pharmacokinetic parameters 
determined for CA4P included the maximum observed plasma concentration (Cmax), the area under the plasma 
concentration time curve (AUC), initial and terminal elimination half-life (T½), mean residence time (MRT), clearance 
(CL), and steady-state volume of distribution (Vss).  For CA4, Cmax, AUC and T½ were determined, and in addition, time 
to reach Cmax (Tmax). 
patient 
CA4P 
dose 
mg/m2 
Infusion 
time 
(h) 
CA4Pmax* 
(µM) 
CA4P 
AUC 
µmol.h.l-1 
clearance 
l.h-1.m2 
AUMC 
µmol.h2.l-1 
MRT 
(h) 
Vdss 
l.m2 
CA4max 
µM 
Tmax 
h 
CA4 AUC 
µmol.h.l-1 
01  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
02  23.8  10.1  11.3  3.05  0.217  2.44  2.13  0.27  2.51 
03  13.1  4.34  26.2  0.885  0.119  3.11  2.81  0.23  1.75 
04  22.1  6.74  16.9  1.58  0.151  2.54  1.63  0.25  2.15 
05  27.9  7.02  16.2  1.72  0.160  2.59  1.73  0.25  1.96 
06  27.8  7.88  14.4  2.11  0.183  2.64  5.41  0.27  4.04 
Mean  22.9  7.22  17.0  1.87  0.166  2.67  2.74  0.25  2.48 
Std dev 
45  0.17 
6.05  2.08  5.58  0.79  0.037  0.26  1.56  0.02  0.91 
 
07  0.30  28.9  8.91  15.3  3.35  0.226  3.46  1.39  0.35  2.04 
08  30.6  8.89  15.3  2.49  0.195  2.99  4.11  0.30  3.10 
09  31.8  7.97  17.1  1.85  0.147  2.52  2.97  0.27  4.14 
10  35.3  8.43  16.2  1.89  0.139  2.25  4.23  0.20  2.67 
11  28.9  8.09  16.9  2.09  0.173  2.92  4.70  0.18  4.65 
12  30.5  10.4  13.1  3.88  0.288  3.78  1.28  0.17  1.39 
Mean  31.0  8.78  15.6  2.59  0.195  2.99  3.11  0.25  3.00 
Std dev 
54 
0.17 
2.4  0.88  1.45  0.84  0.056  0.57  1.49  0.07  1.24 
* - peak CA4P concentration extrapolated from fit back to end of infusion if sample not taken then 
PK parameters for patient #1 not calculated due to contamination of the immediate post-infusion sample with dosing solution 
 
Figures 2.16a,b  – CA4P Clearance - Patients 04 & 06 (Courtesy of Dr M Stratford, Gray Cancer Institute) 
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CA4P pharmacokinetics were in agreement with previous data (Rustin et al., 2003). Data 
for 01 was omitted from the analysis as the sample immediately after CA4P infusion was 
taken from the same intravenous line as the drug, giving an artificially high reading; It is not 
possible to fit the CA4P data to either a monophasic or biphasic model without the end of 
infusion time point, because it is so rapidly cleared. Clearance curves are presented for 
patient 04 and 06 (Figure 2.16 a,b).  
 
CA4P is rapidly hydrolysed by plasma and tissue esterases to the active CA4, with a mean 
initial half-life of 5 min.  In all cases, the maximum plasma CA4P was observed in the first 
sample taken post-start of infusion.  There were no significant differences in T½, Cl or Vss 
between the two doses used, with terminal T½ at the lower and higher doses of 0.36 ± 0.22 
h and 0.45 ± 0.15 h, clearance 29.4 ± 7.21 L.h
-1 and 25.7 ± 13.5 L.h
-1, and Vss 4.69 ± 0.67 
L and 4.71 ± 2.59 L respectively.  As expected, there was an increase in the AUC of the 
parent CA4P (22 %) and active CA4 (21 %) at the higher dose consistent with the 20 % 
higher dose used.  The rapid activation to CA4 was reflected in the time to reach peak CA4 
concentration; in the majority of cases, this occurred in the first post-end of infusion 
sample, although in four patients, the highest level was seen at the same time as the peak 
CA4P, immediately at the end of the infusion.  This included Patient 07 who received the 
longer 18 min infusion. CA4 was cleared from plasma with a half-life of 2.24 ± 1.19 h and 
1.92 ± 0.69 h at the lower and higher doses of CA4P respectively.   
 
SPECT imaging also confirmed no delayed excretion of radioisotope as a result of CA4P 
infusion. Excretion half life was 26 hrs. SPECT graphs and analysis (Figures 2.17–2.20) 
are included courtesy of Dr J Violet (University of London). C
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Figure 2.19 a – g - SPECT Analysis 
A5B7 Organ Antibody Biodistributions. Blood clearance 
faster due to absorption into tissues. Note patient 3 – renal 
excretion delayed. Clearances as expected, with no extended 
antibody retention. No evidence of radioantibody trapping 
within tumour by CA4P 
 
Heart  A0 = 4.507 T1/2 = 36.470 Lung A0 = 1.743 T1/2 = 31.484 
Liver A0 = 4.865 T1/2 = 20.020 Spleen A0 = 3.766, T1/2 = 
44.750 Kidney A0 = 3.767, T1/2 = 44.750 Blood  A0 = 
15.865, T1/2 = 15.479 Whole Body Effective A0 = 1.02, 
effective t1/2 = 26.86 , Residence time = 39.51 MBq.hr 
Courtesy of Dr John Violet, University of London Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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Figure 2.20 A5B7 Tissue & Tumour Dosimetry. The normal tissue and tumour dose is presented as the decay 
corrected % injected dose of radioactivity/kg for 12 131I-A5B7 administrations in 11 patients (Patient 4 
received 2 doses, patient 10 withdrew from study before A5B7). In all normal tissues there was a progressive 
fall in dose at each time point but in the tumour there is evidence of retention of radiation up to the final time 
point consistent with selective targeting. 
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Discussion 
 
The combination of CA4P at 54mg/m
2 with A5B7 at 1600MBq/m
2 is safe, but with dose 
limiting myelosuppression, and shows little indication of activity so far in heavily pretreated 
patients with gastrointestinal cancer (Gaya AM et al,2008). The absence of gastrointestinal 
mucositis (a feature of RIT associated myelosuppression) results in a significantly lower 
rate of sepsis following neutropenia. In Lane’s study (Lane et al., 1994) the haematological 
toxicity seen was manageable. We calculated the starting A5B7 radiation activity of 
1800MBq/m
2 25% below Lane’s MTD. In previous studies of A5B7, thrombocytopenia 
has been dose limiting, either in single or repeated dose trials (Ledermann JA, 1991). The 
bone marrow suppression is most likely caused by perfusion of marrow by blood 
containing radiolabelled antibody, and by gamma emissions from isotope residing in 
neighbouring organs. 
 
In 1994, 5-Fluorouracil was the only effective chemotherapeutic agent for metastatic 
colorectal cancer, given less intensively than today’s combination treatment, so patients 
recruited had greater bone marrow reserve. Most of our patients had received intensive 
multiple combination chemotherapy regimens or pelvic radiotherapy (Table 2.4) which 
may explain the increased haematological toxicity. However, patients experiencing grade 4 
neutropenia had not been more heavily pre-treated. 
 
There may have been interactions between CA4P and A5B7 which caused profound 
myelosuppression. CA4P can delay renal clearance of drugs due to reduced renal blood 
flow following infusion, however this is short lived. In a study by Bilenker (Bilenker JH 
2003) CA4P was given immediately prior to carboplatin chemotherapy leading to delayed 
renal excretion and dose limiting thrombocytopenia at what would otherwise have been a 
safe dose of carboplatin. In this study we administered CA4P 48h following A5B7; SPECT 
analysis showed uptake of A5B7 was predominantly localised to tumour and that excretion 
was not delayed by CA4P.  
 
A Phase I/II study of RIT with 
131I-A5B7 was performed at the Royal Free Hospital in 
patients with CEA expressing metastatic colorectal carcinoma (Lane et al., 1994). Ten 
patients received RIT with 
131I-A5B7. Cyclosporin was administered to prevent the 
formation of HAMA and to allow repeated therapy. The maximum tolerated dose was 
established at 2400MBq/m
2 with dose limiting toxicity of thrombocytopenia and Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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neutropenia. Clinical responses were seen in 10% of patients. Cyclosporin was thought to 
be responsible for the other toxicities experienced, including nausea, vomiting and mild 
abnormalities in liver and renal function tests (Ledermann JA, 1991). The mean half lives 
for tumour & blood clearance of A5B7 were 59.5 & 28.6 hours respectively, which agree 
with our data. Localisation of the radiolabelled antibody to tumour was demonstrated by 
quantitative gamma camera imaging. One partial response was seen in a patient with a lung 
metastasis. 
 
If small volume solid tumours are treated with RIT then higher response rates than those 
reported by Lane are seen. A Phase I/II study of patients with colorectal cancer with total 
tumour bulk ≤2.5cm produced a complete or partial response rate of 26% with an 
additional 39% patients having stabilisation of previously rapidly progressing disease for up 
to 18 months (Behr et al., 1999a; Behr et al., 1999b). These data suggest that, particularly in 
small volume disease, which has relatively little hypovascular component, RIT, alone, may 
be as effective as current conventional chemotherapy, with the advantage of often having 
fewer side-effects. 
 
Blood pressure control was felt to be central to managing the cardiovascular effects of 
CA4P after the experience with patient 03. Patients with baseline hypertension were more 
prone to cardiovascular fluctuation, probably as a result of damaged vascular endothelium 
(Chapter 6). Aggressive hypertension management has prevented any further cardiac 
toxicity to date. Patient 07 experienced ataxia, a known neurological DLT of CA4P, and 
dose cohort A was therefore expanded to six patients. Premedication with dexamethasone 
before CA4P may reduce the risk of neurological DLT in addition to hypertension and 
allow higher CA4P doses to be administered (G Rustin, Personal Communication 2007). 
Whether this will reduce the effectiveness of the drug is not known. Other common 
toxicities of A5B7 (infusion reaction, pyrexia) and CA4P (tumour pain, fatigue, pruritis, 
nausea, QTc prolongation) were short lived, manageable and as previously documented 
(Gaya & Rustin, 2005). 
 
The CA4P dose in the Phase I preclinical A5B7 study was 200 mg.kg
-1 (Pedley et al., 2001). 
The equivalent dose in humans can be estimated using either a conversion factor (Chodera 
& Feller, 1978) or comparison of pharmacokinetic data such as AUC for the active 
metabolite CA4 (Rustin et al., 2003). Either way, the human equivalent dose is ten times 
the mouse MTD of CA4P (Rustin et al., 2003). Clearly this dose could not be safely Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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administered to humans and results from the differing mammalian physiologies and 
intraperitoneal administration. 
 
Indirect evidence that a clinically relevant dose of CA4P should be effective in combination 
with A5B7 comes from a comparison of the effect of three dose levels on tumour antibody 
retention (Lankester K 2004). SW1222 tumour-bearing mice received a dose of A5B7 and 
then either 30,100, or 200 mg.kg
-1 intraperitoneal CA4P 48 hours later, or no further 
treatment in the control group. All three doses significantly increased antibody retention in 
tumour (increases of 71%,78% and 90% against control for 30,100 and 200 mg.kg
-1 
respectively) but not in normal tissues (Lankester, 2005; Lankester et al., 2007) and RB 
Pedley, Personal Communication 2004. The percentage increases were not significantly 
different between the three treatment groups. Although 30mg.kg
-1 CA4P produced only a 
transient decrease in tumour vascular function it still increased radioantibody retention in 
tumour significantly. This dose however is more clinically relevant for human study. 
Exactly why this occurs is not known, but possibly some vessels are permanently destroyed 
by CA4P so antibody has less chance of escaping from tumour. 
 
Pre-clinical efficacy studies of the combination of 
131I-A5B7 and CA4P were performed in 
a xenograft model, using the SW1222 human colon adenocarcinoma implanted in the 
flanks of nude mice. 
131I-A5B7 was administered IV at a dose of 7.4MBq (40μg antibody). 
200mg/kg of CA4P was given intraperitoneally 48h after radiolabelled antibody. 5/6 mice 
(85%) that received the combination showed complete tumour eradication that continued 
to be sustained until the experiment was terminated after 9 months (Pedley et al., 2001). 
No viable tumour cells were subsequently found at the implantation site of the cured mice. 
The only tumour to regrow did so after 97 days. CA4P alone when administered to the 
mice had no effect on tumour growth compared to the controls, and 
131I-A5B7 alone 
produced tumour growth inhibition of approximately 35 days, but all tumours subsequently 
regrew (Pedley et al., 2001). 
 
Following a meeting with the sponsor CR-UK in June 2007 the trial was suspended by 
consensus agreement. DLT had been reached at the first and a subsequently revised dose 
level. It was agreed that the treatment was tolerable with hints of activity, and that the DLT 
definition may need revision.  It was also proposed to omit DCE-MRI from subsequent 
patients to increase accrual rate as proof of mechanism had been documented. A proposal 
was put forward to treat a total of 14 patients at dose level A as per the protocol (including 
five already recruited at dose level A). Due to the ataxia seen at 54mg/m
2 CA4P the Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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sponsor felt this dose was too high, despite data showing it to be safe and well tolerated in 
over 100 patients in other studies. Dexamethasone pre-medication has also been shown to 
reduce the incidence of ataxia and other neurological side effects of CA4P (G Rustin, 
personal communication, 2007). It was felt a CA4P dose lower than this was unlikely to be 
clinically active and a decision was made by the sponsor and chief investigators to close the 
study. 
 
The A5B7/CA4P combination may be optimised further and explored as more effective 
and less toxic therapy with certain refinements. A humanized form of the antibody, 
allowing repeated smaller doses (<1600MBq/m
2), could be used in less heavily pretreated 
patients with smaller metastases which would maximize the 
131I call kill. The performance 
of our radioantibody, as illustrated in figure 2.20, was variable. There are theoretical 
dosimetric advantages to using 
90Yttrium labeled antibody, including stronger binding, 
which may enhance the effectiveness of the combination. Combining the RIT with an 
alternative VDA such as OXi4503, ten times more potent, may also improve the 
therapeutic ratio. Our patient population was relatively frail and heavily pretreated. The 
combination may have a greater chance of success in 1
st line metastatic  colorectal cancer.  
 
Conclusions (Gaya et al., 2008) 
1)  The combination of CA4P at 54mg/m
2 with A5B7 at 1600MBq/m
2 has dose 
limiting myelosuppression in the absence of gastrointestinal mucositis in this 
patient cohort.. 
2)  The cardiovascular effects of CA4P can be controlled by careful patient selection 
and aggressive management of hypertension. 
3)    The combination shows little activity in heavily pretreated patients with 
gastrointestinal cancer. Out of twelve patients, one short lived case of stable disease 
and a minor response was seen. 
4)  Toxicity was manageable. Most SAE’s were not drug related, and there were no 
unexpected or new toxicities with the combination therapy.  
5)  Pharmacokinetic and SPECT studies of CA4P and A5B7 are similar to previous 
single agent studies, and confirm no evidence of antibody retention at these doses.  
6)  There is no evidence of A5B7 trapping within tumour.  
7)  DCE-MRI confirmed CA4P vascular shutdown in patients at 45 and 54 mg/m
2 
(Chapter 3). Chapter 2 – A5B7 Trial, CA4P + 131I-Anti-CEA Antibody 
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8)  MTD was not determined due to closure of the study following dose limiting 
myelosuppression. 
9)  The dose for further study would currently be 1600MBq/m
2 A5B7 and 54mg/m
2 
CA4P. 
10)  Due to limitations in the design of the study it is not certain that the objectives 
have definitely been met, hence the suggestions for further study. Alternative study 
designs have been discussed. 
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Chapter 3 
Variability of DCE-MRI Response Between Patients and Between 
Lesions Following Infusion of CA4P 
 
 
 
 
Abstract 
Tumour blood flow is reduced after treatment with CA4P. We evaluated the 
heterogeneity of blood flow related DCE-MRI parameters between different patients and 
in lesions within patients. DCE-MRI measurements were performed before and four 
hours following CA4P alone on 12 patients in the A5B7 study. Measurement errors were 
estimated for patients (n=12) and their lesions (n=30), and changes in vascular kinetic 
variables after CA4P were documented. Statistically significant falls in tumour K
trans 
values were seen (mean -25.1%; range +63.5 to -100%; paired t-test 0.011). At baseline 
there was greater variability in K
trans between-patients compared to between-
tumours[within-patients] (ratio 1.93). The variability in K
trans changes induced by CA4P 
was also greater between-patients than between-tumours[within-patients] (ratio 2.37). In 
conclusion, metastatic lesions within-patients are more similar compared to between-
patients in DCE-MRI kinetic parameters both at baseline and in their response to CA4P. 
There were greater reductions in kinetic parameters at 54mg/m
2 CA4P versus 45mg/m
2 
consistent with a threshold dose effect.  
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Introduction 
T1-weighted DCE-MRI has been used to investigate the acute effects of CA4P in phase I 
studies which use change in kinetic variables as biomarkers for the anti-vascular effects 
of CA4P (Dowlati et al.,2002; Galbraith et al.,2003; Stevenson et al.,2003). DCE-MRI 
studies have also been used to evaluate antiangiogenic drugs (O'Connor et al., 2007). 
DCE-MRI studies can define the biologically active dose and predict the efficacy of 
treatment on the basis of changes observed (Dowlati et al.,2002; Galbraith et al.,2003; 
Padhani,2003; Stevenson et al.,2003). Without exception, in all prior DCE-MRI phase I 
studies, single lesions were chosen for analysis on the implicit assumption that responses 
of chosen lesions would be representative of responses in all lesions within the same 
patient. Between-patient and intratumoural heterogeneity in DCE-MRI responses to 
CA4P are documented in these studies but the assumption of similarity at baseline and of 
responses of lesions within individual patients has not been formally investigated. 
 
Methods 
 
Patients and Therapy 
Following ethics board approval we performed DCE-MRI scans on 12 patients taking 
part in a CR-UK sponsored Phase I trial of CA4P in combination with 
131I (A5B7) anti-
CEA antibody in advanced gastrointestinal cancer (Study PH1/092 – Chapter 2). All 
patients gave written informed consent. 
 
MRI procedures 
MRI was performed on a 1.5 tesla Magnetom Symphony scanner (Siemens Medical 
Systems, Erlangen, Germany), using body coils. Scans were performed 48h (R1) and 24h 
(R2) before infusion of CA4P to obtain repeatability data, and a third scan 4h following 
CA4P (Rx1) to assess anti-vascular effects. At the start of each procedure T1 and T2-
weighted anatomical images were performed in two orthogonal planes to select three 
suitable contiguous slices through the centre(s) of tumour(s). An experienced 
radiographer used bony landmarks and images from previous examinations to minimize 
positioning errors from day to day. 
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1) MRI data acquisition 
1. Proton density-weighted (PD) images were acquired in the chosen plane and used with 
subsequent T1-weighted images to calculate T1-relaxation rates in the dynamic series. 
Parameters for the PD spoiled gradient-recalled echo (GRE) FLASH sequence were: 
FOV 350*350 mm, acquisition matrix 256*154 pixels reconstructed to 256
2, slice 
thickness 8mm, number of slices 3, TR 350ms, TE 4.76ms, α 20°, TA 4.29s, 5 signal 
averages, total time 21.5s. 
 
2. The dynamic series consisted of 40 navigator-guided T1-weighted GRE FLASH 
images. Parameters were: FOV 350*350 mm, acquisition matrix 256*154 pixels 
reconstructed to 256
2, slice thickness 8mm, number of slices 3 acquired sequentially, TR 
43ms, TE 4.76ms, α 50°, TA (one scan) 6s with 5s for breathing. Gadopentetate 
dimeglumine (Gd-DTPA, Magnevist®, Bayer-Schering Pharma, Newbury, UK) was the 
contrast agent used, injected intravenously using an automatic power injector 
(0.1mmol·kg
-1) at 4ml·s
-1 initiated at the start of the fifth acquisition. Contrast medium 
was administered through an identically-sized cannula on each day. When imaging liver 
metastases, patients were required to breath-hold at the end of passive expiration during 
each dynamic acquisition, following instruction of a radiographer via an intercom system. 
System measurement gain and scaling factors were maintained between acquisition of the 
PD and T1-weighted dynamic series, to enable calculation of changing tissue T1-
relaxivities and contrast agent concentrations at each time point of the dynamic 
acquisition (Parker et al., 1997).  
 
2) Dynamic MRI analysis 
We used Magnetic Resonance Imaging Workbench software (MRIW) for DCE-MRI 
analysis (Institute of Cancer Research, UK (d'Arcy, 2006)). Using information from 
anatomical and post-contrast T1-weighted images, ROIs were drawn around tumour 
edges on all three scan slices by a radiologist who carefully excluded areas of artefact, 
necrosis, blood vessels and normal tissues. Metastases >2cm diameter with no partial 
volume averaging were chosen and up to five metastases per organ were analysed. Similar 
ROIs were used for all MR examinations in an individual patient, all of which were 
drawn at the same session to minimise intra-observer variability in ROI placement 
(Beresford et al., 2006). A control ROI was also drawn within skeletal muscle on the Chapter 3 – DCE-MRI Analysis  
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central slice. MRIW software converts signal intensities of T1-weighted DCE-MRI 
datasets into T1-relaxation rates and then into Gd-DTPA concentrations for individual 
pixels at each of the 40 time points (Parker et al., 1997).  
 
IAUGC60 (Initial Area Under the Gadolinium Concentration time curve) was calculated 
over the first 60s from the onset of signal increase following injection of contrast (units: 
mmol·s
-1). The changing tissue Gd-DTPA curve was fitted to a standard compartmental 
model (Kety, 1960; Tofts, 1997) to characterise the influx of Gd-DTPA into the tumour 
extracellular extravascular space (EES) and its venous efflux. Pixel-by-pixel values of 
transfer constant (K
trans - units min
-1), rate constant (kep - units min
-1) and leakage space 
(ve - units %) were calculated. A literature-based pooled arterial input function (combined 
Fritz-Hansen/Weinmann) was used for the modelling (Walker-Samuel et al., 2006). 
 
Using Microsoft Excel, the ROI pixel data was sorted. For tumour ROIs, pixels from all 
three scan slices were combined for analysis. Enhancing pixels which failed the modelling 
process (e.g. K
trans>5) were excluded, mainly due to non-physiological leakage space (ve) 
estimates of >90%. Non-enhancing voxels (e.g. K
trans=0 or IAUGC60=0) were retained to 
calculate median kinetic parameter estimates for each lesion evaluated. IAUGC60 
estimates did include enhancing pixels that failed the modelling process (i.e. not negative 
or zero values), Table 3.1. Pixel data from all slices per lesion were combined and 
median values were taken as representative of central tendency because histogram 
distributions of some kinetic parameters were skewed. The quality of the fit of the raw 
DCE-MRI data to the model functions is demonstrated in figure 3.1 
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Figure 3.1 – Example of the quality of fit of the raw DCE-MRI data to model function. Patient 
06 – Top screen dump day1, middle is 4 hours post CA4P and bottom screen dump shows muscle 
control data. The estimated parameters are given on screen with the Chi Square value showing the fit to 
the modelling function. The nearer to zero, the better the fit.  Chapter 3 – DCE-MRI Analysis  
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Table 3.1 – Tumour ROI Data Analysis – Proportion of non-enhancing pixels and modelling failures within 
ROIs. Data shown for patients 1 – 7. 
 
Three Slices Through Tumour ROI – Combined Pixels 
Patient 
& Day 
Total 
Pixels 
in ROI 
(A) 
IAUGC60 = 
0 (B)
1 
(Non 
Enhancing) 
IAUGC60 
= 0 & 
K
trans = 
0
2 
K
trans > 5
3 
(modelling 
failures) 
K
trans = 0
4 
(non 
enhancing)
Enhancing 
Pixels A-B 
K
trans 
0.01 – 
5.005 
K
trans 
1.20 – 
5.006 
01 R1  10679  13  8  863  7564  10666  2252  1469 
01 R2  11075  61  58  1112  6606  11014  3296  2310 
01 Rx1  11007  3  3  1054  6972  11004  2978  2391 
02 R1  653*  14  14  16  255  639  368  139 
02 R2  525*  1  1  24  216  524  284  121 
02 Rx1  351*  0  0  88  53  351  210  121 
03 R1  2630  2  2  411  173  2628  2044  1199 
03 R2  2679  0  0  339  153  2679  2187  1396 
03 Rx1  2744  10  1  18  41  2734  2675  1324 
04 R1  4843  230  228  5  988  4613  3620  377 
04 R2  4933  1481  1257  0  784  3452  2668  122 
04 Rx1  4873  913  793  0  967  3960  2993  65 
05 R1  2150  101  89  310  232  2049  1507  442 
05 R2  1665  130  115  2  193  1535  1340  283 
05 Rx1  1799  90  81  7  364  1709  1338  114 
06 R1  2006  23  23  15  513  1983  1455  195 
06 R2  1684  25  19  22  244  1659  1393  249 
06 Rx1  1728  25  21  43  76  1703  1584  362 
07 R1  1747  140  140  27  1492  1607  88  58 
07 R2  1780  100  100  47  1504  1680  129  102 
07 Rx1  1469  29  28  1  873  1440  566  28 
1 – Non Enhancing Pixel Modelling Failures, 2 – Subgroup of 1 above, 3 – Enhancing Pixel Modelling Failures (high) 
4 – Enhancing Pixel Modelling Failures (low), 5 – Enhancing Pixels Modelling OK Kt 0.01 – 5.00, 6 – Enhancing 
Pixels Modelling OK Kt 1.20 – 5.00  * - Slices 2 & 3 only suitable for analysis, Rx1 Slices 1 & 3 
 
3) DCE-MRI Repeatability & Variance Components Analysis 
The analysis was carried out on 30 tumours from 12 patients (Table 3.2) with the 
number of tumours per patient ranging from 1-5.  The DCE-MRI data consisted of four 
kinetic parameters (K
trans, ve, kep and IAUGC60) in multiple lesions (1-5) per patient taken 
at three time points (R1, R2 and Rx1). For these data, the parameter values for each 
tumour cannot be treated as independent samples, as the behaviour of tumours within-
patients share biological environments that are common.  That is we expect some 
correlation between tumours within a particular patient both on baseline studies (R1, R2) 
and in therapy responses (Rx1). Bland and Altman’s variance-components methods 
(Bland & Altman, 1996a; Bland & Altman, 1996b; Galbraith et al., 2002) were extended Chapter 3 – DCE-MRI Analysis  
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to take into account the clustering of tumours within patients according to methods 
described by Rabe-Hesketh & Skrondal (Rabe-Hesketh & Skrondal, 2005). All statistical 
tests were two-tailed and p values ≤0.05 were considered significant. 
 
Table 3.2 – Details of 30 metastatic lesions from 12 patients. 
 
Patient 
ID 
Age/
Sex 
Primary tumour 
site and 
histology 
CA4P 
Dose 
(mg/m2) 
Lesion 
No.  Lesion size (cm)  Metastatic Lesion 
location 
1  10.9  Liver - Left 
2  3.65  01  59F 
 
Rectal 
adenocarcinoma 
3  3.92 
02  72F  Caecal 
adenocarcinoma  1  3.5 
Liver - Right 
1  5.2 
2  4.2 
3  4.2 
4  2.2 
Liver - Right 
03  57F  Sigmoid 
adenocarcinoma 
5  2.4  Liver - Left 
1  7.8 
2  6.5 
3  8.1 
4  7.8 
04  65M  Sigmoid 
adenocarcinoma 
5  5.7 
Liver - Right 
05  70M  Ascending colon 
adenocarcinoma  1  4.6  Liver - Right 
06  32F  Caecal 
adenocarcinoma 
 
 
 
 
 
 
 
 
 
 
 
 
45 
1  4.6  Pelvic - peritoneal mass 
07  72M  Rectal 
adenocarcinoma  1  4.5  Liver - Right 
1  4.9 
2  5.6 
Liver - Right 
3  2.3  Liver - Left 
08  77M  Rectal 
adenocarcinoma 
4  4.5  Liver - Right 
09  66F  Pancreatic 
adenocarcinoma  1  4.2  Liver - Right 
1  4.6 
2  2.7 
10  61M  Rectal 
adenocarcinoma 
3  2.8 
Liver - Right 
1  4.1  Liver - Left 
2  2.7  11  58M  Colorectal 
adenocarcinoma 
3  4.1 
Liver - Right 
1  7.9  Retroperitoneal node 
12  63M  Rectal  
adenocarcinoma 
 
 
 
 
 
 
 
 
54 
2  3.6  Bone 
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a) Repeatability of parameter measurements 
This analysis estimated the variation between repeated measurements for the same 
tumour within each patient. That is, how far from the true value a single measurement 
was likely to be. The value depends on the quantity being measured, and the “between-
tumours[within-patients]” variability is estimated as if it were the same for all. The 
standard-deviation of repeated measurements was obtained, and we would expect 68% 
of observations to fall within one standard deviation and 95% within 1.96 standard 
deviations from the true value. For this data a linear mixed model was used, designed for 
fitting random coefficients and multilevel models. Within the model, patients were 
treated as the grouping factor. This model allowed estimations of the between-patient 
variance and between-tumours[within-patients] variance to derive estimates of 
repeatability at the tumour level using pre-treatment parameter values. Estimation of 
variance components was derived using xtmixed in STATA version 9.2 (StataCorp LP, 
College Station, USA). 
 
For both between-patient and between-tumours[within-patients] analyses, kinetic 
parameter values are expressed as means, standard deviations and interclass correlation 
coefficients (ICCs). The ICC is the average correlation coefficient across all possible 
orderings of the data when there is no obvious choice of X and Y axis for each of the 
pairs of measurements. The repeatability statistic (r) (also expressed as a percentage 
change (r%) is the threshold value below which the absolute difference between two 
measurements on the same patient/tumour (n=1) is expected to lie for 95% of paired 
observations (95% limits of agreement). From this, one can calculate for any number of 
patients/tumours the threshold value needed for a parameter to change at the 95% 
confidence level; that is, a real change rather than simply being due to measurement 
variability. 
 
b) Estimates of variance components due to treatment effect 
We also sought to demonstrate that the behaviour of tumours within a patient following 
CA4P are more highly correlated than the behaviour observed between different 
patients’ tumours. We used a three-level model, adding a fixed treatment effect to the 
three-level model used for the repeatability analysis. The fixed treatment effect was 
nested within patients, and we used a similar linear mixed model (as above) to evaluate 
the data. Chapter 3 – DCE-MRI Analysis  
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Results 
 
1) Baseline variability and repeatability assessments  
The baseline variability analyses for the four kinetic parameters for both between-patient 
and between-tumours[within-patients] analyses are given in Table 3.3. For the kinetic 
parameters K
trans, ve and IAUGC60, baseline values were more similar between-
tumours[within-patients] than between-patient. This is illustrated in Figure 3.2 where the 
baseline variability of the kinetic parameters K
trans and IAUGC60 for the two repeatability 
examinations (R1 and R2) is illustrated. For the kep parameter, variability between-patient 
was similar to between-tumours[within-patients] (sd ratio = 1.05).  
 
Table 3.3 - Estimates of between patient and between tumour variability and repeatability (N=12, 
observations=60). The analysis has allowed for a clustering of tumours within patients on each tumour 
measurement. Produced with David Wellsted & Sue Cliffe, University of Hertfordshire biostatistics Dept. 
 
 
Kinetic parameter 
 
Ktrans  ve  kep  IAUGC60 
Patients (tumours)  12 (29)  12 (29)  12 (29)  12 (30) 
Mean (tumours)  0.395 min-1  0.416  0.938 min-1  22.88 mmol·s-1
Variability 
sd (between-patient)  0.185  0.153  0.274  15.129 
sd (between-tumours[within 
patients])  0.096  0.043  0.261  4.124 
sd (error)  0.105  0.064  0.228  4.534 
sd ratio (between-
patients/between-tumours[within 
patients]) 
1.93  3.56  1.05  3.67 
Repeatability (tumours) 
r  0.29 min-1  0.18  0.63 min-1  12.56 mmol·s-1
r%  73.6  42.6  67.3  54.9 
CV  0.27  0.15  0.24  0.20 
ICC  0.64  0.71  0.55  0.77 
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Figure 3.2 – Range and Repeatability for the Primary Endpoints Ktrans and IAUGC60. Patient ID on X-axis. 
Baseline values on the two repeatability examinations (R1 and R2) are more similar between-tumours[within-patients] 
than between-patients. Patients 11 & 12 had marked motion artefacts at one or more examinations.  
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2) Response to therapy assessments 
Reductions in enhancement within the lesion centre were observed visually in 9/30 
tumours using parametric maps. Representative images for patient 03 are illustrated in 
Figure 3.3. 
 
Treatment-induced changes in DCE-MRI kinetic parameters are given in Table 3.4.  
The mean values of the first and second repeatability examinations were taken to 
represent tumour baseline values against which to assess changes induced on the post-
CA4P examination (Rx1). Highly statistically significant reductions were found in the 
kinetic parameters K
trans, kep and ve (n=29).  IAUGC60 changes (n=30) only just reached 
significance because of one outlier point (patient 11, lesion 2 had marked lesion 
movement). 
 
Comparisons of variability due to treatment (between-patients and between 
tumours[within-patients]) are also given in Table 3.4. For the kinetic parameters K
trans, ve 
and IAUGC60, therapy-induced changes are more similar between-tumours[within-
patients] than between-patients (sd ratios >1). This is illustrated in Figure 3.4 where the 
variabilities of response for the kinetic parameters K
trans and IAUGC60 are shown. For the 
kep parameter, variability between patients was similar to between-tumours[within-
patients] after therapy (sd ratio 1.23).  
 
As an example, For K
trans lower 95% CI limit was -19% fall. 8/12 patients or 17/29 
tumours had significant or borderline reductions at four hours. (Figure 3.4) Chapter 3 – DCE-MRI Analysis  
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Figure 3.3 – Patient 03 Discrepancy Between Visual and Quantitative Analysis 
 
 
Lesion 
ID  Ktrans d1  Ktrans d2  Ktrans d3  % Change  IAUGC60 d1  IAUGC60 d2  IAUGC60 d3  % Change 
03-01 0.346 0.3995  0.31275  -16.1 18.14 20.85 17.47  -10.39 
03-02 0.393 0.3556 0.3043  -18.7 17.83 18.45 15.1  -16.74 
03-03 0.2798 0.3198  0.2089  -30.3 16.52 17.62 11.6  -32.02 
03-04 0.2528  0.25065 0.1361  -45.9 10.25 10.05 7.49  -26.15 
03-05 0.65865 0.5252  0.48755  -17.6 21.18 25.22 20.91  -9.87 
Rapid reduction in kinetic variables withi n  t u m o u r  i n d u c e d  b y  C A 4 P  a t  4 5 m g / m 2. Columns represent serial 
examinations acquired before treatment (48h and 24h before CA4P to assess baseline variability) and 4h after the first 
infusion. Rows show anatomical T1-weighted images (top row), maps of IAUGC60 (2nd row), inflow transfer constant 
(Ktrans; third row) and extra cellular leakage space EES (ve; bottom row) acquired at the 3 imaging time points. 
Reduction in kinetic variables is observed as darker colours on IAUGC60 and Ktrans maps with the  absence of 
morphological change. Note that there is little change in the leakage space (ve) Note marked inter- and intratumoural 
heterogeneity with greatest anti-vascular effects within the centre of some lesions only. The changes visible on images 
are not necessarily reflected in the changes in quantitative parameter estimates in the table. Units of Ktrans are min-1 
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Figure 3.4 – Change in Primary Endpoints Ktrans and IAUGC60 following CA4P – Only values crossing the 
lower 95% CI line (marked on graph) are statistically and clinically significant (-19%), however there are 
widespread falls in variables in most patients following CA4P. Note also the greater falls in variables at 
54mg/m2 CA4P (patients 7 – 12) compared with 45mg/m2 (patients 1-6). Patients 11,12 – Severe motion 
artefact. Patient ID and lesion number listed (e.g. 1-1 is patient 01, lesion 01) 
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Table 3.4 - Treatment induced changes and comparisons of variability 4h after CA4P treatment (between-
patients and between-tumours[within-patients]) 
 
Kinetic parameter 
 
Ktrans  ve  kep  IAUGC60 
Patients (tumours)  12 (29)  12 (29)  12 (29)  12 (30) 
Treatment changes in tumours 
Mean (tumours)  0.395 min-1 0.416  0.938 min-1  22.88 mmol·s-1 
Mean change after CA4P (Rx1)  -0.123  -0.079  -0.23  -3.68 
95% CI  -0.05, -0.19 -0.03, -0.13 -0.10, -0.37  -0.22, -7.13 
z  -3.50  -3.25  -3.33  -2.09 
p  >0.001  0.001  0.001  0.04 
Variability 
sd (between-patients)  0.151  0.144  0.26  11.30 
sd (between-tumours[within-patients]) 0.063  0.034  0.21  3.68 
sd (error)  0.154  0.106  0.31  6.53 
sd ratio (between-patients to between-
tumours[within patients])  2.40  4.23  1.23  3.07 
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Fig. 3.5 – Relationship between Ktrans & IAUGC60.  26 points plotted, as 4 tumours did not have calculated 
values for both Ktrans and IAUGC60.  Regression line shown, correlation r=0.741, a positive correlation 
between the two kinetic variables (p<0.0001). See discussion. 
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3) Dose Response of DCE-MRI Parameters to CA4P 
No significant differences in between the 2 dose cohorts were seen. For K
trans at 
45mg/m
2 CA4P (patients 1-6), the mean fall in K
trans four hours post CA4P was -21.6%, 
compared to -27.4% at the 54mg/m
2 dose (patients 7-12) (the 95% CI for a difference 
was -37.9 to 9.6%, 2p=0.246). For IAUGC60 the values were -19.1% versus -22.3% (95% 
CI -17.1 to 23.5, 2p=0.747). For ve the values were -8.9% and -20.8% (95% CI -33.0 to 
9.0, 2p=0.251). For kep the values were -11.0% and -27.3% (95% CI -16.4 to 18.8%, 
2p=0.897). 
 
4) Control Tissue 
In contrast, alterations in muscle dynamic MRI kinetic variables were variable, with no 
group changes seen outside of the 95% confidence limits at any time point (Table 3.5), 
proof in principle of a differential effect of CA4P on tumour and normal vasculature. 
 
Table 3.5 – Muscle Kinetic Variable Analysis (MRIW 4.2.1), patients 1 – 7 
 
Patient 
ID 
Median 
Ktrans R1 
Median 
Ktrans R2 
Median 
 Ktrans 
Rx1 
Median 
ve R1 
Median 
ve R2 
Median 
ve Rx1 
Median 
kep R1 
Median 
kep R2 
Median 
kep Rx1 
Median 
IAUGC6
0 R1 
Median 
IAUGC6
0 R2 
Median 
IAUGC60 
Rx1 
01  0.302  0.406  0.261  0.649  0.730  0.801  0.461  0.559  0.337  6.041  8.573  6.320 
02  0.267  0.274  0.136  0.305  0.285  0.262  0.888  1.041  0.526  5.922  5.899  3.130 
03  0.324  0.353  0.347  0.264  0.297  0.330  1.263  1.287  1.074  5.156  6.506  6.095 
04  0.111  0.166  0.126  0.119  0.144  0.116  0.978  1.153  1.072  2.246  3.692  2.776 
05  0.120  0.128  0.100  0.220  0.174  0.154  0.551  0.747  0.678  2.634  3.001  2.960 
06  0.062  0.096  0.066  0.124  0.150  0.127  0.511  0.636  0.521  1.989  2.377  1.388 
07  0.327  0.259  0.274  0.389  0.365  0.348  0.891  0.740  0.779  7.691  5.696  6.118 
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Discussion 
 
Decreases in tumour MRI kinetic variables that are related to tumour flow and 
permeability are consistent with the known anti-vascular effects of CA4P (Galbraith et 
al., 2003; Dowlati et al., 2002; (Malcontenti-Wilson et al., 2001; Salmon & Siemann, 
2007). Eight patients experienced significant falls in K
trans following CA4P. There were 
also statistically significant falls in ve and kep in many patients. 
 
In routine clinical practice when evaluating the effects of treatments on tumour size, 
multiple lesions are often chosen to determine the “average” change.  However, DCE-
MRI studies investigating the antivascular effects of vascular disrupting agents and 
antiangiogenic drugs in phase I have without exception, chosen single lesions for ROI 
analysis (O'Connor et al., 2007). The implicit assumption being made is that responses of 
chosen lesions are representative of responses in all lesions within the same patient. 
However heterogeneity of tumour DCE-MRI responses after CA4P, occurring between 
patients and intratumourally, has also been shown in previous preclinical and clinical 
work (Galbraith et al., 2003). The assumption of similar responses to CA4P, of lesions 
within individual patients had not been formally investigated.  
 
We noted significant between-patient variability in DCE-MRI kinetic parameters both at 
baseline and 4h due to treatment with CA4P. We also noted that there was variability 
between-tumours[within-patients] both at baseline and due to treatment with CA4P. 
However between-patient variability was always greater than variability between-
tumours[within-patients] for DCE-MRI parameters related to blood flow and vascular 
permeability (K
trans and IAUGC60). Although between-tumours[within-patients] variability 
was smaller, it was quite marked for some patients; this may in part be related to motion 
artefacts particularly in patients 11 & 12. 
 
These results concur with and further clarify previous DCE-MRI and PET studies on the 
actions of CA4P. Rustin et al have previously reported marked reductions in K
trans values, 
particularly in tumour centres, with some sparing of the peripheral rim. Significant 
reductions were seen in tumour K
trans in 6 of 16 patients treated at ≥52mg/m
2 (Galbraith 
et al.,2002; Rustin et al.,2003). No significant changes were seen in patients treated at 20-
40 mg/m
2, which indicated a threshold dose for DCE-MRI effects (Dowlati et al.,2002; Chapter 3 – DCE-MRI Analysis  
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Galbraith et al.,2003). Our data are also consistent with the work of Dowlati and 
Stevenson et al. (Dowlati et al.,2002; Galbraith et al.,2003; Stevenson et al.,2003). 
 
We have evaluated the variability of response between-tumours in the same patient and 
we have shown that there is a tendency for tumours within-patients to behave similarly 
both at baseline and due to treatment after one dose of CA4P. This was seen in five of 
seven patients who had more than one tumour evaluated. This observation will require 
confirmation in larger patient cohorts and the recent move in DCE-MRI methodology 
towards three-dimensional/whole organ evaluations will provide the opportunity to 
undertake future studies in this regard.  
 
An acute reduction in ve may occur if the ability of Gd-DTPA to access the EES is 
reduced (Maxwell et al.,2002). In other cases, it is possible that early loss of cytokine 
production (e.g. VEGF) by tumour cells in response to chemotherapy or A5B7 results in 
a reduction of vascular permeability and interstitial fluid pressure that could reduce ve. 
Such a change in permeability might not be detected by changes in K
trans, as K
trans is flow-
dominated in tumours (Maxwell et al.,2002; Tofts,1997). Lankester et al (Lankester,2005) 
found K
trans was significantly correlated with kep but not with ve, as expected. IAUGC 
correlated strongly with K
trans and strongly with ve, reflecting its value as a ‘summary’ T1 
parameter. 
 
A positive correlation was found as expected and as previously described between K
trans 
and IAUGC60 (Figure 3.5). IAUGC before peak enhancement should reflect transfer 
constant (wash-in rate) and be related to blood flow (Walker-Samuel et al.,2006 & AR 
Padhani, Personal Communication,2008). IAUGC is a mixed parameter and has a 
complex relationship with K
trans, ve and kep. The range over which IAUGC is taken and 
the nature of the estimated AIF do not affect these relationships. 
 
Limitations 
There are a number of limitations of our study including the repeatability of the MRI 
procedures given that patient studies were performed on different days. These 
uncertainties can be partly taken into account by gauging responses in relation to the 
repeatability statistics which takes into account patient set-up errors, machine 
measurement variability and intrinsic tumour fluctuations of blood flow and Chapter 3 – DCE-MRI Analysis  
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permeability. There are well known uncertainties with regard to the reliability of kinetic 
variable estimates derived from the application of tracer kinetic models to the DCE-MRI 
data. These derive from assumptions implicit in kinetic models and those for the 
measurement of tissue contrast agent concentration. For example, we have used a 
literature based description of the time-varying blood concentration of the contrast agent 
as the arterial input function, and the Tofts’ model assumes that the supply of contrast 
medium is not flow limited, and that tissue blood volume contributes negligibly to signal 
intensity changes compared with that arising from contrast medium in the interstitial 
space. We have also used an established two-point T1 estimation technique (proton 
density and initial T1-weighted image) to calculate relaxation values; however there are 
alternative schemes for calculating these values that may be more or similarly accurate. 
However, it should be stated that the DCE-MRI techniques employed in this study have 
been used successfully to assess vascular response to a variety of therapies that affect 
tumour vasculature. Furthermore, three international consensus meetings have 
recognised that tissue contrast agent modelling remains a controversial area and have 
sought not to be prescriptive in this regard (Leach et al., 2005), recognizing that despite 
these complexities, quantitative DCE-MRI kinetic parameters can provide insights into 
underlying tissue pathophysiological processes, and that they are useful tools for decision 
making in pharmaceutical drug trials. 
 
Conclusions 
CA4P causes statistically significant reductions in tumour DCE-MRI kinetic variables 
related to blood flow and microvessel permeability at 4h, with no systematic decrease in 
CO, effectively excluding decreased CO as an explanatory factor. There is marked 
heterogeneity in tumour response between patients with smaller between 
tumours[within-patients] variability. New whole-organ DCE-MRI methodology will 
provide opportunities to undertake future studies comparing between-patients to intra-
patient variability responses to antiangiogenic and vascular disruptive agents. 
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Chapter 4 
Late CA4P Effects Assessed By Liver Perfusion CT 
 
 
Abstract 
 
We describe the use of perfusion CT to measure arterial liver perfusion (ALP) and portal 
venous perfusion (PVP) in a small series of A5B7 patients with liver metastases. The 
objective was to determine whether there are long term changes in liver perfusion (weeks 
rather than hours) following CA4P. Four out of seven A5B7 patients (3 males,1 female,mean 
age 67) were suitable. A 2.4cm tumour volume was selected consisting of four contiguous 
6mm slices. The dynamic study consisted of two end-expiration 30sec breathold acquisitions 
including both arterial and portal venous phases. Iodinated contrast was adminstered using a 
dual head pump injector. CT data was analysed using commercial perfusion software based 
on the ‘slope method’. ROIs were placed within the aorta(for arterial input), portal vein(for 
PVP), spleen and liver to enable a smoothed arterial enhancement-time curve and corrected 
hepatic enhancement-time curve to be derived in an automated fashion, allowing parametric 
maps for ALP, PVP and hepatic perfusion index (HPI) to be produced, each pixel 
representing a parameter value. A ROI was then drawn freehand around the selected liver 
metastasis. This was repeated for each scan slice in which the lesion was visible and mean 
ALP, PVP and HPI were generated for each selected metastasis. No significant changes in 
liver perfusion were observed. This may be because CA4P has no late effects, disease 
progression, or the changes may be too small to observe with such a small sample in the 
presence of wide inter- and intrapatient variability.  
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Introduction 
 
Results of current clinical trials indicate that conventional imaging strategies using tumour 
size (Gehan & Tefft,2000; Therasse et al.,2000) may not be suitable for monitoring the 
effects of anti-vascular drugs (Li,2000). Biological agents are often cytostatic and hence 
prolonged disease stability is a perfectly valid clinical endpoint. In these situations functional 
imaging such as perfusion CT can provide information on vascular tumour response at the 
physiological level. For example, a reduction in blood flow and blood volume after single 
administration of Bevacizumab (Willett et al.,2004), a reduction in blood volume after 
radiotherapy (Ng et al.,2007) and a reduction in hepatic perfusion after administration of 
AZD2171 and gefitinib (Meijerink et al.,2007). 
 
This chapter discusses perfusion CT (reviewed in Chapter 1 and Appendix 4, page 240) to 
measure ALP and PVP in a small series of A5B7 patients with macroscopic liver metastases. 
The objective was to determine whether there are long term changes in liver perfusion (over 
weeks rather than hours) following treatment with CA4P (Gaya et al.,2008). 
 
Methods 
 
Patients 
Mount Vernon patients participating in the A5B7 study with liver metastases were identified 
and approached. They were given the option of having additional sequences performed 
following their routine tumour assessment CT scans, approximately 4h after the initial scan 
to allow time for contrast washout. Thus patients were scanned at baseline and d29 and d57 
if still on-study. Chapter 4 – Perfusion CT 
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Inclusion criteria 
The patient must fulfil eligibility criteria for the A5B7 study (see Chapter 2); recruited by 
Mount Vernon Hospital; assessable liver metastases (masses at least 2cm diameter and away 
from areas of major vascular pulsation); spleen and aorta visible within the four contiguous 
slices chosen through liver (for modelling); patient able to breath-hold for 30sec; no known 
allergy to x-ray contrast media. 
 
Exclusion criteria 
Patients eligible for A5B7 could not undergo perfusion CT if they were having their 
assessment CT scans at the Royal Free Hospital; if they did not have assessable liver 
metastases; if they were unable to breath hold for 30sec; if there was a history of allergy to x-
ray contrast media. 
 
Perfusion CT Scan Protocol 
Patients were scanned supine using a 4-slice multidetector CT (4-MDCT)(Lightspeed Plus, 
GE Healthcare). They were cannulated prior to the initial assessment scan with a 16-gauge 
cannula or greater. An abdominal study was performed initially without administration of 
intravenous contrast to identify the CT spatial coordinates of the liver metastases with the 
following parameters: 10-mm section thickness, 5-mm section interval, 30mm/sec table 
speed, 120kV, 180mA, 0.6-second rotation speed, 500mm scan field of view, and 
512x512mm acquisition matrix. 
 
A 2.4cm tumour volume was then selected consisting of four contiguous 6mm slices by a 
Consultant Radiologist with experience of perfusion imaging (VG). These slices included the 
spleen, aorta and a portal vein branch in addition to liver metastases to enable the software 
calculations to be made. The dynamic study consisted of two 30s breathold acquisitions thus 
including the arterial and portal venous phases. The first 30s acquisition was at a frequency 
of 1 acquisition/s, and the second 30s acquisition at a frequency of 1 acquisition/2s. There 
was a gap of 5s in between the two acquisitions for a breathing interval. Breatholding was at 
end expiration. Patients were coached before the scan to ensure compliance. Iodinated 
contrast (50ml of iobitridol(300mg iodine/ml(Xenetix 300,Guerbet)) was adminstered using Chapter 4 – Perfusion CT 
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an automatic dual head pump injector (Injektron CT2, Medtron, USA) at 6ml/s followed by 
20ml flush of normal saline at 6ml/s.  The dynamic study was initiated 5s following contrast 
administration using the following parameters: Slice thickness 4x6mm, 120kV, current 
150mA, 1.5mm detector width, acquisition matrix 512x512mm.  
 
Image Analysis 
The CT data was transferred to a dedicated workstation (Leonardo, Siemens Medical, 
Erlangen, Germany) and analysed using commercial perfusion software (Syngo-Body 
Perfusion CT, Siemens Medical, Erlangen, Germany) based on the slope method to calculate 
perfusion.   
 
An assumption is made that the arterial time enhancement curve for the aorta in the field of 
view is the same, with a time shift, as that of the metastasis’ feeding vessel. This assumption 
should hold where there is no stenosis between the feeding vessel and the vessel of the 
tumour and there is no significant circulation from collateral vessels or other circulation 
abnormalities. Hepatic arterial perfusion is calculated by dividing the initial slope of 
corrected hepatic parenchymal enhancement curve by peak aortic enhancement as described 
by Blomley (Blomley et al.,1995). 
 
PVP is calculated by dividing the slope of the rise in attenuation during the PV phase of liver 
enhancement by peak portal venous enhancement. Hepatic perfusion index (HPI) is 
calculated as arterial liver perfusion (ALP) divided by the sum of arterial and PV perfusion 
(PVP). 
 
A processing threshold of -50 to 150 HU was selected to optimize soft tissue visualisation. 
Regions of interest were placed within the aorta (for arterial input), portal vein (to enable for 
PVP), spleen and liver to enable a smoothed arterial enhancement-time curve and corrected 
hepatic enhancement-time curve to be derived in an automated fashion, allowing parametric 
maps for ALP, PVP and HPI to be produced, each pixel representing a parameter value. A Chapter 4 – Perfusion CT 
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ROI was then drawn freehand around the selected liver metastasis using a cursor and mouse 
in order to generate a mean value of ALP, PVP and HPI for the metastasis which was 
recorded for each patient. This was repeated for each scan slice in which the lesion was 
visible and an overall value of ALP, PVP and HPI was generated for each selected metastasis 
by averaging values from the slices analysed. Each pixel location within the functional map 
corresponds to a single quantitative perfusion value resulting from the mathematical 
modelling of the data at that location (Figures 4.1–4.4).  
 
Results 
 
Fig 4.1 – MIP (Maximum Intensity Projection) Jan 2004, Patient 01. This early image shows arterial enhancement 
only. Hepatic portal vein (HPV) has yet to opacify. 
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Fig 4.2a,b - ALP Jan 2004 and Feb 2004 Patient 01 – no significant changes. The colours represent ALP with the figure 
as shown on the scale (range -2 to 150ml/min/100ml) 
 
 
 
Fig 4.3a,b - PVP Perfusion CT Jan 2004 & Feb 2004 Patient 01 – Note increased PVP in Feb scan. The colours 
represent PVP as illustrated on the scale (range -2 to 250ml/min/100ml tissue) 
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Fig 4.4a,b - HPI Perfusion CT Jan 2004 & Feb 2004 Patient 01. General decrease in HPI in Feb scan. Colours 
represent HPI as illustrated on the scale (range -2 to 80) 
 
 
 
Seven patients were eligible and of these four underwent perfusion CT. Of the three 
remaining patients, one refused and withdrew consent, one did not have assessable liver 
disease, and the third was withdrawn by the chief investigator due to concerns over 
hypertension and cardiac ischaemia.  
 
Of the four patients recruited, all had liver metastases from colorectal cancer. There were 
three males and one female. Average age was 67 years (range 60–73). All patients were 
eventually withdrawn from A5B7 for progressive disease although patient 04 was on study 
for 95 days. Four patients underwent seven perfusion CT scans (Tables 4.1 & 4.2)(patient 
05 performance status deteriorated and could not cope with breath holding for the second 
scan).  
 
No significant changes in liver perfusion were observed in this small group of four patients. Chapter 4 – Perfusion CT 
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A5B7 
ID  Date Scan  Slices 
(6mm) 
Liver 
Site 
Liver 
Segment 
Lesion 
size 
(cm) 
ALP  St 
Dev 
ROI 
area 
mm2 
PVP  St 
Dev 
ROI 
area 
mm2 
HPI  St 
Dev 
ROI 
Area 
mm2 
06/01/2004  2  9.2  98.6  23.8  25  105.5  52.2  25  50.2  15.4  25  01 
18/02/2004  2 
Left lobe  2,3 
13.6  87.5  22.9  73.5  236.2  102.3  73.5  29.7  10.4  73.5 
 
05/04/2004  4  9.9  58.5  47.8  54.1  151.4  6.7  54.1  28.2  5.8  54.5 
04 
10/05/2004  4 
Right 
lobe  8,5,1 
9.6  77.6  55.4  57.8  172  96.3  57.8  31  6.7  57.8 
 
12/09/2005  2  4.1  86.5  27.2  16.8  1130.1  310.5  18.8  7.5  2.1  16.8 
07 
17/10/2005  1 
Right 
lobe  7 
5.1  108.8  46.2  19.8  512.4  280.3  19.8  19.9  8.5  19.8 
 
05  12/07/2004  1  Right 
lobe  8  6.3  57.1  21.7  29.7  263.5  145.8  29.7  19.1  4.8  29.7 
 
 
 
 
 
 
ID  Normal lobe for 
comparison  ALP  SD 
ROI 
area 
mm2 
PVP  SD 
ROI 
area 
mm2 
HPI  SD  ROI area 
mm2 
28.8  6.8  1.6  227  31.4  1.6  12.3  3.1  1.6  01  Right lobe 
26.8  5.1  1.6  308.3  63.7  1.6  8.2  2  1.6 
 
54  14.4  3.5  220.6  27.4  3.5  19.7  3.9  3.5 
04  Left lobe 
60.3  15.3  3.5  240.4  41.8  3.5  20.4  4.3  3.5 
 
07 None available - previous left  hepatic lobectomy and problems with patient movement 
 
05  Left lobe  58.9  11.4  0.9  2170.7  47.8  0.9  12.3  1.6  0.9 
Tables 4.1 & 4.2 –Perfusion CT Results for the four patients studied: Top table(4.1) illustrates Perfusion CT results. 
Lower table(4.2) illustrates normal liver in the same group of patients for comparison. Results shown with standard 
deviation. There is wide interpatient and intrapatient variability, see discussion. ALP/PVP units are ml/min/100ml. 
Note the higher HPI in diseased liver. Patient 05 withdrawn from study before 2nd scan due to clinical deterioration 
and disease progression. Chapter 4 – Perfusion CT 
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Discussion 
 
No significant changes in liver perfusion were observed (Gaya A et al,2008). There were only 
small changes seen in ALP, but it should be noted ALP was higher in metastatic lesions than 
in normal tissue as expected. There was an increase in PVP in patient 01 and a 
corresponding fall in 07, of some considerable degree, but of uncertain clinical significance. 
HPI was higher in metastatic lesions than normal liver, with a fall in patient 01 and rise in 07. 
Both values were higher than and agree with the threshold ratios set by Perkins (Perkins et 
al.,1987). The ALP values are in agreement with the Miles & Blomley’s publications which 
suggest values>50 ml/min/100 ml tissue in hepatic metastases (Blomley et al.,1995; Miles et 
al.,1993).  
 
Tables 4.1 and 4.2 illustrate wide interpatient and intrapatient variability in measurement of 
liver perfusion. This variability has also been reported in dynamic MRI assessment of 
colorectal liver metastases (Padhani AR, Taylor NJ Personal Communication 2007). 
Certainly colorectal liver metastases can be extremely heterogeneous in their vascular supply, 
but there may be other reasons for this as well.  Patient movement and respiration can lead 
to a reduction in the sensitivity of measurement. The reproducibility of ROI outlining 
between scans can also lead to intrapatient variability. If non-metastatic tissue is included in 
an ROI (e.g. necrosis, vessels) this will also reduce reproducibility (Taylor et al.,2006). The 
analysis software can also encounter modeling failures during processing however this 
should be constant between patients.  
 
All patients were shown to have disease progression on study. CA4P is short-lived and its 
effects are not known to persist longer than 24h following infusion (Tozer et al.,1999). Thus 
it is probable that the results of this study reflect the patients’ disease progression rather than 
any CA4P effect.  
 
The availability of CT coupled with commercial perfusion software has made this method of 
assessment widely accessible to clinicians. Furthermore, reproducibility of the CT technique Chapter 4 – Perfusion CT 
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(Blomley et al.,1995; Fiorella et al.,2004; Goh et al.,2005; Miles & Griffiths,2003) gives CT 
advantages over other imaging modalities that enable similar vascular assessments. 
 
CT measurements of perfusion have been shown to be reproducible and have been validated 
against a range of reference methods (Blomley et al.,1993; Blomley et al.,1995; Cenic et 
al.,2000; Cenic et al.,1999; Gillard et al.,2001; Gillard et al.,2000; Miles et al.,1993). The 
increasing number of publications reporting a correlation between contrast enhancement 
parameters and histological measurements of angiogenesis, such as microvessel density 
(MVD), validates the use of perfusion CT as a marker of angiogenesis (Jinzaki et al.,2000; 
Swenson et al.,1996; Tateishi et al.,2001). To date, no consensus has emerged as to which 
perfusion CT technique is optimal for the assessment of tumour vascularity. The high image 
frequency required for first pass studies may restrict the volume of tissue that can be 
assessed even using MDCT or table toggling techniques (Roberts et al.,2001). 
 
The relationship between angiogenesis and hepatic perfusion is complex. Hepatic metastases 
derive their blood supply almost exclusively from the arterial system; the portal circulation in 
surrounding liver can be affected by mechanical compression by enlarging metastases, by 
white cell margination within portal vessels adjacent to metastases and by circulating 
hormonal factors (Dugdale & Miles,1999). The physiological linkage between arterial and 
portal circulations is such that reduced portal flow is associated with increased arterial flow, 
which complicates the situation further. Histological studies have shown that unlike primary 
tumours, greater vascularisation of hepatic metastases is associated with a better prognosis 
(Mooteri et al.,1996). This association is reflected by perfusion CT findings amongst patients 
with hepatic metastases. Increased arterial perfusion, particularly in the periphery of the 
metastasis, is associated with a longer survival (Miles et al.,1998), whereas a small series of 
patients with hepatic metastases from colon cancer has suggested that low portal perfusion 
throughout the liver (below 0.22 ml/min/ml) is associated with progressive disease and a 
poor response to chemotherapy (Leggett et al.,1997; Sommerfield et al.,1999). 
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Absolute measurement of perfusion is dependent on the cardiac output(CO) at the time of 
measurement. To normalize perfusion values Miles (Miles et al.,2001) proposed the 
standardized perfusion value(SPV) as the perfusion scaled by the whole body perfusion, 
expressed as CO over weight. CO may be determined from the arterial input time 
attenuation curve provided the dose of contrast material is known. 
 
CT perfusion studies have been performed at a range of energies and beam intensities, from 
120kV at 210mA to 80kV and 80mA. Wintermark (Wintermark et al.,2000) compared the 
use of 80 and 120kV at 200mA on cerebral contrast material enhancement using pre and 
post enhancement images after a bolus of contrast material. 80kV gave increased 
enhancement, greater contrast between white and grey material and lowered the radiation 
dose by a factor of 2.8 compared with 120kV. The difference in noise between 80kV and 
120kV images was not significant. However, the CT perfusion was not calculated from this 
data.  The slope method requires good contrast material enhancement with minimum noise 
in those images used to calculate perfusion. However, it generally has a shorter acquisition 
time and may be able to use acquisition parameters with a greater radiation dose per image. 
There will always be a trade off between radiation dose and increased temporal resolution. 
 
In patients with known liver metastatic disease, increased ALP has been shown by using CT 
perfusion imaging with the slope-ratio analytic methods described by Miles (Miles et 
al.,1993) and Blomley (Blomley et al.,1995). Blomley et al reported a value of 
43mL/min/100mL, and Miles (Miles et al.,1993) reported that of 50mL/min/100mL in 
patients with known metastatic disease versus values of 19mL/min/100mL and 
17mL/min/100mL, respectively, in healthy control groups. Leggett (Leggett et al.,1997) also 
demonstrated increased arterial perfusion (25mL/ min/100mL) in 9/11 patients with 
colorectal liver metastases examined by using CT perfusion with slope methods. The 
relationship between an elevated HPI value and overt metastatic disease has been well 
established (Leveson et al.,1985; Leveson et al.,1983; Perkins et al.,1987). Perkins (Perkins et 
al.,1987) determined a hepatic perfusion index threshold value of 0.37; at values above this 
level, metastatic disease should be suspected. Chapter 4 – Perfusion CT 
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Several authors have studied the effect of liver metastases on perfusion indices (Blomley et 
al.,1995; Miles et al.,1993; Miles et al.,1998) using functional CT. Miles (Miles & Kelley,1997) 
measured capillary permeability in abdominal lymph nodes and Leggett examined the effect 
of occult metastases on hepatic perfusion (Leggett et al.,1997). Surprisingly, little work has 
been published so far on the response of tumours to therapy (Bellomi et al.,2007; Dugdale & 
Miles,1999; Hayano et al.,2007; Kiessling et al.,2004; Makari et al.,2007; Meijerink et al.,2007; 
Ng et al.,2007; Rumboldt et al.,2005; Sahani et al.,2005; Willett et al.,2005). 
 
Conclusions 
 
These results do not suggest that further late time-point studies are worthwhile as there was 
no hint of alterations at these time points. This may be because CA4P has no late effects, it 
may be due to disease progression, or the changes may be too small to observe with such a 
small sample in the presence of wide interpatient and intrapatient variability (Gaya et 
al.,2008). The quantitative data produced by perfusion CT makes it an attractive modality for 
assessing acute perfusion changes, however this has to be balanced against the radiation 
doses involved. Faster MRI scanners now allow direct measurement of arterial input and this 
is therefore likely to be the way forward.  
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Chapter 5 – Cardiac Output Changes Following CA4P 
 
 
 
Abstract 
 
It has been suggested that tumour vascular shutdown following administration of 
VDAs is due to a reduction in systemic cardiac output (CO) and tissue blood delivery, 
i.e. not a wholly tumour specific local effect. In order to confirm or refute this 
hypothesis 12 patients taking part in the A5B7 trial had CO measured by MRI using 
phase contrast sequences through the ascending aorta before and 4h following 
infusion of CA4P at 45–54mg/m
2. Regions of interest (ROI) were drawn on the 
margins of the ascending aorta on the 40 phases obtained and stroke volume (SV) 
calculated using Argus flow software. As heart rate (HR) was measured before each 
scan CO could be calculated as the product of HR and forward SV. There was a mean 
increase in CO of 14.0% (range -6.9% to 47.3%, increased CO in 8/11 assessable 
patients, p=0.026) 4h following CA4P, yet DCE-MRI analysis confirmed significant 
tumour vascular shutdown in several patients, and reductions in the kinetic variables 
K
trans and IAUGC60 in most. There is no evidence for reductions in CO as a cause for 
reduced tumour K
trans after CA4P, effectively excluding a central effect for the reduced 
kinetic variables seen in tumours. 
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Introduction 
 
Phase contrast MRI is a well established non-invasive technique for measurement of 
CO (Diddier et al.,2000). It is based on the principle that the phase of flowing spins 
relative to stationary spins along a magnetic gradient changes proportionally to flow 
velocity. The absolute velocity is calculated at any given time during the cardiac cycle 
at specified locations in the plane of acquisition for each pixel within the ROI. The 
instantaneous flow volume for each time frame during a cardiac cycle is calculated as 
the product of cross-sectional area of the vessel (proximal ascending aorta in our case) 
and spatial mean velocity (the average velocity for all the pixels in the cross-sectional 
area). Integration of all instantaneous flow volumes throughout the cardiac cycle yields 
the flow volume per heart beat, also called the SV, which when muliplied by HR gives 
the CO.  This technique has been evaluated both in vitro and in vivo by several 
investigators and shown to provide an accurate measurement of SV and CO both 
through the aorta and the pulmonary artery (Higgins et al.,1992; Mohiaddin & 
Pennell,1998).  
 
Transient alterations in HR and BP are common following CA4P. It has been 
suggested that the reduction in tumour blood flow detected by DCE-MRI kinetic 
variable alterations after 4h could be due to a reduction in CO (Anderson et al.,2003; 
Galbraith et al.,2003) i.e. not a wholly tumour specific effect.  
 
The objective of this study was to determine whether any significant CO changes are 
seen 4h following infusion of CA4P in the presence of tumour vascular shutdown, in 
order to confirm or refute this hypothesis. Chapter 5 - MRI Cardiac Output Analysis 
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Methods 
 
Following ethics board approval, all 12 patients from the A5B7 trial were consented 
for CO measurement and DCE-MRI. 
 
MRI imaging procedures 
MRI was performed on a 1.5 tesla Magnetom Symphony Scanner (Siemens Medical, 
Erlangen, Germany), using a surface phased array coil. An ECG-gated phase contrast 
sequence to calculate CO, and DCE-MRI were performed 48h (R1) and 24h (R2) 
prior to, and 4h following infusion of CA4P (Rx1). The DCE-MRI data is discussed in 
Chapter 3. 
 
Phase contrast sequences were performed through the proximal ascending aorta just 
above the sino-tubular junction whilst at rest. Scans were obtained in through-plane 
(perpendicular to the long axis of aorta) with retrospective ECG gating using the 
following parameters: Field of view 320*240 mm; Acquisition matrix 256*179; 
TR=68ms; TE=4.8; TA=56s; Flip angle 30° and slice thickness 6 mm. Velocity 
encoding was kept at 150cm/s and increased further if aliasing was detected. ROIs 
were drawn on the margins of the ascending aorta on the 40 phases obtained and the 
following parameters were calculated using Argus flow software (Siemens Medical, 
Erlangen, Germany): Peak velocity (cm/s), average velocity (cm/s), total forward SV 
(ml/s), reverse volume (ml/s), and net forward volume (ml/s) (Figure 5.1). Chapter 5 - MRI Cardiac Output Analysis 
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Figure 5.1 a-f - Procedure for obtaining CO with ECG gated MRI: Oblique tru-FISP sequence images (a 
& b) through the aortic root demonstrating the plane of acquisition of phase-contrast images at sino-
tubular junction (c & d). Magnitude (c) and phase images (d) of the phase contrast sequence with the 
ROI drawn around the aortic wall. (e) demonstrates the time-velocity curve of blood flow through the 
cardiac cycle, whilst (f) gives the different parameters of velocity and flow calculated by the software.  
 
 
   
   
a,b
e,f
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CO was calculated as the product of HR and SV (net forward volume). Three patients 
who did not have HR measured at the time of the MRI had the value taken either 
from the CA4P vital signs table 4h post-infusion, or the population group mean was 
used. 
 
Results 
 
11/12 patients successfully completed at least one pre- and one post-CA4P cardiac 
MRI.  Table 5.1 illustrates CO 48h and 24h pre-CA4P and 4h post-CA4P, 
demonstrated graphically in Figure 5.2. In 8/11 cases there was a rise in CO 4h 
following CA4P (p=0.026, 2-tailed group t-test). The mean CO increase was 14.0% 
(range 0.7% to 47.3%). 3/11 cases showed a small fall in CO (range -6.9% to -0.5%). 
The statistical significance was maintained no matter which method was used to 
estimate missing HR data (vital signs table or group mean HR during MRI). Figure 
3.3 (Chapter 3) illustrates changes in the DCE-MRI kinetic parameters K
trans and 
IAUGC60 4h following CA4P. Falls in these parameters were widespread although 
only a few reached statistical significance (patients 6, 7, 10). This is consistent with a 
global reduction of tumour perfusion following CA4P, in the face of increased CO in 
8/11 patients. 
Table 5.1 – CO Measurement Pre & Post-CA4P 
Patient 
ID 
Scan 
No.  HR 
Peak 
Vel 
(cm/s) 
Av. 
Vel 
(cm/s) 
Av. 
flow 
(ml/s) 
Forward 
Vol ml 
Rev 
vol. 
ml 
Net 
forward 
vol (ml) 
CO 
(L/min) 
Mean 
CO 
R1 & 
R2  
CO 
Rx1 
(Post 
CA4P)
% 
Change 
In CO 
Rx1 
R1  95  121.51  9.78  107.28 68.13  2.69 65.44  6.47     
R2  95  124.61  8.68  95.16  63.81  2.9  60.9  6.06      01 
Rx1  102  107.23  9  99.53  64.67  4.25 60.42  6.60  6.27  6.60 
+6.5 
R1  62  104.81  5.9  74.84  72.74  1.71 71.02  4.51     
R2  61  116.9  5.5  71.7  69.5  1.2  68.2  4.24      02 
Rx1  90  108.6  8.6  89.6  59.8  1.9  58  5.38  4.37  5.38 
+23.0 
R1  108  86.3  8  67.6  39.2  1.4  37.3  4.23     
R2  102  82.1  8.8  75.8  43.6  1.7  41.9  4.45      03 
Rx1  117  101.2  8.8  77.8  43.5  2  41.5  5.09  4.34  5.09 
+11.7 
R1  78  85.11  11.54  83.47  66.34  1.73 64.6  5.17     
R2  78  103.5  11.82  88.46  66.04  2.88 63.16  5.15      04 
Rx1  85  109.5  14.35  103.46 71.02  3.56 67.48  6.04  5.16  6.04 
+17.1 
06  R1  89  93.8  11.7  93.8  72.9  0.3  72.7  6.49      +0.77 Chapter 5 - MRI Cardiac Output Analysis 
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R2  89  82.6  12.7  96.4  73.4  1.2  72.5  6.53       
Rx1  86  95.6  13.85  106.6  76.3  1.6  74.7  6.56  6.51  6.56 
 
R1  67  100.2  10.6  96  86.2  1  85.2  5.78     
R2  60  92.5  10.8  96.1  89.9  1.4  88.5  5.39      05 
Rx1  82  105.5  13.1  118.6  88  1  87  7.22  5.58  7.22 
+29.3 
R1  75  89.7  9.4  61.5  50.4  1.73 48.6  3.78     
R2  76  87.4  8.4  62.5  51.62  2.21 49.41  3.92      07 
Rx1  110  94.3  10.8  73.3  46.1  4.26 41.85  5.07  3.85  5.07 
+31.7 
R1  57  90.6  8.2  70.6  80.7  1.3  79.5  4.60     
R2  61  82.3  7.1  61.5  69.3  5.8  63.5  4.23      08 
Rx1  69  86.3  7.9  66.5  59.5  4.1  55.4  4.11  4.41  4.11 
-6.9 
R1  75  118.7  10.1  60.5  46.6  1.3  45.2  3.50     
R2  80  113.7  10  62.5  47.8  1.1  46.7  3.82      09 
Rx1  102  112.9  10.5  60.5  36.4  1.6  34.9  3.71  3.66  3.71 
-0.55 
10  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
11                    5.37  7.91  +47.3 
12                    5.2  4.9  -5.77 
CO – Cardiac Output (litres/min). CO data extracted by Dr Tarun Mittal. R1 and R2 - baseline studies 1 and 2. 
Rx1 -  examination 4h after 1st dose of CA4P. N/A – Patient not scanned. CO – Cardiac Output, measured in 
litres/min 
 
 
Figure 5.2 – Cardiac Output Changes Following CA4P 
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Bars show group standard error of the mean, p=0.026 significant increase in CO following CA4P using HR data 
from the vital signs table (2-tailed t-test). Using the population average HR instead, p=0.039. CO calculated from 
HR multiplied by net forward SV divided by 1000 giving CO units of litres/min for patients 1 - 12.  
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Discussion 
 
Taking all eleven cases as a cohort there was a statistically significant rise in systemic 
CO 4h following CA4P. The statistical significance was maintained no matter which 
method was used to estimate the missing HR data (A5B7 CRF at 4hrs post CA4P or 
group mean). 
 
Interestingly, patients 8, 9 and 12, who experienced small falls in CO following CA4P 
were all treated with the higher 54mg/m
2 dose, which has been shown to have a 
greater effect on tumour vasculature (Chapter 3, Figure 3.3, (Galbraith et al.,2003)). 
As CA4P dose increases towards the maximum tolerated (~70mg/m
2) there may be a 
greater effect on systemic vasculature leading to the DLTs experienced (cerebellar 
ataxia, cardiac ischaemia) (Tozer et al.,1999).  
 
Following CA4P a significant fall in HR is seen, most prominent at 1h (Figure 5.3) 
(Rustin GJ 2005) as BP increases. After 4h there is overcompensation with a 
corresponding increase in HR and fall in BP. All vital signs normalise by 24h (Rustin 
et al.,2003). The CO rise 4h post-CA4P may reflect the rise in HR seen at this time, 
without a corresponding decrease in SV. In the UK Phase I CA4P study (Rustin et 
al.,2003), mean BP increase at doses ≥52 mg/m
2 was 8–10% over the first hour 
followed by a mean BP decrease of 6–7% at 4h. Microtubule depolymerisation is 
known to affect vasomotor tone and total peripheral resistance. So although CA4P 
has effects on the systemic vasculature at four hours the reductions seen in MRI 
kinetic variables are unlikely to be mediated directly by these systemic effects. 
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Figure 5.3 – Change in Vital Signs Following CA4P. From the UKCTC-207 study (Chapter 6) (Rustin 
GJ 2005) There is a fall in HR of mean 7 bpm 1h post CA4P with a corresponding increase in mean 
heart rate of 9 bpm above baseline at 4h. The BP changes are the opposite, with a rise at 1h and 
corresponding falls at 4h. 
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Galbraith reported that HR dropped during MRI whilst during PET it increased and 
suggested that the effects on CO at the examination times in the PET and DCE-MRI 
studies may therefore have been different. There was no reduction in SV seen in the 
PET study, indicating that the observed changes in HR were reflected in the CO 
change (Galbraith et al.,2003). Anderson et al reported that at doses of CA4P above 
40mg/m
2 BP was significantly increased within the first hour after infusion and was 
associated with a decreased HR but no change in SV. However, this coincided with a 
significant decrease in CO demonstrated by PET  (Anderson et al.,2003). There was 
no significant difference in CO pre-CA4P administration versus 24h post-CA4P. 
However, the rapid 10% decrease in CO to all tissues most likely results from 
increased peripheral vascular resistance caused by CA4P.  
 
There is an apparent paradox, with conflicting data as to the degree and nature of CO 
change following CA4P. Our study has helped resolve this issue, although the full Chapter 5 - MRI Cardiac Output Analysis 
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explanation is likely to be a combination of differing time points and measurement 
techniques. We would like to perform CO measurement 1h post CA4P to determine if 
the HR drop at 1h also corresponds to a decrease in CO. 
 
The effects of 10mg/kg CA4P on mean arterial BP and blood flow rate to the p22 rat 
carcinosarcoma and selected normal tissues have been measured (Prise et al.,2002; 
Tozer,2003). Blood flow rate was measured using the tissue uptake of radiolabelled 
iodo-antipyrine.  Comparison of MABP and skeletal muscle blood flow results 
suggested that the initial hypertensive effect of CA4P was due to vasoconstriction in 
muscle. CA4P caused a 100-fold decrease in blood flow to tumour, with a much 
smaller reduction in blood flow to spleen, skeletal muscle and brain. No significant 
reduction was observed in heart, kidney and intestine (Tozer et al.,1999).  Data such as 
these clearly demonstrate the potential of CA4P for selective tumour vascular 
shutdown, and there may be tissue specific differences in CA4P vascular response. 
CA4P exerts its anti-vascular effect preferentially on tumour vessels which are 
structurally and phenotypically very different to normal vessels (Gaya & Rustin,2005).  
 
The alteration in tumour blood flow following CA4P is much greater than that seen 
with drugs affecting systemic haemodynamics. Limited changes in tumour blood flow 
in rats have been seen with hypertensive agents such as angiotensin II (Tozer & 
Shaffi,1993), but only at doses that caused much larger changes in systemic BP and 
HR than CA4P. Also, larger reductions were seen in normal tissue blood flow. 
Reduced tumour blood flow has also been observed after treatment with high doses 
of the vasodilator hydralazine (Horsman et al.,1992), which reduced systemic BP by 
50%.  
Conclusion 
 
This new MRI CO data clarifies the central effects of CA4P at the 4h time point 
becaue it shows that any early (approximately 30-60 mins) decreases in CO (as noted 
by the PET data) are reversed by 4h. 
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Chapter 6 
A Phase Ib trial of CA4P in Combination with Carboplatin and/or 
Paclitaxel Chemotherapy in Patients with Advanced Cancer (UKCTC-207) 
 
 
Abstract 
 
Animal studies confirm the VDA CA4P has increased activity combined with 
conventional anti-cancer therapies. We describe a Phase Ib dose escalation trial in 
patients with advanced cancer, to establish the optimal schedule, DLT, MTD and 
recommended Phase II dose(RP2D) of combining CA4P with carboplatin and/or 
paclitaxel, and gather preliminary data on anti-tumour efficacy. On day one of each 21-
day cycle patients received CA4P over 10min escalating from 27 – 72mg/m
2, followed 
twenty hours later by either a 60min infusion of carboplatin AUC 4-5 and/or a 3hr 
infusion of paclitaxel (135 – 175mg/m
2). Forty six patients received 179 cycles of 
treatment. Mean age was 58(24–77) with 28 females and 18 males. The most frequent 
primary tumour sites were ovarian(18), melanoma(6), colorectal(5), renal(5), and lung(3). 
WHO PS at study entry was 0(13), 1(27), and 2(6). Most patients were heavily pre-treated 
with chemotherapy. Pharmacokinetic data confirmed no delayed excretion of cytotoxic 
drug following CA4P and changes in vital signs were similar to previous CA4P studies. 
Side effects of CA4P were mild, mainly CTC grade 1 fatigue, tumour pain, flushing, 
pruritis, headache and hypertension. Haematological toxicity was mild in contrast to a 
previous study due to cytotoxic administration following renal recovery from the CA4P 
effect. DLT was cerebellar ataxia at 72mg/m
2 CA4P. The MTD and RP2D are 63mg/m
2 
CA4P, carboplatin AUC5 and paclitaxel 175mg/m
2. Overall RECIST assessment showed 
16%PR, 54%SD and 30%PD. Of 18 patients with ovarian cancer, half had a Ca125 
response >50%. Of 13 RECIST assessable ovarian patients there were 3PR and 6SD. Of 
five platinum resistant ovarian patients there were two cases of RECIST SD and one 
Ca125 response. The triplet combination is now being studied in a Phase II trial for 
platinum resistant ovarian cancer. Chapter 6 – UKCTC-207 Phase I Trial 
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Introduction 
Phase I trials of CA4P have demonstrated minimal single agent activity, and have 
confirmed that it has vascular disruptive activity according to dynamic contrast MRI and 
PET imaging (Anderson et al., 2003; Dowlati et al., 2002; Galbraith et al., 2003; Rustin et 
al., 2003; Stevenson et al., 2003). DLT’s were seen above 60mg/m
2. Enhanced activity 
was seen when CA4P was combined with chemotherapy or radiotherapy in animal 
studies (Chaplin & Dougherty, 1999; Grosios et al., 2000; Wildiers et al., 2004). CA4P 
had greatest effect on the tumour core whilst conventional therapy was active against the 
tumour rim.   
 
Following ethics committee approval we embarked on a Phase I study of 
CA4P+carboplatin and CA4P+paclitaxel, progressing to assessment of the triplet 
combination. 
 
Methods 
Study Objectives 
1) To establish the optimal schedule, DLT, MTD and RP2D of combining CA4P with 
carboplatin, paclitaxel, or both. 
2) To gather preliminary data on anti-tumour efficacy of the combinations. 
 
Patient selection 
Patients with histological confirmation of cancer, not amenable to standard therapy or 
refractory to conventional therapy were eligible for this study.  Other eligibility 
requirements included having RECIST measurable disease or being evaluable by serial 
Ca125 measurements; WHO performance status 0-2; life expectancy ≥4 months; age ≥18 
years; adequate bone marrow function with: a) neutrophil count >1500 cells/mm
3; b) 
Platelet count >100,000 cells/mm
3; adequate hepatic function: a) total bilirubin 
<1.5mg/dl, b) ALT and AST <2.5x upper limit of normal; adequate renal function with 
glomerular filtration rate measured by EDTA clearance ≥50ml/min; on no other anti-
cancer therapy for 4 weeks; no active concurrent malignancies except cone biopsied in 
situ carcinoma of cervix, or adequately treated basal or squamous carcinoma of skin.  Chapter 6 – UKCTC-207 Phase I Trial 
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Patients were excluded if they had brain metastases, serious infection or other non-
malignant illness, >grade 2 neuropathy, major surgery within 4 weeks, prior radical 
radiotherapy or evidence of vascular damage from radiotherapy, a history of peripheral 
or cardiovascular disease or arrhythmias,  uncontrolled hypertension, or on 
anticoagulation apart from low dose warfarin for maintenance of central line patency. 
 
Study Design 
This was an open label phase I dose-escalation trial. The study was conducted at three 
sites – Mount Vernon Hospital, UK; The Churchill Hospital, Oxford, UK; and the 
Henry Ford Hospital, Detroit, Michigan, USA. The study was approved by participating 
hospitals’ ethical review boards, and all enrolled patients provided written informed 
consent.  
 
Entry into the treatment arms was non-randomised and left to the clinician’s discretion. 
This ensured the most appropriate treatment given the type of cancer, therapeutic history 
and potential side-effect profile was offered to each patient, although statistically an 
element of bias was introduced. The starting dose levels were chosen approximately 20 - 
25% below accepted single agent doses for the cytotoxic agents – i.e. Carboplatin AUC4, 
and Paclitaxel 135 mg/m
2. For CA4P, 45 mg/m
2 was felt to be the lowest dose that had a 
reasonable chance of activity in combination with cytotoxic agents. In the carboplatin 
arm, the starting CA4P dose level was 20% below this at 36 mg/m
2 and in the paclitaxel 
arm 40% below at 27 mg/m
2 (because of the increased haematological toxicity expected 
in this arm). The likelihood of significant interactions between CA4P and the cytotoxic 
agents was however felt to be low on the basis of previous combination studies (see 
Chapter 1).  
 
Treatment was administered on an inpatient basis and repeated every 21 days.  Patients 
continued to receive treatment until disease progression was documented or to a 
maximum of 6 cycles or until other withdrawal criteria were met. In the absence of DLT 
in one patient, up to 5 patients were treated at each dose level.  Subsequent dose levels 
were not opened until three patients at the previous dose level had completed 
administration of course 2.  Once the MTD was defined in 3 patients with carboplatin 
and three patients with paclitaxel, the MTD dose of CA4P was assessed in combination Chapter 6 – UKCTC-207 Phase I Trial 
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with both paclitaxel and carboplatin. Adverse events were the primary study endpoint.  
All patients who received any study drug were evaluable for safety.  Adverse events and 
other symptoms were graded according to the NCI CTC v3.0. 
 
Treatment Administration 
CA4P was supplied as a sterile lyophilized cake in amber glass vials containing 90mg of 
CA4P as free acid with 10% additional overfill. The drug was reconstituted with 10ml of 
sterile water for injection and further diluted with 100-150ml of normal saline. The 
carboplatin and paclitaxel were prepared from commercially available vials containing 
sterile aqueous solution, which was diluted with 500mL of 5% dextrose and 500mL 
normal saline respectively.  
 
On Day 1 of each 21-day cycle, patients received a 10min infusion of CA4P. Routine 
pre-medication was not mandatory but if significant toxicity occurred with the first cycle 
pre-medication with dexamethasone 8mg IV and metaclopramide 10mg IV was 
suggested prior to subsequent cycles. If systolic blood pressure was >180mmHg on two 
readings following CA4P glyceryl trinitrate  0.3mg  was given sublingually or amlodipine 
10mg orally. On Day 2, 18-22 hours after the CA4P, patients received a 60-minute 
infusion of carboplatin or a 3h infusion of paclitaxel. This scheduling was chosen on the 
basis of the significant toxicity seen in Bilenker’s study (Bilenker JH 2003). Providing no 
DLT occurred in any of the three patients per cohort, doses were increased as shown in 
Table 6.1.  Once it had been ascertained that no DLTs were seen at a CA4P dose of 
54mg/m
2 (above the threshold dose for CA4P activity from previous studies) in either of 
the doublet arms, patients were then treated with the triplet combination at doses shown 
in Table 6.1. If a DLT was seen three additional patients could be recruited to that dose 
level. The triplet consisted of CA4P on day 1, followed 18-22 hours later by a 3h infusion 
of paclitaxel then a 60-minute infusion of carboplatin. 
 
Dose Limiting Toxicities 
DLT was defined as any of the following events, considered to be probably or definitely 
related to combination study therapy: QTc prolongation ≥500 ms, >Grade 2 ventricular 
arrhythmia, grade 3/4 non-haematologic toxicity (except: fatigue/asthenia, nausea 
and/or vomiting), toxicity resulting in treatment delay >14 days, absolute neutrophil Chapter 6 – UKCTC-207 Phase I Trial 
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count <500 cells/mm
3 for >5 consecutive days or febrile neutropenia with neutrophil 
count  <1000 cells/mm
3, thrombocytopenia <25,000 cells/mm
3 or bleeding episode 
requiring platelet transfusion, grade 2 or worse neuropathy which did not recover to 
grade 1 within 14 days after scheduled re-treatment, or any grade toxicity requiring 
patient removal from the study in the judgement of investigators. 
 
The MTD was defined as the maximum dose level of CA4P, administered in 
combination with carboplatin and paclitaxel, at which one or fewer patients experienced 
a DLT.  The dose level below that at which one or more DLTs were seen was expanded 
to 6 patients and if no DLT’s were seen became the RP2D.  
Treatment Assessment 
Upon enrolment in the study, patients underwent a complete medical history, physical 
examination and biochemical assessment. Thereafter, laboratory assessments were 
performed weekly. Tumour evaluations were done at screening and then every two 
cycles. Criteria for response were based on RECIST and response of Ca125 was based 
on definitions agreed by the Gynaecologic Cancer Intergroup (Rustin, 2003; Therasse et 
al., 2000). Patients were removed from the study on disease progression. Chapter 6 – UKCTC-207 Phase I Trial 
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* The last three subjects treated at MTD continued into the Phase II study. 
Study Procedures and Observations 
Full blood count, biochemistry profile, adverse event assessment, performance status, 
physical examination, and vital signs were all performed prior to drug administration. 
Post CA4P, vital signs (HR,BP, temperature, respiratory rate) were obtained at 1, 2, 3, 4, 
5 and 6h for all cycles. On Day 1 of each cycle, three pre-treatment ECGs were obtained 
at least 5min apart. ECGs were obtained post-administration of CA4P at the following 
time points: 1, 2, 3, 4, 5 and 6h for cycles 1/2; and 2 and 4 hours for subsequent cycles.  
If no abnormalities in the QTc interval were present after 4 cycles, monitoring was 
reduced to one pre-treatment, one at one hour post-treatment and two hours post-
treatment.   
 
End-of-Study Assessments 
To ensure that drug-related adverse events had resolved, the following assessments were 
performed at least 30 days after the final dose of study drug for all patients: Performance 
Table 6.1a -  Dose Escalation Schedule for CA4P/Carboplatin 
Dose Level  CA4P(free acid dose) mg/m2  Carboplatin AUC 
1  36 
2 
4 
3 
45 
4  54 
5 
Table 6.1b  - Dose Escalation Schedule for CA4P/Paclitaxel 
Dose Level  CA4P (free acid dose) mg/m2  Paclitaxel Dose mg/m2 
1  135 
2 
27 
3  36 
4  45 
5  54 
175 
Table 6.1c - Dose Escalation Schedule for CA4P/Carboplatin/Paclitaxel 
Dose Level  CA4P(free acid dose) mg/m2 
Carboplatin 
AUC 
Paclitaxel Dose mg/m2 
1  54 
2  63 
3  72 
5  175 Chapter 6 – UKCTC-207 Phase I Trial 
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status; physical examination; weight; vital signs; full blood count; biochemical profile; 
urinalysis; ECG; adverse event analysis. 
 
Pharmacokinetic analyses 
Plasma samples were taken for carboplatin or paclitaxel pharmacokinetics at the 
following time points, to assess whether excretion of cytotoxic was delayed by the 
administration of CA4P: at the start and end of the CA4P infusion; prior to cytotoxic 
drug infusion; for carboplatin, samples were also taken 5min prior to the end of the 
60min infusion & 1, 2 & 4 hours post infusion; for paclitaxel, samples were also taken 
halfway through and at the end of the 3h infusion & ½, 1, 2 & 3 hours post infusion. 
Urine collections for carboplatin pharmacokinetics were performed from 0–3h, 3–6h and 
6–30h from the start of carboplatin infusion. 
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Results 
 
Between 27/6/03 and 1/11/05 46 patients were enrolled. Median age was 58 (range 24-
77). There were 28 females and 18 males and their tumour types are listed in Table 6.2. 
ECOG performance status at study entry was 0 (13), 1 (27), 2 (6). A total of 179 cycles 
were given to 46 patients, with 15 completing all 6 cycles. Seventeen withdrew due to 
tumour progression, 3 due to early death, 5 because of toxicity and 6 for other reasons. 
Patients’ previous cancer treatment is illustrated in Table 6.3, and the sites and 
measurements of marker lesions in Table 6.4. Patient responses to treatment are 
illustrated in Tables 6.5 – 6.7.  
 
Table 6.2 – Subject Details 
 
Primary Tumour Origin  Number Of Patients 
Ovary  17 
Melanoma  6 
Colorectal  5 
Renal  5 
Lung  3 
Oesophagus  2 
Thyroid  2 
GIST  1 
Neuroendocrine  1 
Cholangiocarcinoma  1 
Leiomyosarcoma Uterus  1 
Testicular  1 
Fallopian Tube  1 
   N=46 Chapter 6 – UKCTC-207 Phase I Trial 
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Table 6.3 – Subjects’ Previous Cancer Treatment 
Trial 
No.  Treatment History Prior To Study 
01  TAH+BSO 10/00, Carbox4,Docetaxel/Gemcitabine x 4 11/00-5/01 (SCOTROC2), cisplatin+etoposide 11/01, 
caelyx 12/02 
02  Docetaxel+Carbo 5/00, Carbo 4/02-6/02, Cisplat+Etoposide 9/02-10/02, Altretamine 7/01-11/02, 
etoposide 11/02-1/03 
03  TAH+BSO+Omentectomy 6/99, Carboplatin x2 Taxol x2 Topotecan x2 7/99-12/99 (sequential trial), Taxol/carbo 
1/01-5/01, Carboplatin/taxotere 10/02-2/03 
04  Carbo x4 12/01-3/02, taxol x6 4/02-7/02, Tamoxifen 7/02-9/02, cisplatin + etoposide 9/02-11/02, etoposide 12/02, 
talc pleurodesis 1/03, caelyx 2/03 - 3/03, Gem/carbo 3/03 - 6/03 
05  TAH+BSO+Oment 11/97, Carbox5 3/99-7/99, carbo x 6 10/01-1/02, biliary stent 4/02, cisplat+etoposide 5/02-6/02, 
etoposide 7/02-8/02 
06  BSO+ Omentectomy 3/01 , Taxol/Carbo 4/01-9/01, Topotecan 9/02-1/03, Carbo 3/03-4/03, Cisplatin 5/03-6/03 
07  BSO+Omentectomy 3/02, Carbo x 6 3/02-7/02, Cisplatin+Taxotere x 5 12/02-1/03, Tamoxifen 1/03-9/03 
08  Sigmoid colectomy 1/02, 5FU/FA 3/02, Oxaliplatin+de Gramont 3/02 - 8/02, Capecitabine 5/03 - 8/03 
09  TAH+BSO+Omentectomy 5/01, Carboplatin x4 & Docetaxel/Gemcitabine x 4 (SCOTROC2) 6/01 - 12/01, 
Carboplatin 9/02 - 7/03, cisplatin+etoposide 9/03 - 10/03 
10  surgery Lt arm 7/99 , Lt axilla dissection 6/02, DTIC 5/03 - 7/03 , BIBF 1120 8/03 - 11/03 
11  Gemcitabine + Cisplatin 10/03 - 12/03 
12  Oxaliplatin + 5FU 11/99, Rt hemihepatectomy 2/00, de Gramont 4/00 - 9/00, Irinotecan 4/01(stopped), Oxaliplatin 
6/01 - 10/01, Xeloda 10/02 - 2/03, Xeloda 8/03 - 1/04 
13 
BSO+Right Hemicolectomy 4/95, Carboplatin 5/95-9/95, Taxol+Carboplatin 3/96-6/96, TAH 6/96, Hexalen 1/97, 
Carboplatin 9/97-11/97, Topotecan 6/98-8/98, Cisplatin + Etoposide 11/98 - 1/99, Gemcitabine Carboplatin 11/99-
2/00, Taxotere+Carboplatin 6/00-9/00, Caelyx+Carboplatin 5/01-8/01, Tamoxifen 1/02-12/02, Carboplatin 1/03-
4/03 
14 
10/99 Left Orchidectomy, POMACE 11/99-1/00, Para-aortic lymphadenectomy 1/00, TIP 8/02-10/02, 
thorascopic resection 12/02, etoposide+stem cell harvest +ABMT 2/03, thorascopic resection 8/03, Taxol 
Gemcitabine Carboplatin 12/03-1/04, thorascopic resection 2/04 
15  Right Nephrectomy 9/01, IFN+IL-2+5FU (RE04 trial) 2/03-4/03 
16  OEO2 trial Cisplatin/5FU 9/01 – 10/01, Oesophagogastrectomy 11/01, Capecitabine 11/03 - 3/04 
17  TAH+BSO 1989, Carboplatin 12/89-4/90, Carboplatin 8/99-11/99, Phase I Tazorotene 10/00-12/00, cisplatin 2/01-
3/01, etoposide 2/01-6/01, Taxol 8/02-9/02 , Tamoxifen 12/02-6/04 
18  TAH+BSO 4/99, Carboplatin 5/99-8/99, Taxol+Carboplatin 9/03-12/03, Tamoxifen 4/04-8/04 
19  Anterior resection 11/01, 5FU+FA 2/02-8/02, Right hepatectomy 12/02, Failed liver resection 6/03, Irinotecan 7/03-
11/03, FOLFOX 3/04-6/04 
20  7/03 Radiotherapy 20Gy/5#, MVP 6/03-7/03, Gemcitabine+Carboplatin 9/04 
21  TAH+BSO 9/03, doxorubicin 1/04, Gemcitabine Taxotere 3/04-6/04 
22  imatinib 5/02-11/02, imatinib 3/03-12/03, Phase I trial BIBF1120 4/04-10/04 
23  Capecitabine 7/04 - 8/04, de Gramont 9/04 - 11/04 
24  BSO+Omentectomy 6/00 , Radiotherapy Para-aortic Nodes 4/04, Carboplatin 8/00-1/01, Etanercept 7/01–10/01 
Paclitaxel 11/01 - 3/02, cyclophosphamide, Methotrexate & celecoxib 8/03-2/04 
25  London lung Study 12 cisplatin etoposide+/-Thalidomide 7/04-10/04 
26  Radiotherapy 1/05 
27  excision melanoma right calf 9/04, right groin dissection 10/04, DTIC 12/04-1/05 
28  Right nephrectomy+adrenalectomy 5/03, IFN+IL-2+5FU(RE04) 10/03-12/03 , Sorafenib  8/04-1/05 
29  Right Radical Nephrectomy/Adrenalectomy 4/04, Interferon alpha 5/04-9/04, Palliative RT 7/04-8/04, 
Vertebroplasty 1/05, Gemcitabine 9/04-12/04, Tarceva+Bevacizumab 12/04-3/05 
30  Oesophagectomy 6/03, Epirubicin cisplatin capecitabine 7/03-9/03, Capecitabine+Mitomycin C 10/04-2/05 
31  Nephrectomy 6/04, Interferon 7/04-10/04, Tarceva+Bevacizumab 1/05-3/05 
32  Carboplatin/Paclitaxel & Carboplatin/Topotecan 01/03–06/03 , Removal Pelvic Cyst 8/03, Liposomal Doxorubicin 
10/04–2/05 
33  Hysterectomy 3/97 , Carboplatin x 6 4/97–9/97 , Carboplatin , Liposomal Doxorubicin, Topotecan 11/04 
34  Radioactive Iodine 220mCi 1/05 
35  TAH+BSO+Omentectomy 10/03 , Gemcitabine+Taxol+Carboplatin 11/03–4/04 
36  Laparotomy+peritoneal biopsy, 9/01, Docetaxel+Carboplatin(SCOTROC2 trial) 11/01-5/02, Interval debulking 
01/02, Vaginal repair 3/02, Altretamine 12/03-5/04, Cisplatin+Etoposide 8/04-9/04, Caelyx 3/05-4/05 Chapter 6 – UKCTC-207 Phase I Trial 
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TAH = Total abdominal hysterectomy 
BSO = Bilateral salpingo-oophorectomy
Table 6.3 Continued 
 
37 
12/00 TAH+BSO+Omentectomy, 2/01-5/01 Carboplatin x 5, 8/03 Radiotherapy 45Gy in 15# to Lt hip+femur, 7/04 
Pamidronate monthly, 1/04-6/04 Tamoxifen, 6/04-7/04 Altretamine, 8/04-12/04 Carboplatin + Taxol x6 
38  Left nephrectomy 9/04, RE04(IFN+IL2+5FU) 10/04-1/05 
39  Temozolomide 2/05, High dose Interferon alpha 20MU 4/05-5/05 
40  Doxorubicin+Ifosfamide 2/05 , Gemcitabine+Docetaxel 5/05–6/05 
41  Wide local excision Nasal Lesion 3/2002, Neck Dissection 8/04, DTIC x2 5/05 
42  BSO+Pelvic Clearance 12/04, Carboplatin+Paclitaxel x3 01/05–2/05, Carboplatin+Doxorubicin x3 3/05 
43  Excision Left ankle melanoma 4/01, Lt groin recurrence 9/04 +pelvic disease, DTIC x6 cycles 4/05 
44  Excision Melanoma 6/03, Right Axillary Dissection 1/05, DTIC+Sorafenib 8/05–9/05 
45 
Anterior Resection Rectum 3/03, 5FU+FA 5/03–10/03, Partial Hepatectomy+RFA Liver 2/04, 
Oxaliplatin+Capecitabine 3/04, Oxaliplatin+Capecitabine+Bevacizumab 7/04–10/04 ,  Capecitabine+Bevacizumab 
10/04–11/04, Bevacizumab 11/04–3/05, Further RFA Liver 4/05, Cetuximab 6/05–7/05, Irinotecan+Cetuximab 7/05 , 
Cetuximab 9/05 
46  Gemcitabine+Carboplatin 4/05–7/05 , Thalidomide/Placebo 7/05–10/05 C
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Table 6.5 – Subjects’ Response 
Trial 
No.  Arm  Cohort  No. Cycles  Clinical 
Improvement
RECIST Best 
Response*  Ca125 Response (>50%)** 
01  Carbo  1  6  Yes  N/E(SD)  Yes 585,226,68,85,97,88 
02  Taxol  1  6  Yes  PR  Yes 268,156,149,85,82,79 
03  Taxol  1  1  No  N/E(PD)  No 297,48 
04  Taxol  1  3  No  PD  No 5976,7038 
05  Taxol  1  6  Yes  SD  Yes 1879,1395,845,862,680,514 
06  Taxol  2  4  No  N/E(PD)  Yes 852,428,483,190 
07  Carbo  1  6  Yes  SD  No 576,423,417,367,527,811 
08  Carbo  1  2  No  SD  N/A 
09  Taxol  2  5  No  N/E(SD)  Yes 1222,380,196,130,149,121 
10  Carbo  2  4  Yes  PD  N/A 
11  Taxol  2  2  No  SD  N/A 
12  Carbo  2  2  No  PD  N/A 
13  Carbo  2  2  No  SD  No 289,461,355 
14  Carbo  3  2  No  PD  N/A 
15  Carbo  3  6  Yes  SD  N/A 
16  Taxol  3  4  No  SD  N/A 
17  Carbo  3  3  No  SD  No 1581,1409,1268,1085 
18  Taxol  3  6  Yes  SD  Yes 1499,488,323,282,323,469,766
19  Taxol  3  1  No  N/E  N/A 
20  Taxol  4  4  No  SD  N/A 
21  Carbo  4  1  No  N/E(PD)  N/A 
22  Taxol  4  1  No  N/E(PD)  N/A 
23  Carbo  4  6  Yes  SD  N/A 
24  Taxol  5  1  No  N/E  No 129,123 
25  Taxol  4  4  Yes  PR  N/A 
26  Taxol  4  2  No  PD  N/A 
27  Taxol  5  2  Yes  PD  N/A 
28  Carbo  4  3  No  SD  N/A 
29  Carbo  4  1  No  N/E  N/A 
30  Taxol  5  6  Yes  PR  N/A 
31  Taxol  5  6  No  SD  N/A 
32  Carbo  4  6  Yes  PR  No 294,248,259,404,591,875,1101 
33  Taxol  5  4  No  PD  Yes 
2759,2247,1280,967,466,367,254 
34  Carbo  4  5  Yes  SD  N/A 
35  Triplet  1  6  Yes  PR  Yes 1080,1139,1257,325,97, 56, 39
36  Triplet  1  6  Yes  SD  Yes 1008,874,587,449,449,308 
37  Triplet  1  6  Yes  PD  No 269,280,456, 501,530,551 
38  Triplet  1  5  No  SD  N/A 
39  Triplet  2  2  No  PD  N/A 
40  Triplet  2  6  No  SD  N/A 
41  Triplet  2  6  Yes  SD  N/A 
42  Triplet  3  4  No  PD  N/A 
43  Triplet  3  2  No  SD  N/A 
44  Triplet  2  6  Yes  PR  N/A 
45  Triplet  2  2  No  PD  N/A 
46  Triplet  2  6  Yes  SD  N/A 
*   PD–Progressive disease, SD–Stable disease. PR–Partial response. N/A –Not applicable (non ovarian) 
**   Value prior to each cycle of treatmentChapter 6 – UKCTC-207 Phase I Trial 
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Table 6.6 – Response In 18 Ovarian Cancer Patients 
Patient 
ID 
Number Of 
Previous 
Treatment 
Regimens 
(Surgery, 
Radiation, 
Chemotherapy) 
Platinum 
Response 
Status 
(Sensitive / 
Resistant) 
RECIST 
Best 
Response* 
GCIG Ca125 
Response 
(>50%)* 
01  4  S  -  Yes 
02  5  S  PR  Yes 
03  4  S  -  No 
04  7  R  PD  No 
05  5  S  SD  Yes 
06  5  S  -  Yes 
07  4  R  SD  No 
09  4  R  -  Yes 
13  13  R  SD  No 
17  8  S  SD  No 
18  4  S  SD  Yes 
24  6  S  -  No 
32  2  S  PR  No 
33  3  S  PD  Yes 
35  2  S  PR  Yes 
36  5  S  SD  Yes 
37  7  S  PD  No 
42  3  R  PD  - 
* Patients Not Evaluable signified by “-“ 
 
 
Table 6.7 - RECIST Best Response Summary 
Response  Number Pts  % Evaluable 
Pts 
% Clinical 
Improvement  Site of Response 
N/E  9  -  11%(1/9)   
CR  0  0%  -   
PR  6  16%  100%(6/6) 
02(Ca ovary) – 
aortocaval node 
25(SCLC) – Right lung 
30(Ca oesophagus) – 
Splenic metastasis, liver 
metastases 
32(ca ovary) 
35(ca ovary) 
44(melanoma) – Right 
SCF, liver, adrenal 
SD  20  54%  45%(9/20)   
PD  11  30%  27%(3/11)   
 Chapter 6 – UKCTC-207 Phase I Trial 
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Vital Signs 
The following Figures 6.1 – 6.9 illustrate the changes observed in patients’ vital signs 
following infusion of CA4P. 
Mean HR/BP Following CA4P
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Figures 6.1 & 6.2 - Change In Mean Vital Signs Following CA4P Infusion 
Mean±Standard Error. Dotted line – Mean baseline value. Significant rise in BP and fall in HR is seen after an 
hour due to alterations in peripheral resistance, with a corresponding increase in heart rate at 3 – 4 hrs as BP 
falls. Change in systolic BP at 1hr from baseline 2p<0.000001 (2-sided group t-test) Chapter 6 – UKCTC-207 Phase I Trial 
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Change In Systolic BP In Patients With Above or Below Average 
Baseline BP
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Figure 6.3 
BP Change Following CA4P (Patients with Baseline BP Above/Below Mean) 
Mean±SE, p=ns. Patients with baseline BP above average are not more prone to alterations in BP following CA4P infusion. Those 
with below average baseline BP appear to have greater fluctuation in BP following CA4P infusion. Thanks to Gavin Shreeves, 
data manager, for assistance in producing this data. Chapter 6 – UKCTC-207 Phase I Trial 
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Mean Temperature Following CA4P
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Figure 6.4 - Mean Temperature Following CA4P Infusion 
Mean±SE. Dotted line – mean baseline value. At 6hrs from baseline, 2p=0.00005 (2-sided group t-test) 
Figure 6.5 - Mean Respiratory Rate Following CA4P Infusion 
Mean±SE. No significant changes seen. 
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QTc Interval Following CA4P Infusion
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Figure 6.6 - Mean QTc Interval Following CA4P Infusion 
Mean±SE. Significant prolongation of QTc Interval seen 4 hrs following CA4P infusion (within the 
normal range) 2p<0.0000001 (2-sided group t-test) C
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Haematological Toxicity 
 
Figures 6.10 – 6.12 and Table 6.8 illustrate the haematological toxicity observed in 
patients during the study. 
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Figure 6.10 - 
Haematological 
Parameters 
During Study. 
Mean±SE. These 
changes over the course 
of the study are as 
expected from cytotoxic 
chemotherapy. The rise 
in lymphocytes is 
unexpected, and was 
also seen in the A5B7 
study (Chapter 2) 
Fig. 6.11: Comparison of Haematological Toxicity With Bilenker Study (Bilenker et al., 2005).
Neutropenia & thrombocytopenia greatly reduced in this study with carboplatin administered 20-
22hrs post CA4P. Chapter 6 – UKCTC-207 Phase I Trial 
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Figure 6.12a,b Box & whisker plots illustrating neutrophil and platelet 
distributions at baseline (Day 1) and nadir. Blood counts were taken weekly 
during the study, the lowest counts are illustrated. Myelosuppression is as 
expected.Chapter 6 – UKCTC-207 Phase I Trial 
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Table 6.8 - Overall Haematological Toxicity In The Three Arms. Number of episodes illustrated. 
 
CTC Grade 1  Carboplatin Paclitaxel  Triplet  Total 
Anaemia  7  9  5  21 
Lymphopenia  3  2  2  7 
Neutropenia  2      2 
Thrombocytopenia  4  2  7  13 
Leucopenia  2  2  1  5 
CTC Grade 2  Carboplatin Paclitaxel  Triplet  Total 
Anaemia  6  5  6  17 
Lymphopenia        0 
Neutropenia  2  6  2  10 
Thrombocytopenia  1      1 
Leucopenia  2  6  7  15 
CTC Grades 3-4   Carboplatin Paclitaxel  Triplet  Total 
Anaemia    1  1  2 
Lymphopenia  2  3  1  6 
Neutropenia      8  8 
Thrombocytopenia    1  1  2 
Leucopenia      2  2 C
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Pharmacokinetics 
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Figs. 6.14a,b,c – Plasma & Urinary Paclitaxel & Carboplatin Clearance Pharmacokinetics 
Courtesy of Covance: N=31 Paclitaxel analysis (complete). Carboplatin analysis final data incomplete (n=8) Paclitaxel plasma 
concentrations decline in a biphasic manner. The initial rapid decline represents distribution to the peripheral compartment 
and elimination of the drug. The later phase is due, in part, to a relatively slow efflux of paclitaxel from the peripheral 
compartment. Carboplatin exhibits linear pharmacokinetics. Urinary PK, n=8 Patients with creatinine clearances of 
approximately 60 mL/min or greater excrete 65% of the dose in the urine within 12 hours and 71% of the dose within 24 
hours. Source: www.rxlist.com. There is NO evidence of delayed excretion of cytotoxic drugs following CA4P administration Chapter 6 – UKCTC-207 Phase I Trial 
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Table 6.9. Carboplatin pharmacokinetics and blood count nadirs. Eyeballing the results 
there is no obvious relationship between degree of neutropenia or thrombocytopenia and 
carboplatin AUC or Cmax. PK measured by Covance Clinical Research Unit, USA. 
www.covance.com  
 
Patient 
ID 
Carboplatin 
AUC given 
to patient 
CA4P 
mg/m2 
Paclitaxel 
Dose 
mg/m2 
Carboplatin 
AUC 
mmol.h.l-1 
Carboplatin 
Cmax mM 
Hb 
nadir 
x109/L 
Neuts 
nadir 
x109/L 
Plt 
nadir 
x109/L 
10  4  45  -  67190  24700  12.7  2.31  203 
12  4  45  -  67990  24800  8.5  5.40  302 
13  4  45  -  144390  105000  12.0  2.26  147 
14  5  45  -  96430  41100  11.0  2.72  103 
15  5  45  -  92480  31900  8.6  3.32  175 
17  5  45  -  87250  41300  10.0  3.31  165 
21  5  54  -  111770  31200  10.1  2.85  106 
23  5  54  -  89660  33200  10.6  2.51  215 
32  5  54  -  76710  21000  10.1  1.78  172 
34  5  54  -  54570  11500  12.4  1.60  196 
39  5  63  175  66340  15700  9.7  0.63  323 
41  5  63  175  64170  21100  10.5  0.68  137 Chapter 6 – UKCTC-207 Phase I Trial 
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Non-Haematological Toxicity 
Table 6.10. Drug-Related Toxicity seen in 5 or more patients (Number of episodes per CTC 
grade) 
 
Carboplatin Arm  Paclitaxel Arm  Triplet Arm  Toxicity: 
G1  G2  G3  G1  G2  G3  G1  G2  G3 
Total 
Fatigue  4  5  3  5  7    3  6    33 
Hypertension  6  1  1  9    1  8  1  1  28 
Pain, other  4  4  1  3  7  3    5  1  28 
Paraesthesia  6    1  8  1  1  6  3    26 
Alopecia  2      2  12    1  8    25 
Tachycardia  10      8      6      24 
Hypotension  4  1    6  3    8  1    23 
Nausea  4  5    4  2    3  5    23 
Pain, abdominal  5  1  1  2  4  2    1  1  17 
Pain, headache  1  5  1  3  1    1  4    16 
Fever  5      6  3    1      15 
Vomiting  3  2  1  3  3    1  1  1  15 
Constipation    4    1  4    1  3    13 
Diarrhoea  2  1    3  1  1  1  2  1  12 
Flushing  3  1    1      2  1    8 
Itching  3      1      4      8 
Infection    1      1  2  2  1    7 
Anorexia  1  1          4  1    7 
Myalgia  1      3      2  1    7 
Oedema  2  1    1  1    1      6 
Rash    1    1  1    3      6 
Stomatitis  1      1  1    2      5 
Dyspnoea  2  1      1    1      5 
Itching, perianal  3      1      1      5 
Muzzy head  2      2      1      5 
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Table 6.11. Toxicities seen in less than 5 patients but including at least one grade 3 or 4 
event. 
Carboplatin Arm  Paclitaxel Arm  Triplet Arm  Toxicity: 
G1  G2  G3  G4  G1  G2  G3  G1  G2  G3 
Total 
Agitation  2    1    1            4 
Allergic reaction        1      1  1      3 
Motor 
Neuropathy    1  1        1        3 
Cough    1      1    1        3 
Dysphasia  1    1                2 
Ataxia                  1  1  2 
Dehydration              1        1 
Incontinence      1                1 
Sepsis      1                1 
 
Table 6.12 – Serious Adverse Events, Including Grade 4 Toxicity 
Patient ID  SAE  Drug Related 
03  Intestinal Obstruction  No 
06 
Catheter Sepsis 
Hydronephrosis 
Death 
No 
09  Central Line Infection 
Nausea & Vomiting 
No 
Possibly 
13 
Clonic Convulsion 
Nausea & Vomiting 
Neck Pain 
No 
Possibly 
No 
14  Rectal Haemorrhage  No 
16  Upper Abdominal Pain  Possibly 
17  Drug Hypersensitivity Reaction 
Food Poisoning 
Carboplatin 
No 
19 
Abdominal Pain 
Abdominal Distension 
Death 
No 
No 
No 
20  Lower Respiratory Tract Infection  Unlikely 
21  Renal Failure 
Sepsis  Unlikely 
24 
Abdominal Pain 
Anorexia 
Pyrexia 
Fatigue 
No 
No 
No 
No 
25  Lower Respiratory Tract Infection  No 
29  Asthenia  Possibly 
30  Dehydration  No 
36  Constipation 
Dehydration 
Unlikely 
No 
39  Dehydration  No 
43  Ataxia  CA4P DLT Chapter 6 – UKCTC-207 Phase I Trial 
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Discussion 
 
We have shown CA4P combination therapy to be safe and well-tolerated with promising 
indications of activity especially in ovarian cancer (Gaya et al,2005). We have also 
demonstrated safe and effective scheduling of CA4P with carboplatin with no delayed 
renal excretion or increased toxicity.  
 
The alterations in vital signs following CA4P have been documented previously in single 
agent phase I CA4P studies (Anderson et al., 2003; Dowlati et al., 2002; Rustin et al., 
2003), and the A5B7 study (Chapter 2), and are thought to be due to alterations in 
peripheral resistance (Ley et al., 2007; Prise et al., 2002; Tozer et al., 1999). In this study, 
following CA4P there was a mean 13mmHg rise in systolic BP, and a mean 9mmHg rise 
in diastolic BP one hour after infusion, with a corresponding mean 7 bpm fall in HR.  
 
Patients with a baseline BP above the mean of 124/75 did not experience greater 
alterations in vital signs than those with baseline BP below the mean. Longstanding 
vascular disease may alter the body’s ability to adapt to the vascular assault of CA4P, or 
the endothelium may already be damaged and therefore more prone to CA4P endothelial 
cell attack. These patients certainly have a higher degree of pre-existing endothelial 
damage as a result of their hypertension (Ferroni et al., 2006; Taddei et al., 2006), 
however we have not demonstrated that they are significantly more prone to alterations 
in peripheral resistance following the CA4P endothelial assault. These patients are also 
more likely to suffer cardiovascular complications following CA4P (Chaplin et al., 2006). 
 
A rise in core body temperature was demonstrated, most pronounced 4h following 
CA4P. This is most likely an inflammatory response to the CA4P induced endothelial cell 
damage, and has been previously demonstrated in vitro (Brooks et al., 2003). Rises in 
neutrophil counts were documented in the A5B7 study 4 hours following CA4P.  
 
The effect of CA4P on cardiac conduction has been well documented (Cooney et al., 
2004). Our study showed a mean 15ms lengthening of the QTc interval four hours 
following CA4P infusion within the normal range, with no significant clinical 
consequences. Phase I single agent studies showed normalisation of QTc by 24 hours 
(Anderson et al., 2003; Dowlati et al., 2002; Rustin et al., 2003). Chapter 6 – UKCTC-207 Phase I Trial 
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Haematological toxicity was not increased with the addition of CA4P from that expected 
with the cytotoxic agents alone. It has been previously shown that paclitaxel antagonises 
the thrombocytopenic effects of carboplatin in the megakaryoblast cell line MEG-01, 
and this may account for some of the reduced haematological toxicity seen in our study 
(Guminski et al., 2001), in addition to scheduling,  as only two cases of grade 3 
thrombocytopenia were observed. Rates of grade 3 neutropenia or anaemia were as 
expected and not dose limiting. 
 
The importance of the chronological scheduling of CA4P and cytotoxic chemotherapy 
can be dramatically illustrated by Bilenker’s Phase I trial of CA4P in combination with 
carboplatin in advanced malignancy (Bilenker et al., 2005). The study was terminated 
early after sixteen patients received 40 cycles of CA4P at doses escalating from just 27 - 
36mg/m
2, with carboplatin dosed to an initial AUC5. Carboplatin was given as a 30min 
infusion on day 1 followed one hour later by CA4P infused over 10min.  
 
Interestingly in this study, platelet trends were analysed in the context of a previously 
published formula relating carboplatin dosage and changes in platelet count (Egorin et 
al., 1984): 
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Out of six patients at the first dose level of CA4P 27mg/m
2 with carboplatin AUC5, 
there was one case of grade 3 neutropenia lasting six weeks, which was considered a 
DLT. There were also three cases of grade 3 thrombocytopenia. At the next dose level of 
CA4P 36mg/m
2 with carboplatin AUC5, two out of six patients experienced dose 
limiting grade 4 thrombocytopenia, and another two grade 3 thrombocytopenia. There 
were also two cases of grade 4 neutropenia. The last four patients received CA4P 
36mg/m
2 with carboplatin AUC4. Grades 2 and 3 thrombocytopenia, and grade 3 
neutropenia occurred at this dose level. Non-haematological toxicity was generally mild, 
and not dose limiting. Six out of 16 patients showed RECIST stable disease. 
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Using the formula above, the authors concluded that the predicted mean platelet nadir 
was 127, whereas the actual mean platelet nadir was 117. The mean ratio of observed 
AUC to predicted AUC was 1.16. Linear regression analysis indicated a strong 
correlation between the observed to predicted ratio of carboplatin AUC with CA4 AUC 
(p=0.008) (Fig 6.15), highly suggestive of a pharmacokinetic interaction. 
 
 
 
Fig. 6.15 Plot of Observed/Predicted Ratio Of Carboplatin AUC by CA4 AUC (mg x 
min/mL) with Fitted Regression Line (p=0.008) From Bilenker (Bilenker et al., 2005) 
 
This data suggests that when giving CA4P in combination with carboplatin the reduction 
in renal perfusion induced by CA4P must recover prior to administering the carboplatin. 
Giving carboplatin 24 hours after CA4P has been shown in the murine model to be as 
effective as giving it 1 or 4 hours apart (Siim et al., 2003; Staflin et al., 2006). Twenty four 
hours after CA4P administration it is suspected that there is rapid proliferation of the 
viable tumour rim stimulated by circulating endothelial progenitor cells (Shaked et al., 
2006). This might therefore be the best time to give carboplatin. In clinical practice 
carboplatin is frequently given in combination with paclitaxel for lung and ovarian 
cancers. As this combination showed enhanced activity when given with CA4P in the 
murine model and better therapies are needed for these cancers, a clinical trial was 
indicated. In view of the toxicity seen by Bilenker and colleagues we planned our dose 
escalation study initially combining CA4P with carboplatin or paclitaxel as doublets 
before combining all three drugs. The difference in haematological toxicity is dramatically 
illustrated in Table 6.13 and Figure 6.11.  Table 6.9 shows there is no obvious 
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or Cmax so the difference is due to the timing of administration of carboplatin following 
renal recovery from the CA4P effect. 
 
Table 6.13: Comparison of haematological toxicity in two studies following carboplatin + CA4P. N=16 in 
both studies 
CTC 
Grade 
% Neutropenia 
(Bilenker) 
% Neutropenia 
(Gaya) 
% Thrombocytopenia 
(Bilenker) 
% Thrombocytopenia 
(Gaya) 
0  44  56  12  62 
1  6  25  25  38 
2  19  13  6  0 
3  19  6  38  0 
4  12  0  19  0 
 
The most efficacious timing of cytotoxic agents in relation to CA4P is unknown. Our 
regimen of administering the cytotoxics 20h after CA4P has shown activity and little 
increased toxicity. The pharmacokinetic data confirms no delayed excretion of 
carboplatin or paclitaxel following CA4P. The increased cell killing would probably result 
from death of hypoxic cells at the tumour core after CA4P followed by conventional 
cytotoxic cell death 20h later. This resistant proportion of hypoxic cells, which would 
conventionally lead to repopulation of the tumour, may be reduced with the increased 
cell killing of the combination therapy. CA4P has also recently shown increased 
antitumour activity in combination with radiotherapy in lung cancer & prostate cancer 
(Mandeville et al., 2007; Ng et al., 2007).  
 
There is no noticeable increase in toxicity from combination therapy with the addition of 
CA4P. CA4P was well tolerated up to the MTD of 63mg/m
2. The toxicity of paclitaxel 
and carboplatin was as expected – fatigue, paraesthesia, alopecia, nausea, diarrhoea, 
anorexia, myelosuppression. Side effects from the CA4P were mild and short lived, 
consisting mainly of CTC grade 1 toxicities – tumour pain, fatigue, flushing, pruritis, 
headaches,nausea, and hypertension. The DLT was neurological – cerebellar ataxia, as 
confirmed in previous studies (Dowlati et al., 2002; Rustin et al., 2003). The majority of 
serious adverse events were not drug related, or unexpected, until DLT was reached 
(Table 6.12). 
 
There were some dramatic tumour responses with therapy. 27% of patients with 
RECIST PD and 45% of those with SD experienced a clinical improvement in Chapter 6 – UKCTC-207 Phase I Trial 
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symptoms. Overall RECIST assessment showed 16% PR, 54% SD and 30% PD. Patient 
02 experienced a reduction in an aorto-caval lymph node from 24mm to 16mm; patient 
25 a lung metastasis reduced from 50mm to 25mm; patient 30 a splenic metastasis 
(72mm to 35mm) and liver metastasis (72mm to 40mm). Patient 40 showed a reduction 
in right supraclavicular metastasis (30mm to 7mm) and a liver metastasis (20mm to 
9mm). 
 
Of 18 heavily pretreated patients with ovarian cancer (including one case of fallopian 
tube carcinoma), half had a Ca125 fall over 50%. Of 13 RECIST assessible patients there 
were 3 partial responses and 6 cases of disease stability through the study. Of 5 platinum 
resistant patients, 3 responded, one had a Ca125 drop >50%, and two had RECIST SD. 
CA4P induced cell death from vascular shutdown occurs independently of the platinum 
sensitivity of the tumour cell; it is dependent solely on the endothelial cell damage within 
any particular tumour cell population. The response of platinum resistant ovarian cancer 
to the combination therapy will be assessed further in the Phase II component of the 
study. 
 
Conclusions 
 
The combination of CA4P with Paclitaxel and Carboplatin at doses of 63mg/m
2, 
175mg/m
2, and AUC5 respectively, is safe, well tolerated, and shows early indications of 
activity in heavily pretreated patients. Haematological toxicity is greatly reduced 
administering cytotoxics 20-22h post CA4P due to normalisation of renal function. The 
combinations appear particularly active in both platinum sensitive and platinum resistant 
ovarian cancer. These doses will be used in the Phase II component of the study in 
patients with platinum resistant ovarian cancer, and are also being used in non small cell 
lung cancer (NSCLC) in combination with Bevacizumab. Further dose escalation of 
CA4P with these cytotoxic agents would not be safe on the basis of significant phase I 
preclinical and clinical combination data. CA4P efficacy data in combination with other 
cytotoxic agents is awaited. 
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Chapter 7                                                                      
Relationship Between Human Tumour Angiogenic Profile And 
Combretastatin-Induced Vascular Shutdown – An Exploratory Study. 
 
 
Abstract  
 
CA4P acts most effectively against immature tumour vasculature. We investigated whether 
histological angiogenic profile can explain the differential sensitivity of human tumours to 
CA4P, by correlating the kinetic changes demonstrated by DCE-MRI in response to CA4P 
with tumour immunohistochemical angiogenic markers. Tissue was received from 24 
patients (mean age 59, range 32–73, 18 females, 6 males). An angiogenic profile was 
performed using standard immunohistochemical techniques. Dynamic MRI data were 
obtained for the same patients before and four hours after CA4P. Three patients showed a 
statistically significant fall in K
trans following CA4P, and only 1 patient a statistically 
significant fall in IAUGC60. There were widespread falls in kinetic parameters om other 
patients which did not achieve statistical significance. No statistically significant correlations 
were seen between the continuous or categorical variables and the DCE-MRI kinetic 
parameters other than between ang-2 and K
trans  (p=0.044). In conclusion, we found no 
strong relationships between changes in DCE-MRI kinetic parameters and the 
immunohistochemical angiogenic profile.  
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Introduction 
 
CA4P is a tubulin-binding selective VDA which causes rapid shutdown of blood flow to 
tumours with minimal effects on normal vasculature. Tumour endothelial cells are often 
immunohistochemically immature, lacking smooth muscle and pericyte coverage, and more 
sensitive to the effects of VDAs probably because the intracellular cytoskeleton is less 
developed (Tozer et al., 2005). Our aim was to determine human tumour vascular maturity 
using an immunohistochemical angiogenic profile, and to study any relationship with CA4P 
response assessed by change in DCE-MRI kinetic parameters (Gaya et al., 2008). 
 
We selected antibodies to differentiate immature vascular endothelium - CD105 (endoglin); 
CD61 (β3-integrin); the pericyte marker alpha smooth muscle actin (αSMA); a marker of 
hypoxia (Glut-1); proliferation marker (Ki-67); and markers associated with the angiogenic 
switch (VEGF, PDGFB, angiopoietin-1, angiopoietin-2).  
 
Materials & Methods 
 
Following ethics approval, patients enrolled in Mount Vernon Phase I CA4P studies 
(PH1/066 & PH1/092) who underwent DCE-MRI analysis were identified. Records were 
obtained from 26 identified patients and tissue was available for 24 (Table 7.1). A full set of 
DCE-MRI data was available for 21. Tissue blocks were coded to conceal patient identity.  
4μm sections were cut onto slides, and stained with the panel of antibodies at 
concentrations and with control samples illustrated in Table 7.2.  
 
No patient from the PH1/066 study was alive at the time of this project. The ethics 
committee approved this study without the need to obtain additional consent from the 
relatives of the deceased; it was felt this would cause considerable distress to the relatives, in 
some cases years after their loved ones died. In addition, the stored tissues were considered 
surplus to clinical requirements. Patients from the PH1/092 study gave full informed 
consent for their stored tissues to be used. This study was performed in compliance with the 
Human Tissue Act (2005). 
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Table 7.1 – Characteristics of Patients’ Tumours – G1/2/3 = Well/moderately/poorly 
differentiated 
 
 
Patient 
ID 
Phase I 
Trial 
Primary 
Tumour Site 
Nature of 
Specimen  Histology 
Date 
Specimen 
Taken 
CA4P 
Dose 
(mg/m
2) 
01  Paratesticular  Spindle Cell 
Sarcoma  08/1999  52 
02  Adrenal  Carcinoma  06/1993  68 
03  Uterus  Leiomyosarcoma  03/1999  88 
04  Renal  Renal Papillary 
Carcinoma  11/1997  40 
05  Breast  Ductal Carcinoma  02/1993  68 
06  Uterus  11/1982  52 
07  Rectum 
Leiomyosarcoma 
01/1997  52 
08  Ovary  Papillary 
Adenocarcinoma  05/1994  5 
09  Uterus 
Primary Tumour 
Excision 
Leiomyosarcoma  05/1998  88 
10  Peritoneum  Biopsy  Primary Peritoneal 
Carcinoma  09/1999  52 
11  Right tibia  Leiomyosarcoma  10/1997  68 
12  Ovary 
Primary Tumour 
Excision  Papillary Serous 
Adenocarcinoma  03/1994  114 
13  Lung 
Excision Biopsy 
Cervical lymph 
node 
G3 Adenocarcinoma  04/1998  40 
14  Renal  Spindle Cell Renal 
Carcinoma  12/1999  114 
15  Renal  Spindle Cell Renal 
Carcinoma  08/1999  114 
16  Ovary  Papillary 
Adenocarcinoma  11/1991  88 
17 
PH1/066 
Single 
Agent 
CA4P 
Colon  11/1998  68 
18  Colon 
Grade 3 
Adenocarcinoma  05/2003  45 
19  Colon  G2 Adenocarcinoma  02/1999  45 
20 
PH1/092 
(A5B7) 
Colon  G3 Adenocarcinoma  11/2001  45 
21  PH1/066  Uterus  Leiomyosarcoma  07/1998  N/A 
22  Colon  10/2003  45 
23  Colon  08/2001  45 
24 
PH1/092 
Colon 
Primary Tumour 
Excision 
Grade 2 
Adenocarcinoma 
11/2002  45 
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Table 7.2: Panel of antibodies. The optimum concentrations were previously determined from titration experiments 
performed by Dr F Daley at the Gray Cancer Institute. Immunostaining for PDGF, CD61, ang-1 and ang-2 were 
performed by Dr U Qureshi at the NTRAC laboratory,Royal Free Hospital 
Antibody  Type of 
Marker  Source  Concentration
Specificity & 
Non-Specific 
Staining 
Control 
Sample 
CD34  Novocastra NCL-
END  1:60 
Endothelium, 
Connective Tissue, 
erythrocytes 
Tonsil 
αSMA  Sigma A2547  1:20000  Smooth Muscle  Tonsil 
CD105 
(Endoglin)  Dako M3527  1:1000 
Proliferating 
endothelium, activated 
macrophages 
Human 
Breast 
Carcinoma 
CD61 (β3-
integrin) 
Novocastra NCL-
CD61-308  1:100 
Endothelium,Platelets, 
Megakaryocytes, 
monocytes, 
macrophages 
Tonsil, 
Human 
Placenta 
VEGF 
Vascular 
Neomarkers MS-
1467  1:100  121,165,189 Isoforms 
Human 
Breast 
Carcinoma 
Ki-67  Proliferation  Dako M7240  1:200  345, 395 Isoforms. 
Nuclear Expression  Tonsil 
Glut-1  Hypoxia  Dako A3536  1:200  Erythrocytes,tumour  Tonsil 
PDGF 
Novocastra NCL-
PDEGF P-
GF.44c 
1:60  Tumour,macrophages, 
stroma,glia,epithelia 
Tonsil, 
Human 
Placenta 
Angiopoietin 
-1 
Santa Cruz 
Biotech Inc.H-98 
(sc-8357) 
1:50 
Tumour,Myocardium, 
vascular smooth 
muscle,lung,liver 
Human 
Placenta 
Angiopoietin 
-2 
Vascular / 
Tumour / 
Stromal 
Santa Cruz 
Biotech Inc. H-70 
(sc-20718) 
1:50  Tumour,Ovary, 
placenta,uterus 
Human 
Placenta 
 
1) Immunohistochemical Procedures 
Sections were deparaffinised in xylene for 5 minutes and rehydrated through graded alcohols 
(100%, 90%, and 70%) to water. Slides were stained using standard immunohistochemical 
techniques (Appendix 2). A summary of these techniques is presented below. 
 
CD34 and αSMA Doublestaining:  Dako’s Cytomation Envision doublestain system 
(K5361) was used performed according to the manufacturer’s instructions. The system is 
based on horseradish peroxidase (HRP) and alkaline phosphatase (ALP) labelled polymers 
which are conjugated with secondary antibodies against mouse and rabbit immunoglobulins. 
The polymers do not contain avidin or biotin, and so non-specific staining resulting from 
endogenous avidin-biotin activity in normal tissues is avoided. The least abundant antigen 
(CD34) was stained first followed by staining of the most abundant antigen (αSMA), to 
prevent flooding. Specimens were counterstained using Gills haematoxylin (Surgipath 
Europe Ltd 01500E) for seven seconds and washed. The samples were not dehydrated Chapter 7 – Angiogenic Profile and CA4P DCE-MRI Response 
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through graded alcohols to xylene, as fast red forms an end product which is soluble in 
organic compounds; specimens were therefore mounted and coverslipped using an aqueous 
based mounting medium (Dako Faramount Aqueous Mounting Medium S3025).  
 
CD105:  We used Dako’s Catalysed Signal Amplification staining system (K1497) and 
followed the manufacturer’s instructions exactly. The system incorporates a signal 
amplification method, based on the peroxidase-catalyzed deposition of a fluorescein-labelled 
phenolic compound, followed by a secondary reaction with a peroxidase-conjugated anti-
fluorescein (Bobrow MN, 1989; Von Wasielewski R, 1997). Antigen retrieval was not 
required on the rehydrated slides, using this high sensitivity detection system.  
 
Specimens were first incubated with 3% hydrogen peroxide to quench endogenous 
peroxidase activity, then incubated with protein block solution to suppress non-specific 
binding of subsequent reagents, followed by incubation with the mouse primary antibody 
(CD105). This was followed by sequential incubations with anti-mouse immunoglobulin-
HRP, fluorescyl-tyramide hydrogen peroxide (amplification reagent) and anti-fluorescein-
HRP. Staining was completed by incubation with diaminobenzidine/hydrogen peroxide, 
which resulted in a brown precipitate at the CD105 antigen site. Slides were then 
counterstained for 7 - 8 seconds in Gills Haematoxylin (Surgipath Europe Ltd 01500E), 
washed, dehydrated through graded alcohols to xylene,  mounted  using DPX (Surgipath 
08600E), and coverslipped. 
 
VEGF, Ki-67, Glut-1: Dako’s Universal autostainer machine was used. Antigen retrieval 
was performed in 0.01M citric acid pH6. Glut-1 & Ki-67 were microwaved for 3 x 4 min 
and VEGF for 4 x 4 min. Optimum antigen retrieval times were determined from titration 
experiments. Slides were transferred to the Dako Autostainer containing peroxidase block, 
the detection reagents (CheMate HRP,Dako K5001), and anti-human antibody (Table 7.2) 
in antibody diluent (Dako S2023). The autostainer programme included 5 minutes in 
peroxidase block, 1 hour incubation with primary antibody, 30 minute incubation with 
CheMate secondary and tertiary reagents and 5 minutes in diaminobenzidine substrate. 
When the programme was complete slides were removed from the machine and 
counterstained in Gills Haematoxylin for seven seconds, washed in tap water, dehydrated 
through graded alcohols (70, 90, 100%), cleared in xylene and mounted in DPX. 
 
Ang-1, Ang-2, PDGF, CD61: Benchside manual staining procedures were used (appendix 
2). Endogenous peroxidase activity was quenched with 1.5% hydrogen peroxide in methanol Chapter 7 – Angiogenic Profile and CA4P DCE-MRI Response 
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for ten minutes. Antigen retrieval was performed by microwaving in 0.01M citric acid pH6 
for ten minutes (ang-1) and twenty minutes (ang-2). After washing in Tris-Buffered Saline 
Tween (TBST) primary antibody was applied as shown in Table 7.2, and incubated 
overnight at 4°C. After rinsing in TBST, Dako Envision anti-rabbit secondary antibody 
(K5007) with peroxidase was applied for thirty minutes. Antigen was developed with 
diaminobenzidine, slides counterstained with haematoxylin, dehydrated, cleared and 
mounted. For CD61 & PDGF Vectastain’s mouse IgG normal horse serum (Vector Labs, 
California) diluted in TBS was applied for thirty minutes. A horse anti-mouse biotinylated 
secondary was then applied, followed by incubation with streptavidin-peroxidase reagent. 
 
The integrin most commonly associated with proliferating endothelium is αvβ3 
(CD51/CD61 Vitronectin receptor complex). The CD51 αv component is destroyed by the 
paraffin wax histological fixation method; consequently only the CD61 β3 component of the 
integrin was assessable on our sections. The antibody had been tested previously on human 
tumours (Merono et al., 2002). 
 
2) Immunohistochemical Profile Analysis 
Each slide was assessed using a Zeiss Axioskop microscope, with Visilog 5.0 (Noesis) image 
capture software (fig. 7.1). The random field techniques described by Eberhard (Eberhard et 
al., 2000) were used. Every fifth field was captured digitally at x400 magnification (figures 
7.2 – 7.13). At least twenty fields were captured per slide. In small samples the entire 
specimen was captured. Any immunoreactive endothelial cells that were separate from 
adjacent microvessels were considered countable vessels, and recorded as the number of 
vessels per high power field (HPF). αSMA staining was analysed concurrently - any CD34
+ 
vessel also αSMA
+ was recorded. Mean microvessel density (MVD/mm
2) and pericyte 
coverage index (PCI) were calculated after analysing at least 20 random fields per slide 
(Table 7.3). To determine the Ki-67 proliferation index(%) or Glut-1 hypoxia index(%) 
each slide was scanned at low & high magnification. A semi-quantitative visual assessment 
was made across the slide of the proportion of tumour cells staining positively (Table 7.3). 
 
The following antigens were analysed using a categorical scale, with the proportion of 
immunoreactive cells graded as weak, moderate or strong by direct visual assessment at low 
(x50) and high (x400) magnification (Table 7.3). The most appropriate cut off values were 
selected from previous studies. VEGF: Absent (<5%), weak (5 – 25%), moderate (25 – Chapter 7 – Angiogenic Profile and CA4P DCE-MRI Response 
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50%), strong (>50%) (Erdem et al., 2007). Ang-1/2: Cytoplasmic expression predominantly 
and grading system as for VEGF (J. Lind et al., 2005). PDGF: Highly expressed in stroma; 
absent (<1% tumour staining), weak (1 – 10%), moderate (10 – 25%) and strong (>25%) 
(Barnhill et al., 1996). 
 
 
Figure 7.1 Visilog 5.0 Software, used for microscope image capture and analysis. 
 
Random results were checked by an experienced immunohistochemist (FD), who had not 
seen the initial data. In case of disagreement as to the correct result, that slide was analysed 
by a Consultant Histopathologist. The author was trained to use the software and to analyse 
the samples by Dr Frances Daley in the Gray Cancer Institute, Northwood, UK.  
 
3) DCE-MRI Data 
DCE-MRI involves the rapid acquisition of sets of T1-weighted images through tumour as 
an intravenous bolus of contrast agent is injected.  The change in signal intensity over time 
can be analysed with mathematical models (Tofts, 1997). Quantitative kinetic parameters are 
derived which provide information about tumour microcirculation as they are indirectly 
related to perfusion, vascular permeability and vessel surface area (d'Arcy, 2006). Chapter 7 – Angiogenic Profile and CA4P DCE-MRI Response 
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Studies were performed on a 1.5 Tesla scanner as previously described (see Chapter 3 and 
(Galbraith et al., 2003)). Images were analysed using specialist software (Magnetic Resonance 
Imaging Workbench (MRIW), Institute of Cancer Research, London) (d'Arcy, 2006). A 
dynamic analysis was performed using MRIW for each pixel within the ROI on each slice. 
MRIW converts signal intensities of the T1-weighted DCE-MRI dataset into T1 relaxation 
rates and then into Gd-DTPA concentrations for individual voxels, using the methods 
described by Parker (Parker et al., 1997). Standardised terms were employed as defined in 
Tofts (Tofts et al., 1999). The percentage change from mean baseline kinetic parameters 
following CA4P was calculated (Table 7.4). 
 
4) Statistical Analysis 
Measurement error (Bland & Altman, 1996) was used to define repeatability confidence 
intervals for the MRI parameters. Linear regression & correlation analysis were used to test 
for relationships between the continuous variables and MRI parameters. Analysis of 
Variance (ANOVA) was used to test for relationships between categorical variables and 
MRI parameters. 
 
Results 
 
Tissue was received from 24 patients (mean age 59, range 32 – 73, 18 females, 6 males). 18 
patients were taken from the PH1/066 single agent UK CA4P trial (Rustin et al., 2003), and 
6 from the PH1/092 CA4P + A5B7 anti-CEA antibody study (currently unpublished). The 
most common histological subtypes (Table 7.1) were colorectal adenocarcinoma(7), uterine 
leiomyosarcoma(4) and ovarian adenocarcinoma(3). The age of the tumour blocks varied 
between 6 months and 21 years. All but one block contained primary tumour from surgical 
specimens, not metastatic tissue as patients were not rebiopsied before entrance to the phase 
I trials. We only studied patients who received doses of CA4P 40-114 mg/m
2 that have been 
associated with changes in DCE-MRI kinetic parameters. There was excellent agreement in 
scoring between samples analysed by the author and random samples analysed by Dr Daley. 
No samples had to be referred to a 3rd opinion. 
 
There was wide intrapatient variability in kinetic parameter change following CA4P (Table 
7.4). Percentage change in K
trans from mean baseline following CA4P varied between +111% Chapter 7 – Angiogenic Profile and CA4P DCE-MRI Response 
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and -75%, and IAUGC60 between +186% and -90%. In reality, only falls in these parameters 
(consistent with tumour vascular shutdown) are clinically significant. The 95% confidence 
interval for K
trans change (determined from repeatability analysis in the individual studies and 
repeated with the combined data) was -62.5% to +166.5%, IAUGC60±80%. There was no 
obvious visual relationship seen between CA4P dose and fall in kinetic parameters (Table 
7.4). Three patients (3, 10, 12) showed a statistically significant fall in K
trans following CA4P, 
and only 1 patient (12) a statistically significant fall in IAUGC60. 
 
There was wide variation in CD34 MVD & PCI (Fig. 7.14). Lowest values for PCI (01, 14, 
15, 21) were sarcomas. The two tumours with highest MVD (03, 24) were a leiomyosarcoma 
and adenocarcinoma respectively. High PCI should indicate a more mature vascular network 
within the tumour – 04, the highest PCI, is a renal papillary carcinoma, and renal tumours 
are known for their vascularity. 
 
Tumours with the highest proportion of CD105
+ vessels were 03 (leiomyosarcoma), 11 
(leiomyosarcoma), 14 (spindle cell renal carcinoma) and 24 (colorectal adenocarcinoma).  
 
Glut-1 expression was at a low level in most specimens studied. Several tumours showed 
marked hypoxia – 21 (leiomyosarcoma), 10 (primary peritoneal carcinoma), 12 (papillary 
serous ovarian adenocarcinoma), 15 (spindle cell renal carcinoma), and 22 (colorectal 
adenocarcinoma). The tumours with the highest ki-67 proliferation index were 18 (colorectal 
adenocarcinoma), 10 (primary peritoneal carcinoma), 12 (papillary serous ovarian 
adenocarcinoma), 22 & 23 (colorectal adenocarcinoma). The most hypoxic tumour (21) also 
had the lowest proliferation index.     
 
Highest ang-1 expression levels were in 02 (adrenal carcinoma), 06 (uterine 
leiomyosarcoma), and 24 (colorectal adenocarcinoma) fig. 7.15. Most tumours expressed 
PDGF only in stromal tissue. The five specimens expressing tumour PDGF were 04 (renal 
papillary carcinoma), 10 (primary peritoneal carcinoma), 16 (papillary ovarian 
adenocarcinoma), 21 (uterine leiomyosarcoma), and 24 (colorectal adenocarcinoma). Ang-2 
was expressed in all the tumour specimens analysed, and in many at a high level.  
 
No statistically significant correlations were seen between the continuous or categorical 
variables and the DCE-MRI kinetic parameters (Tables 7.5 & 7.6) other than between ang-
2 and K
trans(p=0.044). Upon visual inspection of Tables 7.3 & 7.4, there are no obvious 
relationships between the angiogenic profile and the DCE-MRI data. C
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Table 7.4 Percentage Change in DCE-MRI kinetic parameters 4h following CA4P. 95% Confidence Interval For 
K
trans change is -62.5% to +166.5%, ve ±29%, kep -41.8% to +71.8%, IAUGC60±80% . Values outside the 95% 
confidence intervals are in bold. There is no obvious relationship in this series between CA4P dose and fall in kinetic 
parameters, or correlation with vascular markers. There are 3 missing patients: 08 CA4P dose too low, 21 no data. 22 
motion artefact.  
 
 
Patient ID  CA4P Dose 
mg/m2 
% Change 
Ktrans post 
CA4P 
% Change ve 
post CA4P 
% Change 
kep post 
CA4P 
% Change 
IAUGC60 
post CA4P 
04  63.27  24.03  -20.49  15.66 
13 
40 
15.02  -65.84  30.19  186.00 
18  -22.91  3.36  -48.46  -8.38 
19  26.53  -1.92  -85.80  17.99 
20  39.71  8.94  -57.64  31.94 
23  -30.32  -0.96  -31.34  -30.03 
24 
45 
36.51  -1.66  -18.95  29.43 
01  -29.56  7.27  -30.12  -12.26 
06  65.75  18.76  34.98  146.30 
07  7.38  -5.74  14.72  -23.81 
10 
52 
-67.14  -30.34  -51.33  -58.92 
02  -30.61  -20.91  -5.76  -19.23 
05  1.59  -3.88  -10.51  -7.32 
11  -0.35  -11.52  -10.98  -17.02 
17 
68 
111.84  -26.64  216.06  -15.44 
03  -75.20  -44.06  -64.82  -57.65 
09  -58.02  -13.26  -52.53  -58.26 
16 
88 
33.01  -13.83  50.55  -1.88 
12  -65.49  -27.99  67.59  -90.21 
14  -20.00  -3.71  -16.43  -13.87 
15 
114 
93.46  76.58  86.10  82.38 Chapter 7 – Angiogenic Profile and CA4P DCE-MRI Response 
  203
Results - Example Images 
 
 
 
 
 
 
 
 
 
 
Fig 7.2 – CD34 (brown) staining endothelium, with 
non specific connective tissue uptake,  & SMA (red)  
staining pericytes and perivascular connective tissue 
x400, Patient 09 
Fig 7.3 Illustrates the difficulty of analysing vessels in 
sarcomas, where there is widespread uptake of SMA in 
the connective tissue tumour, ‘flooding’ visualisation 
of vessels (brown). CD34 was counted as single stain 
Fig 7.4 –  CD105+ immature vessel (brown) within a 
poorly differentiated colorectal cancer (x400) Pt 24 
Fig 7.5 – patient 10,  Ki67 tumour nuclear proliferation 
(x400) Ki-67+ nuclei brown. High proliferative index 
Fig 7.6 – patient 10 Glut-1 stain for hypoxic tumour 
cells (brown) x200. Note both membrane and 
cytoplasmic staining 
 
Fig 7.7 – VEGF Strongly Positive (brown) , patient 23 
x100. Staining endothelial cells, stromal cells and 
cytoplasmic positivity. Chapter 7 – Angiogenic Profile and CA4P DCE-MRI Response 
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Fig 7.8 – Patient 02, Angiopoietin-1 (x400) – 
Predominantly cytoplasmic uptake in tumour, with 
non specific clumping of antibody in places 
(?precipitation) 
Fig 7.11 – Example, Patient 22 PDGF x100 to illustrate 
strong stromal uptake, no uptake at all within tumour 
 
Fig 7.10 – Patient 02,  PDGF (brown nuclei)  x400. 
Many slides showed stromal uptake only. Here, 
scattered tumour nuclei stain positive, and 
macrophages 
Fig 7.13 – 08 CD61 (x400) –  non specific staining of 
the antibody in cases, which was not included in the 
analysis 
Fig 7.9 – Angiopoietin 2, Patient 19 Colorectal 
adenocarcinoma (x400) Note platelet staining within 
blood vessels, nuclear and cytoplasmic staining, 
vessels well visualised. 
Fig 7.12 – Patient 02 CD61 (x400) – Illustrates 
immature vessels and endothelial cells within tumour Chapter 7 – Angiogenic Profile and CA4P DCE-MRI Response 
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Table 7.5 and 7.6  – Correlation Coefficients and regression analysis between continuous, categorical 
variables, and MRI parameters. a) Correlation Coefficients (r2) and statistical significance between 
continuous variables, and MRI parameters (n=21). The majority of calculations yield a negative regression line 
i.e. fall in MRI parameter following CA4P is greater if higher MVD. b) ANOVA test for relationships between 
categorical variables and MRI parameters (F value, degrees of freedom and p value shown). Regression graphs 
in appendix 3. 
 
 
Continuous Immunohistochemical Variable 
MRI 
Parameter  CD34 
MVD 
αSMA 
PCI 
CD105 
MVD 
CD61 
MVD 
Ki-67  
(%) 
Glut-1 
(%) 
K
trans 
min
-1 
r
2<-0.001 
p=0.98 
r
2=-0.079 
p=0.23 
r
2<-0.001 
p=0.957 
r
2=-0.011 
p=0.539 
r
2=-0.077 
p=0.233 
r
2=0.018 
p=0.488 
ve % 
r
2=0.002 
p=0.867 
r
2=-0.124 
p=0.128 
r
2=-0.052 
p=0.335 
r
2<-0.001 
p=0.983 
r
2<-0.001 
p=0.868 
r
2=0.020 
p=0.556 
kep min
-1 
r
2=-0.0035 
p=0.805 
r
2=-0.020 
p=0.556 
r
2=0.007 
p=0.731 
r
2=-0.046 
p=0.285 
r
2=-0.112 
p=0.170 
r
2=0.037 
p=0.416 
IAUGC60 
mM Gd.s
-1 
r
2<-0.001 
p=0.899 
r
2=-0.095 
p=0.185 
r
2=-0.002 
p=0.852 
r
2<-0.001 
p=0.925 
r
2=-0.011 
p=0.478 
r
2=0.036 
p=0.422 
 
 
Categorical Variable 
MRI 
Parameter 
Ang-1  Ang-2  PDGF  VEGF 
K
trans 
min
-1 
F = 0.965 
df (3,15) 
p=0.435 
F = 3.812 
df (2,16) 
p=0.044 
F = 0.197 
df (2,16) 
p=0.823 
F = 1.654 
df (3,16) 
p=0.217 
ve % 
F = 1.801 
df (3,15) 
p=0.190 
F = 1.472 
df (2,16) 
p=0.259 
F = 0.484 
df (2,16) 
p=0.625 
F = 1.764 
df (3,16) 
p=0.194 
kep min
-1 
F = 0.720 
df (3,15) 
p=0.556 
F = 3.698 
df (2,16) 
p=0.048 
F = 0.565 
df (2,16) 
p=0.579 
F = 0.963 
df (3,16) 
p=0.434 
IAUGC60 
mM Gd.s
-1 
F = 1.284 
df (3,15) 
p=0.316 
F = 1.728 
df (2,16) 
p=0.209 
F = 0.468 
df (2,16) 
p=0.635 
F = 2.064 
df (3,16) 
p=0.145 Chapter 7 – Angiogenic Profile and CA4P DCE-MRI Response 
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Distribution Of VEGF, Ang-1, Ang-2, PDGF
0 1 2 3
VEGF
Ang-1
Ang-2
PDGF
min < 2SD -[ mean ± 95% confidence interval ]- 2SD > max
 
 
 
 
 
Distribution Of CD34, SMA PCI, CD105, CD61
0 50 100 150 200
CD34 MVD
CD105 MVD
CD61 MVD
SMA PCI
min < 2SD -[ mean ± 95% confidence interval ]- 2SD > max
Fig. 7.14 Distribution of CD34, SMA PCI, CD105, CD61 - confidence intervals around the mean show 
that the majority of tumours fall close around the mean values, however there are outliers which may 
skew the results. The box represents the mean ± 95% confidence interval. The whiskers represent 
minimum and maximum values. The X-axis represents MVD (/mm2) 
Figure 7.15 - Box & Whisker plot. Wide distributions for these categorical variables Chapter 7 – Angiogenic Profile and CA4P DCE-MRI Response 
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Distribution of Ki-67 & Glut-1
0.0 0.2 0.4 0.6 0.8
Ki-67
Glut-1
min < 2SD -[ mean ± 95% confidence interval ]- 2SD > max
 
 
 
Distribution Of MRI Variables
-100 -50 0 50 100
% Change Kt @ 4hrs Post CA4P
% Change Ve @ 4hrs Post CA4P
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Figures 7.16, 7.17 – Box & Whisker plots. Wide distributions for the categorical variables, however 
MRI parameters are more tightly distributed about the mean. The X-axis represents categories in 
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Discussion 
 
We found no strong visual or statistical relationships between changes in DCE-MRI kinetic 
parameters and the immunohistochemical angiogenic profile (see also Appendix 3 and 
Gaya AM et al 2008). This suggests that immunohistochemical analysis of patients’ tumours 
is unlikely to be useful in predicting response to VDA therapy. There is enormous variability 
seen both in the DCE-MRI kinetic parameters and the immunohistochemistry.  It is difficult 
to know whether the variability is related to the MRI and immunohistochemical techniques 
or is due to specific tumour characteristics that are of interest to us e.g. vascular maturity. 
 
Antibody selection was chosen to give a broad selection of vascular markers. Antibodies 
against vascular endothelium, immature vascular endothelium, pericytes, proliferation 
marker and antibodies against molecules or receptors intimately involved in the angiogenic 
process were all chosen. All antibodies were purchased from commercial suppliers and had 
been previously tested on human samples. In addition, all antibodies were validated in the 
laboratory before use by Dr Frances Daley and Dr Uzma Qureshi. Titration experiments 
were also performed to determine the optimum concentrations.  
 
The variability of CD34 and CD105 MVD is consistent with previous studies. MVD has 
been correlated with risk of metastasis, prediction of efficacy of anti-cancer therapy, and 
prognosis in a variety of tumour types (Barresi et al., 2007; Calvin et al., 2007; Des Guetz et 
al., 2006; Gadducci et al., 2006; Gulubova & Vlaykova, 2007; Kavantzas et al., 2007; Trivella 
et al., 2007; Zhao et al., 2006). The PCI results agree with Eberhard’s data (Eberhard et al., 
2000). We have found no evidence that mature vasculature with higher PCI responds poorly 
to CA4P, or that immature CD105
+ vasculature responds better. Tumours with higher 
CD34 MVD may also have higher CD105
+ MVD, however it does not necessarily follow 
that active angiogenesis takes place.  
 
Generally, CD31 has been accepted as the pan-endothelial marker of choice for paraffin 
sections (Hasan et al., 2002). In a review by Fox (Fox et al., 2001), when studies on breast 
cancer with multivariate analysis that used antibodies to CD31 or CD34 were examined, 
most revealed a positive association with relapse free survival (13/14) and all for overall 
survival (OS) (12/12). With studies using Factor VIII, only 8/13 were positive for RFS and 
7/10 for OS. When I attempted CD31/αSMA double staining, the antibody was far less 
reliable as a pan endothelial marker. Despite using double stain block solution, it appeared 
that the addition of the 2
nd antibody was affecting the distribution of the first. We felt that Chapter 7 – Angiogenic Profile and CA4P DCE-MRI Response 
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the weak stromal cross reactivity with CD34 would not interfere with the identification of 
vessels, so CD34 was used as the pan endothelial marker for this study. 
 
The two validated methods of microscopic vessel counting are the random point scoring 
system ‘Chalkley Counting’ (Chalkley, 1943; Fox et al., 1995; Smith et al., 1988) and the 
‘random field’ methods (Eberhard et al., 2000), although few studies have directly compared 
these two methods of microvessel quantification (Fox et al., 1995). It was felt that a random 
field method of counting was preferable as some of the tumour samples, especially 
diagnostic biopsies, were too small for Chalkley counting. 
 
There are a number of aspects of this study which undermine the power of our conclusions. 
We obtained only small numbers of samples with a heterogeneous mix of different tumour 
types. However, our sample was limited to patients who had received CA4P and undergone 
DCE-MRI. Within the ANOVA categorical analysis especially, this greatly reduced the 
statistical power. Our paraffin blocks, up to 21 years old, were taken from the primary 
surgical procedure whilst patients received CA4P during Phase I trials many years later after 
metastatic relapse. There is a loss of staining intensity for several markers in stored tissue 
slides over time (Bertheau et al., 1998; Van den Broek & Van de Vijver, 2000), and the 
degradation in antigenicity may begin after as little as 3-6 months. It is however 
controversial and less well documented whether antigenicity decreases in tissue blocks as 
well (Fergenbaum et al., 2004). Our slides were cut from the tissue blocks within a few 
months of staining. In addition, most antibodies used at the Gray Cancer Institute are tested 
for this phenomenon (Frances Daley, Personal Communication 2006). There are also 
suggestions that the angiogenic phenotype might continuously evolve from primary tumour 
through to metastasis (Sullivan & Graham, 2007). 
 
PDGF stromal expression may be clinically significant in inducing tumour angiogenesis. The 
recruitment of stromal fibroblast cells can be critical for tumour angiogenesis (Dong et al., 
2004). Tumour-stroma interactions play a significant role in tumour development and 
progression. Alterations in the stromal microenvironment, including enhanced angiogenesis, 
modified extracellular matrix composition, inflammatory cells, and protease activity are 
essential regulatory factors of tumour growth and invasion (Mueller & Fusenig, 2002). 
PDGF probably has a major role in signalling for tumour pericyte recruitment. PDGF 
receptors within the stroma also have a function as regulators of tumour interstitial fluid 
pressure, tumour transvascular transport and tumour drug uptake (Ostman, 2004). 
 Chapter 7 – Angiogenic Profile and CA4P DCE-MRI Response 
  210
There were widespread falls in MRI kinetic parameters following CA4P however for most 
patients these did not achieve statistical significance. For some this was because the CA4P 
dose received was below the threshold level of 50 mg/m
2 (Galbraith et al., 2003) - for others 
the CA4P simply did not have the expected tumour blood flow effect. 95% CI for K
trans 
change was -62.5% to +166.5%, IAUGC60±80%. Conversely, taking the two separate trials 
individually, in PH1/066 the lower 95% confidence limit for K
trans was -44% and in 
PH1/092 it was -76.5%. This wide DCE-MRI parameter variability is in line with previously 
published data (Padhani et al., 2002; Taylor et al., 2004; Taylor et al., 2006). Combining 
DCE-MRI data from separate studies can adversely affect statistical confidence intervals due 
to the differences in scan sequences and calibration methods used (Taylor et al., 2006). 
There was wide intrapatient variability, patient motion, and an estimated arterial input 
function. Modified Fritz-Hansen arterial input co-efficients, which are currently used, 
demonstrate better reproducibility (Fritz-Hansen et al., 1996; Taylor et al., 2007). Averaging 
the kinetic parameters over a whole lesion also dilutes the effect of CA4P central vascular 
shutdown because of relative sparing at the tumour periphery.  
 
MVD does not reflect the functional properties of vessels, including permeability, which 
contribute to DCE-MRI parameters. Studies reporting correlations between MRI 
parameters and MVD have therefore found only moderate associations (Su et al., 2003; 
Tuncbilek et al., 2004). Several studies (Buckley et al., 1997; Stomper et al., 1997; Su et al., 
2003) show conflicting data relating immunohistochemical expression with DCE-MRI 
parameters. The different analysis methods used may have affected the results. Hawighorst 
(Hawighorst et al., 1998) showed that MRI parameters were better indicators of patient 
survival than MVD or VEGF. 
 
The significant correlation between ang-2 and K
trans is probably a false positive statistical 
quirk due to the sheer number of variables tested. However it might be explained thus: 
Angiopoietins are involved in the angiogenic switch (Ahmad et al., 2001; Tanaka et al., 
2003). Ang-1 stabilises vessels by maintaining pericyte coverage; ang-2 promotes pericyte 
removal, which in the presence of VEGF facilitates the angiogenic response and in the 
absence of VEGF induces vessel regression (Bach et al., 2007; Moon et al., 2006; Shim et al., 
2007; Winter et al., 2007). Depending on the tumour model, stabilization of blood vessels by 
ang-1 may either promote tumour angiogenesis or reduce tumour growth (Metheny-Barlow 
& Li, 2003). Wang (Wang et al., 2007) has shown ang-2 correlates with active angiogenesis in 
human colorectal carcinomas, and that ang-2 also correlates with VEGF. Thus, unstable Chapter 7 – Angiogenic Profile and CA4P DCE-MRI Response 
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immature ang-2 expressing vasculature undergoing neoangiogenesis is probably more 
susceptible to the effects of VDAs and thus detectable by DCE-MRI. 
 
Conclusions 
There was wide intrapatient variability in angiogenic profile expression, and DCE-MRI 
analysis also revealed widespread falls in kinetic parameters following CA4P. There is no 
obvious correlation between falls in MRI kinetic parameters and vascular markers, however 
sample numbers were small. Immunohistochemical analysis of patients’ tumours is unlikely 
to be useful in predicting response to VDA therapy.  
 
This was an exploratory study which we hoped would suggest some leads for further 
analysis. This study could be expanded to look at larger population numbers and use fresh 
tumour samples of a single cancer type; this could be performed for example as a biological 
sub study within a phase 1, 2 or 3 drug trial, especially as functional imaging is now 
becoming more widely available (Gaya et al., 2008). To date however this has not been 
carried out. 
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Final Summary 
 
 
The work for this thesis began in 2003, and completed in 2005. There was a delay in 
waiting for additional clinical trial data before the write-up could commence. 
Consequently much has progressed in the field of vascular targeting in the 
intervening five years. Antiangiogenic agents are now routinely used in clinical 
practice, new generations of molecules are being developed, and VDAs are now into 
phase 3 study. 
 
The A5B7 study has completed and publication is pending (Meyer et al., 2009). 
Lessons have been learnt which will be applied in future Radioimmunotherapy 
combination trials. CA4P has moved into a phase 2 study in platinum resistant 
ovarian cancer (with paclitaxel and carboplatin) following the success of UKCTC-
207, and in anaplastic thyroid cancer (in combination with doxorubicin). There is a 
phase 2 study in NSCLC of paclitaxel and carboplatin with CA4P and Bevacizumab 
following a promising phase I, and a prostate cancer phase 2 study of docetaxel in 
combination with CA4P. DMXAA is now being tested in a phase 3 trial with 
paclitaxel and carboplatin in non small cell lung cancer and AVE8062 is also now in 
phase 3 trials.  
 
The latest MRI scanners can image so much faster that direct estimation of the 
arterial input function is now possible, which will greatly improve reproducibility, 
and reduce scanning time. The higher resolution available on new 3T magnets and 
developments in MRI coil technology will also provide interesting new data. 
Publication of our DCE-MRI and cardiac output data is pending but has been 
published so far in abstract form (Andrew M Gaya et al., 2008; Gaya et al., 2008). 
DCE-MRI is now a well accepted surrogate endpoint in trials of antiangiogenic 
agents and VDAs. There are no plans to look further at perfusion CT to assess late 
vascular changes with CA4P, but late effects of other long acting anti-vascular 
compounds can be seen (Koukourakis et al., 2007; Ma et al., 2008; Sabir et al., 2008).  
 
The immunohistochemistry project had many pitfalls, not least the age of the tissue 
and the heterogeneity of tumour types. New studies are now being designed where 
biopsy of tumour tissue throughout treatment leads to direct assessment of the 
effects of antivascular drugs (Dickler et al., 2008) and changes in vascular chemistry. 
I believe that prediction of patients’ response to VDAs and/or antiangiogenic agents 
on the basis of immunohistochemical marker expression and genetic analysis is not 
too far away. Despite the many problems encountered during this research the future 
does look bright in this field. 
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Appendices 
 
Appendix 1 - Overview of MRI Physics 
Atomic nuclei containing odd numbers of protons or neutrons possess nuclear spin visible by 
MRI.  These nuclei possess positive charge, and thus induce magnetic fields (they are moving 
charged particles).  Each nucleus is effectively a tiny magnet spinning on its long axis. MRI is 
derived from the interaction of this nuclear ‘spin’ with an externally applied magnetic field.  
1Hydrogen, which possesses a single proton, is commonly used as it is abundant in tissue and 
produces the strongest signal. Other isotopes such as 
13carbon, 
19fluorine, 
23sodium or 
31phosphorus have also been used. A magnetic dipole moment vector with a defined 
magnitude and axis of rotation can represent each of the nuclear spins present in a defined 
volume of tissue. These vectors are orientated randomly in all directions, so when summed, 
the net magnetisation vector is zero.  
If the tissue is placed in an external magnetic field, B0 (units = tesla, T) there is an interaction 
between the nuclear spins and B0 such that individual spins rotate, or ‘precess’, gyroscopically 
around the axis of B0 and the magnetic dipole moment vector of each spin lines up either 
parallel or anti-parallel to B0 .  The spins precess at a frequency proportional to the magnetic 
field strength of B0, known as the Larmor frequency: 
0 0 B γ ω =       (1)   
where ω0 is the Larmor frequency(radian.s
-1), γ is the gyromagnetic ratio(s
-1.T
-1) of the nuclear 
spin and B0 is the external magnetic field(T).  γ is a constant which is an intrinsic property of a 
particular nuclear spin.  For a 1.5T magnet the Larmor frequency is approximately 63MHz but 
can vary depending upon the scanner. 
Hydrogen nuclei can exist at two energy levels.  Nuclei at the lower energy level have magnetic 
vectors aligned parallel with B0(spin-up), as this requires less energy than anti-parallel(spin-
down) alignment.  A tiny excess number of hydrogen nuclei (7/10 million) have magnetic 
vectors in anti-parallel alignment, creating a net magnetisation vector, M0, in the same direction 
as B0 Appendices 
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The application of a radio-frequency (RF) pulse, B1, at the Larmor (resonance) frequency, in 
the transverse (XY) plane (i.e. perpendicular to B0), causes the nuclear spins to precess around 
B1 instead so the net magnetisation vector rotates out of alignment with B0.  The flip angle, α, 
is the angle of rotation produced by B1.  For example, a flip angle of 90
0 indicates an RF pulse 
of sufficient energy to rotate M0 into the transverse (XY) plane, where it is now termed M1. 
At equilibrium the spins will populate the lower of the energy states in slight preference to the 
higher. If the spins are at a temperature T then it can be shown that this difference in the 
populations is 
and for a group of nuclei precessing randomly around the main field there will be a resultant 
macroscopic magnetisation Mo pointing along the Z axis. This is responsible for the bulk 
magnetic susceptibility χo  since 
 If a resonant radiofrequency field is applied, the net absorption of energy will decrease the z 
component Mz and create an in-phase component in the xy plane Mxy. 
 
There is now a moving magnetic field in the transverse plane that induces voltage in a receiver 
coil.  This electric voltage is the magnetic resonance signal.  Once the RF pulse is switched off, 
the net magnetisation vector will realign with B0 along the longitudinal (Z) axis (as the nuclear 
spins will rotate back to precess around B0).  As only magnetisation in the transverse plane 
(XY) can induce voltage in the receiver coil, the MR signal will decay as M1 rotates back to M0 
– known as ‘free induction decay’.  An MR image can be constructed from this signal, though 
it is usually too fast to allow spatial encoding and so other RF pulses are generally used, in 
sequence with magnetic field gradients, to form encoded echoes.  These can then be Fourier 
transformed into final images. 
 
no. of spin
no. of spin
↑
↓
−
 = e kT
ΔE
 ( 2) 
  B M o o o     =   χ  (3) Appendices 
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The RF pulse provides the energy required to excite nuclear spins from the lower energy level 
to the higher energy level – but only if its frequency is at the ‘resonant’ Larmor frequency.  
The moment the RF pulse ceases, the excited spins will revert to the lower energy level in a 
process called ‘relaxation’, which is a re-establishment of thermal equilibrium.  There are two 
relaxation processes: the recovery of longitudinal magnetisation (MZ) and the decay of 
transverse magnetisation (MXY) – governed by relaxation time constants, T1 and T2 
respectively.   
T1  (‘spin-lattice’ relaxation) depends on how quickly nuclear spins give up energy to the 
surrounding tissue or ‘lattice’ and is defined as the time taken for MZ to return to 63% of its 
original value (M0), i.e. to increase MZ by a factor of e (Figure 8.1a).   
T2(‘spin-spin’ relaxation) depends on the interaction with adjacent spins.  At the end of the RF 
pulse, all spins are precessing in the transverse (XY) plane (assuming a 90
0 flip angle has been 
applied) at the same frequency and are ‘in phase’ with each other.  Once the RF pulse is 
switched off, the precessional frequency of a particular spin is altered by interactions with 
adjacent nuclear spins, resulting in a gradual loss of phase coherence and hence transverse 
magnetisation.  T2 is defined as the time taken for MXY to decay to 37% of its maximum value, 
i.e. to decrease MXY by a factor of e (Figure 8.1b).   
Figure 8.1a:  T1 relaxation time-curve, Fig 8.1b: T2 relaxation time-curve 
 
MXY
time
MZ
time
T1 T2
MZ=M0(1-e -t/T1)
M0
MXY=M0e-t/T2
M1
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B0 is not uniform, as there are local field distortions due to magnetic susceptibility differences 
between different tissues and the imperfect winding of the magnet coil. ‘Magnetic 
susceptibility’ is a measure of the degree to which a material becomes magnetised when placed 
in a magnetic field.  Air, bone and other tissues all have different magnetic susceptibilities, 
resulting in distortions in B0 at interfaces between different structures.  Local inhomogeneities 
in B0 will influence the rate of decay of transverse magnetisation.  The effective transverse 
relaxation under these circumstances is faster than T2 and the term T2* is used to describe it 
and: 
+ + =
2 2 2
1 1
*
1
T T T
   (4) 
where T2
+ is the extra relaxation component due to B0 inhomogeneities. The T2 relaxivity (R2) 
is equal to 1/T2
 and similarly R2
*=1/T2
*. These are important in BOLD imaging. 
FLASH MRI (Fast Low Angle Shot MRI) is a basic measuring principle for rapid MRI. 
FLASH sequences allow for a drastic shortening of the measuring times without a 
substantial loss in image quality. The measuring principle led to a broad range of completely 
new imaging sequences. For example, cross-sectional images with acquisition times of a few 
seconds enable MRI studies of the thorax and abdomen within a single breathhold, dynamic 
acquisitions synchronized to the electrocardiogram generate movies of the beating heart, and 
sequential acquisitions monitor the differential uptake of contrast media into body tissues. 
The FLASH technique is a gradient echo sequence which combines a low-flip angle radio-
frequency excitation of the NMR signal with a rapid repetition of the basic sequence. The 
repetition time (see below) is usually much shorter than the typical T1 relaxation time of the 
protons in biological tissue.  
Image Contrast 
 
Tissues have characteristic T1 and T2 values.  T1 values in the body vary between about 0.2 and 
4 seconds and are longer than T2 values.  To create an image, a particular sequence of RF 
pulses and magnetic field gradients is applied – called a pulse sequence.  The size, direction, Appendices 
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timing and frequency of these pulses and gradients can be manipulated such that tissues with 
different relaxation times will have different signal intensities and there is contrast between 
them in the resultant image.  The repetition time (TR) is the time between acquisition of one 
phase encoded line and the next. The echo time (TE) is the time between centre of the initial 
pulse and the time when the MR signal is measured.  On a ‘T1-weighted image’ (short TR, 
short TE), tissues with a short T1 appear bright and those with a long T1 appear dark.  The 
opposite occurs with a T2 weighted image (long TR, long TE): tissues with a long T2 appear 
bright whereas those with a short T2 appear dark. 
k-space is a formalism widely used in MRI, introduced by Ljunggren
 and Twieg. k-space is the 
temporary image space in which data from digitized MR signals are stored during data 
acquisition. When k-space is full (at the end of the scan), the data are mathematically 
processed using Fourier transformation to produce a final image. Thus k-space holds raw data 
before reconstruction. During the scan, k-space is filled with raw data one line per TR. 
MRI visible protons are those within soft tissues and liquids.  Solid tissues such as bone have a 
fixed lattice and appear black on all image types.  Image contrast may also be produced by 
using pulse sequences sensitive to the relative number of mobile protons available within a 
tissue.  This is termed ‘proton density’ (PD) image contrast.  For example, cerebrospinal fluid 
has a high proton density whereas brain tissue has a lower proton density.  The proton density 
is responsible for the maximum magnitude of signal generated by a given tissue (signal 
amplitude).  Proton density contrast is regarded as ‘basic’ MR contrast as it is not dependent 
on tissue relaxation times.  Measured PD images do have some T 1 and T2 contrast by the 
nature of the sequence timings used in their measurement.   
Image contrast may be enhanced by the use of intravenous contrast agents such as the low 
molecular weight agent gadolinium diethylene triamine pentaacetic acid (Gd-DTPA, or 
gadopentetate dimeglumine (Magnevist®)).  Gd-DTPA is paramagnetic
1, as the gadolinium 
                                                 
 
 
 
1 A paramagnetic material will develop a weak attractive force if placed in an magnetic field. Appendices 
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ion contains seven unpaired electrons and so has a large magnetic dipole moment.  The 
presence of Gd-DTPA in a tissue shortens the T1 and T2 relaxation times, increasing the 
‘relaxation rates’, 1/T1 and 1/T2, such that 
C r
T T obs
1
1 1 ) 0 (
1 1
+ =    (5) 
where 1/T1obs is the observed value in the presence of Gd-DTPA, 1/T1(0) is the innate value, 
C is the concentration of Gd-DTPA(mM) and r1 is the ‘relaxivity’ of Gd-DTPA in mM
-1.s
-1 
(specific relaxation rate of Gd-DTPA).  (The equation may be written in a similar fashion 
substituting T2 for T1).  The effect of Gd-DTPA is to increase signal intensity on a T1-
weighted image (as tissues with a short T1 are bright) and to decrease signal intensity on a T2 
(or T2*) weighted image (as tissues with a short T2 are dark).  Gd-DTPA is used primarily as a 
T1-agent as its effect on T1 is greater than on T2 for the same dose of contrast agent (as 
T1>T2).   
Gd-DTPA is an extracellular contrast agent and has an excellent safety record. In a study of 
over 5000 patients, an adverse reaction rate of 2.2% was reported. The commonest event was 
flushing, and the rate of anaphylaxis currently estimated is 1/200,000. This compound 
contains unpaired electrons, which produce a dipole-dipole interaction with proton nuclear 
spins, enhancing their relaxation. It is excreted renally, with a plasma half-life of 90 minutes. 
Recently, a disease known as Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing 
Dermopathy (NSF/NFD) that occurs in patients with kidney failure has been described. Our 
patients were required to have a GFR>50 mls/min. 
Gd-DTPA has a low molecular weight (0.57 kD) and so diffuses out of blood vessels into the 
extracellular space (except in cerebral imaging when the blood-brain barrier is intact).  Tumour 
vessels are more permeable than normal vessels, so Gd-DTPA diffuses more rapidly into 
tumour EES than into normal tissue EES, providing contrast by increasing tumour signal 
intensity on T1-weighted images. 
Conversion of Signal Intensity into Gd-DTPA concentration  
Signal intensity on spoiled gradient echo images (the T1-weighted sequence used) is given by:  Appendices 
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*) / exp(
) / exp( cos 1
) / exp( 1
sin 2
1
1
max T TE
T TR
T TR
S S − ×
− × −
− −
=
α
α    (6) 
where Smax. is the maximal signal intensity (for TR>>T1 and TE<< T2) and α is the flip angle. 
If TE << T2*, the term exp (-TE/T2*) can be ignored and equation(6) simplified to: 
)] / exp( 1 [ 1 max T TR K S S × − − × =  (7) 
where K is a flip angle correction factor (Hittmair et al.,1994) and is equal to 1.40 for our 
acquisition conditions (obtained by simulation).  The ratio of signal intensity at time t, St to 
baseline (pre-contrast) signal intensity, S0, is then: 
)] 0 ( / exp[ 1
)] ( / exp[ 1
1
1
0 T TR K
t T TR K
S
St
× − −
× − −
=  (8) 
where T1(t) is the post-contrast signal intensity at time t, and T1(0) is the pre-contrast 
relaxation time  respectively. 
T1(0) is calculated from an inversion recovery sequence (see below) and T1(t) calculated by 
rearranging equation(8): 
⎥
⎦
⎤
⎢
⎣
⎡
× − − − ×
×
− = )] 0 ( / exp[ 1 ( 1 ln
1
) (
1
1
0 1
T TR K
S
S
TR K t T
t  (9) 
The concentration of Gd-DTPA present at time t, Ct, can then be calculated from equation(9) 
(Donahue et al., 1994): 
1
1 1 ) 0 (
1
) (
1
r
T t T
Ct
⎟
⎠
⎞ ⎜
⎝
⎛ −
=  (10) 
where r1 is the longitudinal relaxivity of protons in vivo due to Gd-DTPA (mM
-1.s
-1). r1 is 
estimated to be 4.5mM
-1s
-1 for a 1.5T system (Donahue et al., 1994). Appendices 
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Calculation of T1(0)   
In an inversion recovery sequence, a 180
o pulse is applied which flips the net magnetisation 
vector down to the –Z axis.  When the pulse is removed, longitudinal magnetisation (MZ) will 
begin to relax back to alignment with B0 (along the +Z axis).  This is described by equation 
(11): 
)] exp( 2 1 [
1
0 T
t M M Z − − =  (11) 
where M0 is the equilibrium magnetisation.  
If a 90
o pulse is applied after a time known as ‘inversion time’, TI (time from the original 
inverting 180
o pulse) then MZ will be converted into MXY (magnetisation in the transverse (XY) 
plane) and it will induce a signal.  The resultant signal intensity is a measure of MZ.  If a series 
of 180
o and 90
o pulses are applied with varying inversion times, then a graph of signal intensity 
versus inversion time can be plotted and fitted to the equation below:  
)] / exp( 2 1 [ ) ( ) ( 1 0 T TI M TI M TI S Z − − = =  (12) 
where  S(TI) is the signal intensity at inversion time, TI.  As TI→∞, full relaxation will have 
occurred so signal intensity will→M0.  Values for the two unknown parameters T1 and M0 may 
be obtained from curve-fitting. The proton density-weighted image can be used to get 
a ratio which is used with a lookup table to get T1 rather than the 
inversion recovery method. The lookup is made by imaging a eurospin phantom 
with multiple gels of differing and known T1 values as per Parker (1997), and it 
is important for accuracy: 
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Appendix 2 – Standard Immunostaining Protocols 
Preparation of Solutions and Reagents 
 
TRIS  Buffer Saline(TBS) 
8.1g Sodium Chloride added to 100ml Tris Buffer, made up to 1000ml with deionised water, 
pH adjusted to 7.6. Intensity of staining is affected by the pH and buffer ion concentration. 
TRIS Buffered Saline Tween(TBST) 
For automated staining 0.04% TBST.  Add 40μl of Tween-20 to 100ml TBS. Manual staining 
0.05% TBST. Add 50μl of Tween-20 to 100ml TBS. 
Dilution of Antibodies 
Primary Antibodies are diluted in ‘Dako antibody diluent’ to an optimal concentration. Optimum 
antibody titre is defined as the highest dilution of an antibody that results in maximum specific 
staining with the least amount of background staining under specific conditions. Secondary 
antibodies are diluted in TBS. Dilutions of these reagents can vary from batch to batch.  
Diaminobenzadine(DAB) for HRP 
Automated staining using Dako ChemMate HRP/ChemMate Envision HRP reagents: Mix 
20µl Diaminobenzidine solution with 980µl of substrate buffer containing hydrogen peroxide 
and preservative. Manual staining using Vector labs DAB substrate kit: To 5ml of distilled 
H2O add 2 drops of buffer stock solution and mix, 4 drops DAB and mix, 2 drops Hydrogen 
Peroxide and mix. If a grey-black stain is desired add 2 drops of Nickel solution and mix. 
Fast Red for AP (Dako double stain kit) 
Transfer 3ml of Buffered Substrate to test tube and add a Fast Red tablet. Dissolve and mix 
thoroughly. 
Removal of paraffin wax prior to staining 
Label slides with name of antigen to be demonstrated and place in a staining rack making sure 
that control slides are included. Place in a bath of Xylene for 5min followed by consecutive Appendices 
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baths of 100, 90 and 70% Industrial Methylated Spirit each for 2min. Transfer to running tap 
water, and then proceed with staining protocol. 
 
Antigen Retrieval  -Pre-treatment of samples prior to staining. 
Demonstration of antigens in formalin fixed paraffin material may in some instances rely on 
prior treatment with either proteolytic enzymes or by heat induced epitope retrieval (HEIR). 
 
Heat Induced Epitope Retrieval (HIER) 
•  Place 250ml of 10mM citric acid, or 1mM EDTA into a plastic trough and alter to 
appropriate pH using 2M sodium hydroxide (Dependent on antigen and can be 
pH2-10) 
•  Put slides into a rack, place in trough and cover in microwave 
•  Set high power for 4min 
•  After 4min replace lost fluid with distilled water 
•  Repeat last 2 steps as necessary (dependent on antibody) 
•  When microwaving is complete remove trough, top up with water and leave to stand 
for 20min. Place rack in sink and leave slides to wash for 5min    
•  Continue staining protocol 
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Autostainer Procedure 
 
Automatic staining with Dako Autostainer – Used for VEGF, Ki-67, Glut-1 
•  Enter slide information 
•  Enter number of slides to be stained 
•  Click on Auto until Program appears. Click on desired staining method e.g. 
ChemMate, Envision, ABC 
•  Click on Program until Auto appears 
•  Click on the blank box for each slide in the Primary Antibody column. 
•  Once all the slides have an antibody assigned to them left click on Next (Run time 
message appears, indicating protocol length, number of probe washes, amount of 
buffer and deionised water needed) 
•  Check volume of all reagents Click on OK. 
•  Place reagent vials in the white rack on the Autostainer as indicated on the screen. 
•  Place slides for current run in the Autostainer racks as indicated on the screen. 
•  Click on Start Run. 
•  When the run is complete the machine beeps. Click on Yes to save run log. 
•  The slides can now be removed and placed in running tap water prior to 
counterstaining. The machine should be wiped dry. 
•  Counterstaining: Place slides in a bath of Gills Haematoxylin for 7-15sec, remove 
and wash in running tap water for 5min. 
•  Place slides in bath of 70% IMS for 2min, followed by consecutive baths of 90% and 
100% IMS each for 2min.  
•  Transfer slides to 2 consecutive baths of Xylene, 2min in each. 
•  Remove a slide from the staining rack & place a small amount of mounting media 
onto an appropriately sized cover slip and place on top of the section. Remove any 
air bubbles formed, wipe off any excess mounting media and allow drying. 
•  Slides are ready for analysis. 
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DakoCytomation Envision® Doublestain System – Used for CD34 + SMA 
 
Reagents used : 
•  Peroxidase block – 0.03% hydrogen peroxide containing sodium azide 
•  Labelled polymer HRP – Horseradish peroxidase labelled polymer conjugated to 
affinity purified goat anti-rabbit and goat anti-mouse immunoglobulins in Tris-HCl 
buffer containing stabilising protein and an anti-microbial agent 
•  Diaminobenzidine(DAB) substrate buffer – Imidazole–HCl buffer, pH7.5, 
containing hydrogen peroxide and an anti-microbial agent.  
•  DAB Chromogen – 3,3’–diaminobenzidine in chromogen solution 
•  Doublestain block reagent 
•  Labelled polymer AP – Alkaline phosphatase labelled polymer conjugated to affinity 
purified goat anti-rabbit and goat anti-mouse immunoglobulins in phosphate 
buffered saline buffer containing stabilising protein and 0.015mmol/L sodium azide. 
•  Substrate buffer for Fast Red – Substrate buffered naphthol solution in Tris buffer. 
•  Fast Red tablets – 3mg Fast Red per tablet. 
 
Staining Protocol 
 
1)  Tap off excess buffer and wipe slides 
2)  Apply peroxidase block to specimen 
3) Incubate  5min. 
4)  Rinse gently with buffer solution 
5)  Place in fresh buffer bath 
6)  Tap off excess buffer and wipe slides 
7)  Apply primary antibody to specimen 
8)  Incubate for 60min 
9) Repeat  4&5 
10) Repeat  1 
11)  Apply labelled polymer HRP to specimen Appendices 
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12) Incubate  30min 
13) Repeat  4&5 
14) Repeat  1 
15)  Apply DAB solution to specimen 
16)  Incubate for 10min 
17)  Rinse with distilled water 
18) Repeat  1 
19)  Apply doublestain block to specimen 
20) Incubate  3min 
21) Repeat  4&5 
22) Repeat  1 
23)  Apply second antibody to specimen 
24) Incubate  60min 
25) Repeat  4&5 
26) Repeat  1 
27)  Apply labelled polymer AP to specimen 
28) Incubate  30min 
29) Repeat  4&5 
30) Repeat  1 
31)  Apply fast red substrate chromogen solution to specimen 
32)  Incubate for 5–10min 
33)  Rinse with distilled water 
34)  Immerse slides in bath of aqueous haematoxylin solution(7sec) 
35)  Rinse in tap water 
36)  Mount (aqueous mounting medium) 
 
DakoCytomation CSA II Staining System – Used for CD105(Endoglin) Staining 
Procedure 
 
1)  Remove excess liquid from slide 
2)  Apply hydrogen peroxide block to specimen 
3) Incubate  5min Appendices 
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4)  Rinse gently with wash buffer solution (3 times in 5min to reduce non-specific 
background staining) 
5) Repeat  1 
6)  Apply protein block 
7)  Incubate 5min at room temperature 
8)  Don’t rinse off protein block! 
9) Repeat  1 
10)  Apply primary antibody (Mouse anti-human CD105) 
11) Incubate  60min 
12) Repeat  4&1 
13)  Apply anti-mouse immunoglobulin – HRP to specimen 
14) Incubate  15min 
15) Repeat  4&1 
16)  Apply amplification reagent to specimen  
17)  Incubate 15min at room temperature (protect from light) 
18) Repeat  4&1 
19)  Apply anti-fluorescein-HRP to specimen 
20)  Incubate 15min at room temperature 
21) Repeat  4&1 
22)  Apply DAB substrate chromogen to specimen 
23)  Incubate for 7min 
24)  Rinse with distilled water 
25)  Counterstain with haematoxylin(7sec) 
26)  Dehydrate specimens down to xylene 
27) Mount 
 
Manual Staining Procedures For Other Antibodies 
 
Angiopoietin 1 
Antibody : Santa Cruz Biotech H-98 Cat No. sc-8357 Rabbit Polyclonal 
Control – Human placenta, formalin fixed, paraffin embedded Appendices 
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1)  Deparaffinise sections in histoclear for 10min 
2)  Rehydrate in alcohol 
3)  Block endogenous peroxidase in 1.5% hydrogen peroxide in methanol for 10min 
4)  Wash in tap water 
5)  Microwave in 0.01M citrate buffer pH6 for 10min 
6) Repeat  4 
7)  Wash in TBST 
8)  Apply Ang-1 antibody diluted 1/50 and leave overnight at 4
oc 
9) Repeat  7 
10)  Apply Dako Envision Anti Rabbit Secondary Antibody, Cat No. K5007 with 
peroxidase, for 30min 
11) Repeat  7 
12) Apply  DAB 
13)  Counterstain in haematoxylin, dehydrate, clear and mount. 
 
Angiopoietin 2 
Antibody : Santa Cruz Biotech H-70 Cat No. sc-20718 Rabbit polyclonal 
Control – Human placenta, formalin fixed, paraffin embedded 
 
Method as for Ang-1 except microwave in citrate buffer for 20min 
 
CD61 (beta-3 integrin) 
Antibody : Novacastra NCL-CD61-308 
Control – Human tonsil and placenta, frozen or paraffin 
 
1)  Deparaffinise sections in histoclear for 10min 
2)  Dehydrate in IMS and wash in tap water 
3)  Block endogenous peroxidase in 1.5% hydrogen peroxide in methanol for 10min 
4)  Wash in tap water 
5)  Microwave in Dako’s ‘Target Retrieval Solution’ S1700 or 0.01M citrate buffer pH6 
for 20–30min Appendices 
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6) Repeat  4 
7)  Apply Vectastain’s mouse IgG normal horse serum diluted in Tris buffered 
saline(TBS) for 30min 
8)  Apply CD61 antibody diluted in TBS 1/100, for either 1 hour or overnight at 4
oc.  
9)  Wash in TBS 
10)  Apply horse anti-mouse biotinylated secondary, diluted in TBS, for 1h 
11) Repeat  9 
12)  Apply ABC diluted in TBS for 30min 
13) Repeat  9 
14)  Apply DAB diluted in distilled water for up to 10min 
15)  Wash in tap water 
16)  Counterstain, dehydrate and mount 
 
PDGF 
Novacastra NCL-PDEGF 
Control – human tonsil and placenta, paraffin embedded 
 
Method as for CD61, except primary antibody dilution is 1/60 in TBS. Appendices 
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Appendix 3 - Vascular Immunohistochemistry Additional Data 
a) Correlations between Continuous Variables & K
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Fig 8.2(a – f). Correlation between the continuous variables CD34,SMA,CD105,CD61,Ki-67,Glut-1 against percentage change 
in Ktrans 4hrs post CA4P. There are no correlations of any clinical significance. Lines of best fit are predominantly horizontal, indicating 
no correlation. The slopes of the best fit line are expressed in the format y=mx+c. Regression statistics calculated using Microsoft Excel. 
Correlation co-efficients are shown with standard error. p-values were calculated using t-test. SMA & Ki-67 report p values(t-test) of 0.23. 
For SMA(b) this result is the opposite expected. Tumours with higher SMA PCI (more mature vessels) should be less likely to respond to 
CA4P, however the vascular effect assessed on DCE-MRI appears to be greater! For Ki-67(e), there is a general trend towards more rapidly 
proliferating tumours having a greater change in blood flow after CA4P. Appendices 
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b) Correlations between Continuous Variables & ve 
CD34 MVD Against % Change Ve at 4hrs
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CD105 MVD Against % Change Ve at 4hrs
y = -0.2677x + 0.8885
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Ki-67 Expression Against % Change Ve at 4hrs
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Fig 8.3(a – f). Correlation between the continuous variables CD34,SMA,CD105,CD61,Ki-67,Glut-1 against percentage change 
in ve 4h post-CA4P. There are no correlations of any significance. Lines of best fit are predominantly horizontal, indicating no correlation. 
The slopes of the best fit line are expressed in the format y=mx+c. Regression statistics calculated using Microsoft Excel. Correlation co-
efficients are shown with standard error. P-values were calculated using t-test. Again, SMA & ve initially looks promising R=0.12, p=0.128. 
However, again the tumours with the highest PCI(mature) appear to have the sharpest drop in ve 4h post-CA4P, the opposite predicted. 
There is a trend in favour of CD105/ve (p=0.335) suggesting tumours with more immature vasculature may respond on MRI. 
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c) Correlations between Continuous Variables & kep 
CD34 MVD Against % Change Kep at 4hrs
y = -0.0428x - 12.215
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CD105 MVD Against % Change Kep at 4hrs
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CD61 MVD Against % Change Kep at 4hrs
y = -0.5691x - 7.0445
R2 = 0.0462 , SE = 30.81
p = 0.285
-70
-60
-50
-40
-30
-20
-10
0
10
20
30
40
50
0 1 02 03 04 05 06 0
CD61 MVD (/mm2)
%
 
C
h
a
n
g
e
 
K
e
p
 
@
 
4
h
r
s
cc
 
   c         d  
Ki-67 Expression Against % Change Kep at 4hrs
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Fig 8.4(a – f). Correlation between the continuous variables CD34,SMA,CD105,CD61,Ki-67,Glut-1 against percentage change 
in kep 4h post-CA4P. There are no correlations of any clinical significance. The lines of best fit are predominantly horizontal. The only 
correlation showing any general trend is graph e) Ki-67/kep, p=0.17, suggesting a trend towards greater response to CA4P on DCE-MRI 
for more actively proliferating tumours. Graph f) Glut-1/kep may be skewed as most of the data points are at the lower end of the scale, 
making a correlation line of best fit difficult. Appendices 
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d) Correlations between Continuous Variables & IAUGC60 
CD34 MVD Against % Change IAUGC at 4hrs
y = -0.023x - 20.042
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CD105 MVD Against % Change IAUGC at 4hrs
y = -0.0617x - 20.903
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Ki-67 Expression Against % Change IAUGC at 4hrs
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Fig 8.5(a – f). Correlation between the continuous variables CD34,SMA,CD105,CD61,Ki-67,Glut-1 against percentage change 
in IAUGC60 4h post-CA4P. There are no correlations of any clinical significance. The only graph showing a general trend, p=0.185, is 
b)SMA/IAUGC, however, again the trend is the opposite expected, with the more mature vascular tumours seeming to undergo a greater 
drop in MRI parameter following CA4P Appendices 
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e) Angiopoietin-1 & MRI Parameters 
 
Ang-1 Expression Against % Change Kt at 4hrs
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Fig 8.6(a–d). Relationship between Ang-1 against percentage change in Ktrans,ve,kep,IAUGC60 4h post-CA4P. 
Graphs produced using Microsoft Excel. Regression analysis and Correlation is not valid for use on categorical or interval 
variables. Instead we must use ANOVA (Analysis Of Variance). Statistics calculated using SPSS v11.0. The ANOVA analysis 
table for these graphs with explanations, is shown below. Note the graph of ang-1 against ve, which appears to show a trend 
in favour of increasing change in the MRI parameter with higher expression. 
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Angiopoietin-1 ANOVA Test 
Table 8.1 – Angiopoietin-1 ANOVA Descriptives 
Descriptives
2 -48.5289 27.79451 19.65369 -298.2526 201.1949 -68.18 -28.88
9 -18.2226 45.47287 15.15762 -53.1761 16.7310 -75.22 93.54
5 -39.1215 23.56999 10.54082 -68.3875 -9.8555 -66.56 -2.90
3 -2.5218 25.76178 14.87357 -66.5176 61.4740 -30.61 20.00
19 -24.4334 37.18700 8.53128 -42.3569 -6.5098 -75.22 93.54
37.29549 8.55617 -42.6704 -6.1963
8.55617a -51.6629a 2.7962a -11.41986
2 -36.7173 5.00807 3.54124 -81.7131 8.2784 -40.26 -33.18
9 4.4167 32.87741 10.95914 -20.8551 29.6885 -40.87 76.58
5 -18.4138 14.63148 6.54340 -36.5812 -.2464 -43.43 -7.73
3 -10.1479 14.88497 8.59384 -47.1243 26.8284 -20.91 6.84
19 -8.2209 27.45098 6.29769 -21.4519 5.0100 -43.43 76.58
25.78361 5.91517 -20.8288 4.3870
8.73723 -36.0267 19.5849 125.44009
2 -15.3441 52.44794 37.08629 -486.5702 455.8819 -52.43 21.74
9 -21.8196 32.25845 10.75282 -46.6156 2.9765 -65.28 48.03
5 -22.6807 28.15582 12.59167 -57.6408 12.2794 -55.23 15.29
3 7.5061 20.85498 12.04063 -44.3005 59.3128 -15.30 25.61
19 -16.7342 30.99525 7.11080 -31.6734 -1.7949 -65.28 48.03
31.74535 7.28288 -32.2573 -1.2111
7.28288a -39.9116a 6.4432a -66.50850
2 -42.6596 23.17479 16.38705 -250.8769 165.5576 -59.05 -26.27
9 -11.8945 37.92647 12.64216 -41.0473 17.2584 -56.26 82.38
5 -41.7371 25.26166 11.29736 -73.1035 -10.3706 -71.65 -6.57
3 -14.3837 14.64011 8.45247 -50.7518 21.9844 -25.98 2.07
19 -23.3792 32.39003 7.43078 -38.9907 -7.7678 -71.65 82.38
31.64983 7.26097 -38.8556 -7.9029
8.64894 -50.9040 4.1455 66.98975
0
1
2
3
Total
Fixed Effects
Random Effects
Model
0
1
2
3
Total
Fixed Effects
Random Effects
Model
0
1
2
3
Total
Fixed Effects
Random Effects
Model
0
1
2
3
Total
Fixed Effects
Random Effects
Model
% Ch Kt @ 4hrs
% Ch Ve @ 4hrs
% Ch Kep @ 4hrs
% Ch AUC @ 4hrs
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
Between-
Component
Variance
Warning: Between-component variance is negative. It was replaced by 0.0 in computing this random effects measure. a. 
 
Table 8.2 – Angiopoietin 1 - ANOVA Test 
ANOVA
4027.409 3 1342.470 .965 .435
20864.308 15 1390.954
24891.716 18
3592.095 3 1197.365 1.801 .190
9971.921 15 664.795
13564.016 18
2176.193 3 725.398 .720 .556
15116.507 15 1007.767
17292.700 18
3858.374 3 1286.125 1.284 .316
15025.679 15 1001.712
18884.053 18
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
% Ch Kt @ 4hrs
% Ch Ve @ 4hrs
% Ch Kep @ 4hrs
% Ch AUC @ 4hrs
Sum of
Squares df Mean Square F Sig.
 
a)  For each of the MRI variables Ktrans,ve,kep,IAUGC60, they are subdivided into component parts fitting into category 0,1,2, & 
3, with a total of 19 samples analysed. Means, SD and confidence intervals for each category are shown, and finally a ‘between 
component’ variance is calculated. Note that for 2 variables this variance is negative, which is statistically meaningless, and 
probably due to the small sample size in that category. 
 
b)  ANOVA test – There is no statistically significant relationship, however the ang-1/ve relationship is interesting and worth 
mentioning, p=0.19 . There appears to be a trend in favour of increasing MR response in tumours with higher expression. 
However it can also be seen that the number of samples in the higher expression categories is very limited. Appendices 
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f) Angiopoietin-2 & MRI Parameters 
 
Angiopoietin-2 Expression Against % Change Kt at 4hrs
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Fig 8.7(a–d). Relationship between the Categorical Variable Ang-2 against percentage change in 
Ktrans,ve,kep,IAUGC60 4h post-CA4P. Note the graphs of ang-2 against Ktrans & kep. There may be a U-shaped 
distribution, although sample size is small. 
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Angiopoietin-2 ANOVA Test 
Table 8.3 – Angiopoietin-2 ANOVA Descriptives 
Descriptives
6 -28.0169 21.39489 8.73443 -50.4694 -5.5643 -66.56 -2.90
8 -42.2934 20.34432 7.19280 -59.3017 -25.2851 -75.22 -20.55
5 8.4429 54.01994 24.15845 -58.6317 75.5176 -44.39 93.54
19 -24.4334 37.18700 8.53128 -42.3569 -6.5098 -75.22 93.54
32.46013 7.44686 -40.2200 -8.6467
14.85428 -88.3462 39.4795 477.08005
6 -15.6200 14.28499 5.83182 -30.6112 -.6289 -40.26 -2.13
8 -13.6528 18.01440 6.36905 -28.7132 1.4076 -40.87 18.75
5 9.3491 45.17751 20.20400 -46.7462 65.4444 -43.43 76.58
19 -8.2209 27.45098 6.29769 -21.4519 5.0100 -43.43 76.58
26.75813 6.13874 -21.2344 4.7926
7.51867 -40.5711 24.1293 54.42826
6 -11.6720 28.01552 11.43729 -41.0725 17.7285 -55.23 21.74
8 -34.9448 19.30477 6.82527 -51.0840 -18.8056 -65.28 -10.98
5 6.3282 36.37822 16.26883 -38.8413 51.4977 -48.46 48.03
19 -16.7342 30.99525 7.11080 -31.6734 -1.7949 -65.28 48.03
27.18751 6.23724 -29.9565 -3.5118
12.25035 -69.4432 35.9748 321.05267
6 -28.0614 22.40622 9.14730 -51.5753 -4.5475 -71.65 -6.57
8 -33.5488 17.04713 6.02707 -47.8005 -19.2970 -59.05 -13.40
5 -1.4894 52.40445 23.43598 -66.5581 63.5793 -59.02 82.38
19 -23.3792 32.39003 7.43078 -38.9907 -7.7678 -71.65 82.38
31.15418 7.14726 -38.5308 -8.2277
9.51256 -64.3085 17.5500 113.80310
1
2
3
Total
Fixed Effects
Random Effects
Model
1
2
3
Total
Fixed Effects
Random Effects
Model
1
2
3
Total
Fixed Effects
Random Effects
Model
1
2
3
Total
Fixed Effects
Random Effects
Model
% Ch Kt @ 4hrs
% Ch Ve @ 4hrs
% Ch Kep @ 4hrs
% Ch AUC @ 4hrs
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
Between-
Component
Variance
 
Table 8.4 – Ang-2 ANOVA Test 
ANOVA
8033.156 2 4016.578 3.812 .044
16858.560 16 1053.660
24891.716 18
2108.052 2 1054.026 1.472 .259
11455.964 16 715.998
13564.016 18
5466.133 2 2733.066 3.698 .048
11826.567 16 739.160
17292.700 18
3354.721 2 1677.360 1.728 .209
15529.332 16 970.583
18884.053 18
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
% Ch Kt @ 4hrs
% Ch Ve @ 4hrs
% Ch Kep @ 4hrs
% Ch AUC @ 4hrs
Sum of
Squares df Mean Square F Sig.
 
 
a)  For each of the MRI variables Ktrans,ve,kep,IAUGC60, they are subdivided into component parts fitting into category 0,1,2, & 
3, with a total of 19 samples analysed. Means, SD and confidence intervals for each category are shown, and finally a ‘between 
component’ variance is calculated.  
 
b)  ANOVA test – Two relationships are statistically significant, that between ang-2 & Ktrans(p=0.044) and ang-2 and 
kep(p=0.048). There appears to be a U-shaped relationship, with the largest MRI changes visible with moderate expression, 
however smaller changes visible at lower and higher concentrations of angiopoietin-2. However it can also be seen that the 
number of samples in the higher expression categories is very limited. 
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g) PDGF & MRI Parameters 
 
PDGF Expression Against % ChangeKt at 4hrs
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Fig 8.8(a–d). Relationship between the Categorical Variable PDGF against percentage change in 
Ktrans,ve,kep,IAUGC60 4h post-CA4P. Very few tumour samples stained positively for PDGF, it was predominantly a 
stromal stain. Thus, the sample size is very small. 
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PDGF ANOVA Test 
Table 8.5 – PDGF ANOVA Descriptives 
Descriptives
16 -24.7624 38.08509 9.52127 -45.0565 -4.4683 -75.22 93.54
2 -32.5666 50.36860 35.61598 -485.1105 419.9774 -68.18 3.05
1 -2.9026 . . . . -2.90 -2.90
19 -24.4334 37.18700 8.53128 -42.3569 -6.5098 -75.22 93.54
38.96642 8.93951 -43.3843 -5.4824
8.93951a -62.8970a 14.0303a -463.44017
16 -5.5040 29.03941 7.25985 -20.9780 9.9700 -43.43 76.58
2 -24.7771 11.87800 8.39901 -131.4966 81.9425 -33.18 -16.38
1 -18.5793 . . . . -18.58 -18.58
19 -8.2209 27.45098 6.29769 -21.4519 5.0100 -43.43 76.58
28.27366 6.48642 -21.9715 5.5297
6.48642a -36.1297a 19.6879a -156.78483
16 -19.1511 29.55944 7.38986 -34.9023 -3.4000 -65.28 48.03
2 -13.4086 55.18519 39.02182 -509.2278 482.4106 -52.43 25.61
1 15.2861 . . . . 15.29 15.29
19 -16.7342 30.99525 7.11080 -31.6734 -1.7949 -65.28 48.03
31.77245 7.28910 -32.1864 -1.2820
7.28910a -48.0966a 14.6283a -166.83733
16 -22.0377 33.95469 8.48867 -40.1309 -3.9445 -71.65 82.38
2 -42.5155 23.37865 16.53120 -252.5643 167.5333 -59.05 -25.98
1 -6.5718 . . . . -6.57 -6.57
19 -23.3792 32.39003 7.43078 -38.9907 -7.7678 -71.65 82.38
33.39197 7.66064 -39.6191 -7.1394
7.66064a -56.3403a 9.5818a -225.40999
0
1
2
Total
Fixed Effects
Random Effects
Model
0
1
2
Total
Fixed Effects
Random Effects
Model
0
1
2
Total
Fixed Effects
Random Effects
Model
0
1
2
Total
Fixed Effects
Random Effects
Model
% Ch Kt @ 4hrs
% Ch Ve @ 4hrs
% Ch Kep @ 4hrs
% Ch AUC @ 4hrs
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
Between-
Component
Variance
Warning: Between-component variance is negative. It was replaced by 0.0 in computing this random effects measure. a.   
Table 8.6 – PDGF ANOVA Test 
ANOVA
597.605 2 298.803 .197 .823
24294.111 16 1518.382
24891.716 18
773.617 2 386.808 .484 .625
12790.399 16 799.400
13564.016 18
1140.886 2 570.443 .565 .579
16151.815 16 1009.488
17292.700 18
1043.678 2 521.839 .468 .635
17840.374 16 1115.023
18884.053 18
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
% Ch Kt @ 4hrs
% Ch Ve @ 4hrs
% Ch Kep @ 4hrs
% Ch AUC @ 4hrs
Sum of
Squares df Mean Square F Sig.
 
a)  For each of the MRI variables Ktrans,ve,kep,IAUGC60, they are subdivided into component parts fitting into category 0,1,2, & 
3, with a total of 19 samples analysed. Means, SD and confidence intervals for each category are shown, and finally a ‘between 
component’ variance is calculated.  
 
b)  ANOVA test – None of the relationships are statistically significant. The sample sizes are too small. There are only two values 
for weak staining, and 1 value for moderate staining, no values for strong staining within the tumour. 
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h) VEGF & MRI Parameters 
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Fig 8.9(a–d). Relationship between the Categorical or Interval Variable VEGF against percentage change in 
Ktrans,ve,kep,IAUGC60 4h post-CA4P. There are no obvious graphical relationships. Appendices 
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VEGF ANOVA Test 
Table 8.7 – VEGF ANOVA Descriptives 
Descriptives
6 -29.1343 36.60799 14.94515 -67.5520 9.2835 -75.22 20.00
3 15.5634 67.91366 39.20997 -153.1435 184.2703 -30.61 93.54
9 -34.7536 19.58697 6.52899 -49.8095 -19.6977 -68.18 3.05
2 -26.4500 5.00763 3.54093 -71.4418 18.5417 -29.99 -22.91
20 -24.6899 36.21335 8.09755 -41.6383 -7.7415 -75.22 93.54
34.47783 7.70948 -41.0332 -8.3465
10.74958 -58.8999 9.5201 172.66910
6 -10.7636 17.95720 7.33100 -29.6085 8.0813 -40.87 7.27
3 17.1833 52.11643 30.08944 -112.2811 146.6477 -20.91 76.58
9 -17.4340 19.36480 6.45493 -32.3191 -2.5489 -43.43 18.75
2 10.5066 17.86755 12.63427 -150.0270 171.0402 -2.13 23.14
20 -7.4462 26.94249 6.02452 -20.0557 5.1632 -43.43 76.58
25.45064 5.69094 -19.5105 4.6180
8.25463 -33.7161 18.8237 110.00644
6 -22.3538 33.83524 13.81318 -57.8618 13.1541 -65.28 15.29
3 6.9789 35.59800 20.55251 -81.4514 95.4092 -15.30 48.03
9 -17.9652 27.95669 9.31890 -39.4546 3.5242 -52.43 25.61
2 -36.5963 16.77959 11.86496 -187.3549 114.1624 -48.46 -24.73
20 -17.4033 30.31660 6.77900 -31.5919 -3.2147 -65.28 48.03
30.40633 6.79906 -31.8166 -2.9899
6.79906a -39.0409a 4.2344a -7.66869
6 -26.9490 29.76091 12.14984 -58.1812 4.2832 -71.65 2.07
3 13.3088 59.84852 34.55356 -135.3631 161.9808 -23.22 82.38
9 -34.0422 15.81924 5.27308 -46.2020 -21.8825 -59.05 -13.40
2 -14.1572 10.27898 7.26833 -106.5101 78.1958 -21.43 -6.89
20 -22.8231 31.62410 7.07136 -37.6236 -8.0226 -71.65 82.38
29.26164 6.54310 -36.6938 -8.9523
10.42141 -55.9887 10.3425 202.44208
0
1
2
3
Total
Fixed Effects
Random Effects
Model
0
1
2
3
Total
Fixed Effects
Random Effects
Model
0
1
2
3
Total
Fixed Effects
Random Effects
Model
0
1
2
3
Total
Fixed Effects
Random Effects
Model
% Ch Kt @ 4hrs
% Ch Ve @ 4hrs
% Ch Kep @ 4hrs
% Ch AUC @ 4hrs
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
Between-
Component
Variance
Warning: Between-component variance is negative. It was replaced by 0.0 in computing this random effects measure. a.   
Table 8.8 – VEGF ANOVA Test 
ANOVA
5897.195 3 1965.732 1.654 .217
19019.529 16 1188.721
24916.724 19
3428.293 3 1142.764 1.764 .194
10363.764 16 647.735
13792.057 19
2670.107 3 890.036 .963 .434
14792.717 16 924.545
17462.824 19
5301.698 3 1767.233 2.064 .145
13699.894 16 856.243
19001.592 19
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
% Ch Kt @ 4hrs
% Ch Ve @ 4hrs
% Ch Kep @ 4hrs
% Ch AUC @ 4hrs
Sum of
Squares df Mean Square F Sig.
 
a)  For each of the MRI variables Ktrans,ve,kep,IAUGC60, they are subdivided into component parts fitting into category 0,1,2, & 
3, with a total of 19 samples analysed. Means, SD and confidence intervals for each category are shown, and finally a ‘between 
component’ variance is calculated.  
 
b)  ANOVA – None of the relationships are statistically significant. Only 2 samples are present in the ‘strong staining’ category. Appendices 
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Appendix 4 – Perfusion CT Mathematical Modelling 
 
Mathematical modelling techniques employed during Perfusion CT include both uni-and bi-
compartmental analysis methods. Uni-compartment techniques based on the Fick principle are 
most commonly used to estimate perfusion (blood flow per unit volume of tissue). This 
effectively considers the intravascular and EES as a single compartment. By evaluating data for 
time points prior to the moment when contrast medium appears in the draining veins of the 
tissue of interest,  perfusion may be calculated either from the maximal slope of the tissue 
concentration–time curve known as the slope method (Miles et al.,2000) or from its peak 
height normalized to the AIF (known as the peak or Mullani-Gould method (Miles et al.,2000; 
Miles & Griffiths,2003).  
 
a. Slope method 
Perfusion (Flow/Volume) can be calculated as the maximum slope of tissue enhancement 
curve divided by the maximum arterial enhancement. c(t) is peak tissue enhancement, and a*(t) 
is the gamma fit to the arterial curve to correct for recirculation. 
 
The principle advantage of the slope method is that it allows calculation of perfusion sooner, as 
the tissue time enhancement curve reaches its peak gradient well before its peak enhancement 
value. This reduces the chance of the no venous out flow assumption being broken. The peak 
arterial enhancement and maximum slope in most tissues occur prior to any recirculation thus 
avoiding the requirement of curve modelling. The earlier time of perfusion assessment also 
reduces the likelihood of patient movement and may enable perfusion studies in a single breath 
hold. However, the slope technique is innately sensitive to noise as the data set is differentiated.  
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b. Peak method 
Perfusion is calculated as the concentration of contrast material in the tissue divided by the 
difference between total amount of contrast material that has flowed into the tissue and the 
amount of contrast material that has flowed out of the tissue (equation 4). Typically perfusion is 
calculated at time t’. By restricting the time of measurement to prior to the time the contrast 
starts to flow out of the tissue, the venous term in the denominator becomes zero, thus: 
 
The method is prone to underestimation of higher values of perfusion as the assumption of 
‘‘no venous washout’’ is violated at high flow. Failure to correct the arterial time enhancement 
curve for recirculation can lead to an over estimation of the area under the curve causing a 
decrease of perfusion values. 
 
c. Patlak analysis 
A two compartment model based on Patlak analysis is used for measurements of capillary 
permeability and blood volume; this simplified model assumes the back flux of contrast 
medium from EES to intravascular space is negligible, which holds for the first 1 to 2 minutes 
following contrast injection (Miles et al.,2000). Consider the one-way transfer of contrast 
medium from the blood to the ECF with a blood clearance value of contrast, α. The amount of 
contrast medium that has left the blood will be α times the amount of blood that has flowed 
through the tissue. The concentration of contrast medium or the enhancement of the ECF will 
be α /V × AUC of the blood curve, where V is the volume of the tissue. The enhancement of 
the tissue due to blood in the tissue is determined by the relative blood volume to tissue 
volume (rBV) multiplied by the concentration of contrast medium in the blood. Thus the total 
concentration of contrast medium, i.e. enhancement of the tissue at time t’ is given by the sum 
of the concentrations of the contrast medium in the blood and ECF (equation 5). 
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Rearranging this equation gives: 
 
in the form y=mx+c. A plot of the ratio of the tissue to blood concentration, c(t’)/b(t’), against 
the ratio of the AUC of the blood curve to the blood concentration, for various time values, t’, 
has an intercept of the tissue’s relative blood volume and a slope equal to the blood clearance 
per unit volume or permeability. 
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